| Date | Title | | | 05/06/13 | Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients with Psoriatic Arthritis| PALACE 4 was the first apremilast trial in DMARD-naïve patients and
included more than 500 patients
No new safety and tolerability signals identified, with fewer AEs and
SAEs reported than in (PALACE 1, 2&3)
Apremilast NDA/NDS for psoriatic arthritis submitted to health
authorities in the US and Canada in Q1’2013 and Q2’2013 respectively
Apremilast NDA in US for psoriasis and combined psoriatic
arthritis/psoriasis MAA s... |
|  | | 04/29/13 | Celgene Corporation to Webcast at Upcoming Investor Conferences and Analyst Day| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 29, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming
investor conferences in May. The conferences will be webcast live and
the webcasts will be available in the Investor Relations section of the
Company’s website at www.celgene.com.
Celgene management will provide an overview of the Company.
Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock
Conference at 1... |
| | | 04/26/13 | Oral Anti-Cancer Therapy REVLIMID® Receives Positive CHMP Opinion as Treatment for Patients with Form of Rare Blood Cancer Deletion 5Q Myelodysplastic Syndromes| BOUDRY, Switzerland--(BUSINESS WIRE)--Apr. 26, 2013--
Celgene International Sàrl (NASDAQ: CELG) today announced the European
Medicines Agency’s (EMA): Committee for Medicinal Products for Human Use
(CHMP) has adopted a positive opinion for REVLIMID®
for the treatment of patients with transfusion-dependent anemia due to
low or intermediate-1-risk myelodysplastic syndromes (MDS) associated
with an isolated deletion 5q cytogenetic abnormality when other
... |
| | | 04/25/13 | Celgene Reports First Quarter 2013 Operating and Financial Results| — Net Product Sales of $1.43 Billion, Increased 15 Percent Y/Y
— Total Revenue of $1.46 Billion, Increased 15 Percent Y/Y
— Adjusted Diluted Earnings Per Share of $1.37, Increased 27 Percent
Y/Y
—2013 Adjusted Diluted EPS Guidance Raised; Net Product Sales
Guidance Affirmed
SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 25, 2013--
Celgene Corporation (NASDAQ: CELG) reported net product sales of $1,429
million for the first ... |
| | | 04/03/13 | Celgene Corporation to Announce First Quarter 2013 Results on April 25, 2013| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 3, 2013--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, April 25, 2013 at 9
a.m. ET to discuss the company’s first quarter 2013 financial and
operational results. The webcast will be available in the investor
relations section of the Company’s Web site at www.celgene.com.
About Celgene
Celgene Corporation, headquartered in Sum... |
| | | 03/02/13 | Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of PASI-75 in the First Phase III Study (ESTEEM 1) in Patients with Psoriasis|
Apremilast significantly improved signs and symptoms of psoriasis
across a range of patient types—from systemic treatment-naïve to
biologic-treatment failure patients
Apremilast demonstrated significant improvement in the primary
endpoint and major secondary endpoint in the study
No new safety signals were observed; safety and tolerability
consistent with phase III psoriatic arthritis trials
BOUDRY, Switzerland--(BUSINE... |
| | | 02/28/13 | Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the American Academy of Dermatology Annual Meeting| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 28, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming
investor conferences. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Tuesday, March 5, 2013 Celgene will present at the Cowen and Company
33rd Annual Health Care Conference at 11:... |
| | | 02/27/13 | The European Organisation for Rare Diseases (EURORDIS) Awards Celgene Corporation for Excellence in Medical Innovation in Rare Diseases| BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 27, 2013--
EURORDIS (The European Organisation for Rare Diseases) announced today
that Celgene Corporation (NASDAQ:CELG) has been awarded the prestigious
EURORDIS Company Award for excellence in the field of rare diseases. The
award, presented just in advance of Rare Diseases Day, February 28,
recognises Celgene’s established track record in the area of orphan
diseases, with multiple orphan designations and ... |
| | | 02/20/13 | Celgene Announces $600 Million Accelerated Share Repurchase Program| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 20, 2013--
Celgene Corporation (NASDAQ: CELG) announced today that it has entered
into an accelerated share repurchase (ASR) agreement with an investment
bank to repurchase an aggregate of $600 million of the company’s common
stock. The ASR is part of the existing Board authorized share repurchase
program. Year-to-date, Celgene has repurchased approximately $385
million of its common stock and has approximately $1,... |
| | | 02/11/13 | Celgene Provides REVLIMID® Regulatory Update|
REVLIMID Granted Approval for Treatment of Patients with Relapsed or
Refractory Multiple Myeloma in China
REVLIMID Granted Priority Review as Treatment for Patients with
Relapsed or Refractory Mantle Cell Lymphoma - U.S. FDA PDUFA Date Set
for June 5, 2013
BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 11, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), today announced that REVLIMID® (lenalido... |
| | | 02/08/13 | U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 8, 2013--
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and
Drug Administration (FDA) has approved POMALYST® brand
therapy (pomalidomide) for patients with multiple myeloma who have
received at least two prior therapies including lenalidomide and
bortezomib and have demonstrated disease progression on or within 60
days of completion of the last therapy.
POMALYST(R) brand therapy (P... |
| | | 02/04/13 | Celgene Corporation to Webcast at Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 4, 2013--
Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming
investor conferences. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Monday, February 11, 2013 Celgene will present at the 15th Annual BIO
CEO & Investor Conference at 8:00 a... |
| | | 01/24/13 | Celgene Reports Strong Fourth Quarter and Full Year 2012 Operating and Financial Results|
Total Revenues of $5.5 Billion, Increased 14 Percent Y/Y
Adjusted Diluted Earnings per Share of $4.91, Increased 30 Percent
Y/Y; GAAP Diluted Earnings per Share of $3.30 Increased 16 Percent Y/Y
New and Updated Data on Over Ten Pivotal Phase III Trials Expected in
2013
Affirms 2013 Financial Outlook
SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 24, 2013--
Celgene Corporation (NASDAQ: CELG) reported net product sales of $1... |
| | | 01/22/13 | ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer|
Abraxane plus gemcitabine was superior to gemcitabine alone with
statistically significant and clinically meaningful results across
primary and key secondary endpoints and patient subgroups
Oral Presentation Scheduled for Friday, January 25th
at ASCO’s Gastrointestinal Cancers Symposium Annual Meeting
BOUDRY, Switzerland--(BUSINESS WIRE)--Jan. 22, 2013--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
C... |
| | | 01/07/13 | Celgene Corporation Announces Financial Outlook and Preliminary 2012 Results|
2012 Adjusted Diluted EPS Expected to be at the Higher End of
Previous Guidance Range at Approximately $4.90 (GAAP Range $3.37 to
$3.39)
REVLIMID® Achieved Q4 2012 Net Sales of Just
Over $1.0 Billion
2013 Guidance: Total Net Product Sales of $6.0 Billion; REVLIMID $4.1
Billion to $4.2 Billion; Adjusted Diluted EPS $5.50 to $5.60 (GAAP Range
$4.67 to $4.79)
Long-Term 2015 Targets of $8.0- 9.0 Billion in Total ... |
| | | 01/07/13 | Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint in Pivotal Phase III Psoriasis Trials|
Clinical Data from two pivotal phase III (ESTEEM 1&2) randomized,
placebo-controlled studies including approximately 1,250 patients
demonstrated statistically significant and clinically meaningful
improvements for the primary and major secondary endpoint
NDA submission based on ESTEEM program in psoriasis planned for
H2’2013; MAA submission for psoriasis and psoriatic arthritis planned
for H2’2013
No new safety signals ... |
| | | 12/21/12 | Celgene Corporation to Present at the 31st Annual J.P. Morgan Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 21, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 31st Annual J.P. Morgan Healthcare
Conference on January 7, 2013 at 11:00a.m. E.T. will be webcast live and
will be available in the investor relations section of the company’s Web
site at www.celgene.com.
Celgene management will provide an overview of the company.
About Celgene
Celgene Corporation, h... |
| | | 12/11/12 | Phase III Study (MM-003) of Pomalidomide Plus Low-Dose Dexamethasone Demonstrates Significant Progression-Free and Overall Survival Improvement for Patients with Relapsed or Refractory Multiple Myeloma|
Study presented as a late-breaking abstract at 54th
American Society of Hematology annual meeting
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced data from its phase III, multi-center, randomized
(2:1), open-label study (MM-003, n=455) of pomalidomide plus low-dose
dexamethasone compared with high-dose dexamethasone in patients with
ref... |
| | | 12/11/12 | Results of Pivotal Study (MCL-001) Evaluating REVLIMID in Mantle-Cell Lymphoma Presented at 54th American Society of Hematology Annual Meeting| BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012--
Celgene International Sàrl (NASDAQ: CELG) today announced results from
the “EMERGE” study (MCL-001), a phase II, multi-center, single-arm trial
evaluating REVLIMID® (lenalidomide) in patients with
previously treated mantle cell lymphoma (MCL).
In the study, 134 patients who had failed prior treatment with
rituximab, cyclophosphamide, an anthracycline (or mitoxantrone), and
bortezomi... |
| | | 12/11/12 | Analysis of Post-Progression Outcomes in MM-015 Study Presented at the 54th American Society of Hematology Annual Meeting| BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012--
Celgene International Sàrl (NASDAQ: CELG) today announced results from
an analysis of post-progression outcomes in MM-015, a phase III study of
continuous REVLIMID® (lenalidomide) plus melphalan and
prednisone (MPR-R, n=152) compared with a fixed cycle of MPR followed by
placebo (n=153) or of melphalan and prednisone followed by placebo (MP,
n-154) in newly diagnosed multiple myeloma patients.
... |
| | | 12/11/12 | Data Evaluating Combination Treatments Including REVLIMID® Plus Antibody Therapies in Patients with Various Difficult-to-Treat Forms of Non-Hodgkin Lymphoma Presented at the 54th American Society of Hematology Annual Meeting|
ABSTRACTS 689, 901, 3668, and 3692
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), announced results from several studies evaluating combination
treatment with REVLIMID® (lenalidomide) and antibody therapy
in non-Hodgkin lymphoma (NHL). The data were presented at the 54th
Annual Meeting of the American Society of Hematology (ASH) in Atlanta,
GA.
... |
| | | 12/10/12 | REVLIMID® and VIDAZA® Combination Therapy Achieves Nearly 30 Percent Complete Response in Untreated Elderly Patients with Acute Myeloid Leukemia| BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2012--
Celgene International Sàrl (NASDAQ: CELG) today announced that results
from a study evaluating the combination of REVLIMID (lenalidomide) plus
VIDAZA (azacitidine) in patients 60 years or older with untreated acute
myeloid leukemia (AML) were presented at the American Society of
Hematology annual meeting in Atlanta, GA.
In the phase II investigator-initiated study, patients received
... |
| | | 12/10/12 | Study to Evaluate Dose and Schedule for Oral Epigenetic Therapy CC-486 in Lower-Risk MDS Presented at ASH|
ABSTRACT #424
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), today announced that data from a phase I study of oral,
epigenetic therapy CC-486 (oral azacitidine) in patients with lower-risk
myelodysplastic syndromes (MDS) was presented at the 54th
Annual Meeting of the American Society of Hematology in Atlanta, GA.
In the study, patients with... |
| | | 11/28/12 | Celgene Corporation to Webcast at an Upcoming Investor Conference and the 54th American Society of Hematology Annual Meeting| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 28, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at an upcoming investor conference and at the 54th American
Society of Hematology (ASH) annual meeting will be webcast live and will
be available in the investor relations section of the company’s web site
at www.celgene.com.
Celgene management will provide an overview of the company.
On Tuesday, December 4, 201... |
| | | 11/27/12 | More Than 250 Presentations and Posters Evaluating Celgene Products to Be Highlighted at the 54th American Society of Hematology Annual Meeting| BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 27, 2012--
Celgene International Sàrl (NASDAQ: CELG) today announced that clinical
investigators from leading cancer research centers will present data
from recent and on-going clinical trials in more than 250 posters and
presentations, evaluating Celgene products in blood cancers including
multiple myeloma, myelodysplastic syndromes, acute myeloid leukemia,
non-Hodgkin’s lymphomas, myelofibrosis and chronic... |
| | | 11/13/12 | Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis|
Apremilast significantly improves signs and symptoms of PsA in
DMARDs-failure patients, including biologic-treatment-failure patients
Apremilast monotherapy demonstrates robust improvement across primary
and secondary endpoints
Highest response demonstrated in biologic-naïve patient population
No significant safety signals were observed and tolerability improved
over phase II program
BOUDRY, Switzerland--(BUSINE... |
| | | 11/09/12 | ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study| BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 9, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced that its phase III study of ABRAXANE®
(paclitaxel protein-bound particles for injectable suspension)
(albumin-bound) in combination with gemcitabine in treatment-naïve
patients with advanced pancreatic cancer met its primary endpoint of
overall survival. In the study, ABRAXANE in combination with gemcitab... |
| | | 11/07/12 | Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the American College of Rheumatology| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 7, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Wednesday, November 14, 2012, Celgene will present at the Credit
Suisse Healthcare Confer... |
| | | 10/25/12 | Celgene Reports Third Quarter 2012 Operating and Financial Results|
— Total Revenue of $1.42 Billion and Net Product Sales of
$1.39 Billion, Increased 14 Percent Y/Y
— Adjusted (Non-GAAP) Diluted Earnings per Share of $1.29,
Increased 26 Percent Y/Y; GAAP Diluted Earnings per Share of $0.97
Increased 20 Percent Y/Y
— Raising 2012 Adjusted Earnings Guidance; Narrowing Revenue
Guidance
— Over 150 Data Presentations Highlighting Our Products and
Science at Major Medical Meetings... |
| | | 10/25/12 | ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients|
Society for Melanoma Research Abstracts Published Online in
Organization’s Journal
BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 25, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced that abstracts for the upcoming Society for
Melanoma Research meeting have been published online in the
organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract.
The ... |
| | | 10/23/12 | Pomalidomide Demonstrated Significant Progression-Free Survival and Overall Survival Advantages in Phase III Study of Heavily Pre-Treated Myeloma Patients| BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 23, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced that its phase III, multi-center, randomized,
open-label study (MM-003) of pomalidomide plus low-dose dexamethasone
compared to high-dose dexamethasone in patients with relapsed and/or
refractory multiple myeloma was reviewed by a data safety monitoring
board (DSMB). The DSMB determined MM-003 met the pr... |
| | | 10/12/12 | FDA Approves ABRAXANE® for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer|
Approval Based on Significantly Improved Overall Response Rates in
all Patients Regardless of Histology
Adds a New Therapeutic Option for Patients with Lung Cancer, the
Leading Cause of Cancer Deaths in the United States
SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 12, 2012--
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and
Drug Administration (FDA) has approved ABRAXANE® (paclitaxel
protein-bound particles for injec... |
| | | 10/08/12 | Celgene Corporation to Announce Third Quarter 2012 Results on October 25, 2012| SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 8, 2012--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, October 25, 2012 at
9 a.m. ET to discuss the company’s third quarter 2012 financial and
operational results. The webcast will be available in the investor
relations section of the Company’s Web site at www.celgene.com.
About Celgene
Celgene Corporation, headquartered ... |
| | | 10/03/12 | Celgene Corporation Provides Update on FDA Advisory Committee for Pomalidomide| SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 3, 2012--
Celgene Corporation (NASDAQ: CELG) today announced it was notified by
the U.S. Food and Drug Administration (FDA) that there will not be an
Oncologic Drugs Advisory Committee (“ODAC”) meeting scheduled for
November 8, 2012. The agency has informed the Company the review of its
new drug application (“NDA”) for pomalidomide is continuing with the
previously announced Prescription Drug User Fee Act (PDUFA) a... |
| | | 10/02/12 | ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study| BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 2, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced results of its phase III, randomized,
international study (CA033) of ABRAXANE® (paclitaxel
protein-bound particles for injectable suspension) (albumin-bound) in
chemotherapy-naïve patients with metastatic melanoma. In the study, the
primary endpoint was met with patients receiving ABRAXANE demonstrating
... |
| | | 09/19/12 | Celgene Corporation Announces Pomalidomide Will Be Reviewed at FDA Advisory Committee|
ODAC will discuss pomalidomide NDA for the treatment of patients with
relapsed and refractory multiple myeloma
SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 19, 2012--
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and
Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold
a review of the Company’s new drug application (NDA) for pomalidomide at
its meeting on November 8, 2012. The Company is seeking approval to
... |
| | | 09/06/12 | Apremilast Palace Program Demonstrates Robust and Consistent Statistically Significant Clinical Benefit Across Three Pivotal Phase III Studies (PALACE-1, 2 & 3) in Psoriatic Arthritis|
To date, three pivotal phase III, randomized, placebo-controlled
studies including approximately 1,500 patients (PALACE-1, 2 & 3) achieve
statistical significance and clinically meaningful improvements for the
primary endpoint, as well as other measures of signs and symptoms and
physical function
Safety consistent with previous studies and tolerability improved
over phase II program
Celgene targets first apremilast NDA ... |
| | | 08/27/12 | Celgene Corporation to Present at Investor Conferences in September| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 27, 2012--
Celgene Corporation (NASDAQ: CELG) announced its presentations at four
upcoming investor conferences will be webcast live and will be available
in the investor relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Thursday, September 6, 2012 Celgene will present at the Stifel
Nicolaus Healthcare Conference at 9:10 a... |
| | | 08/07/12 | Celgene Prices $1.5 Billion of Senior Unsecured Notes| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 7, 2012--
Celgene Corporation (NASDAQ: CELG) today announced the successful
pricing of two series of senior unsecured notes for an aggregate
principal amount of $1.5 billion. Of these notes, $500 million will
mature in 2017 and will bear interest at an annual rate of 1.900%, and
$1 billion will mature in 2022 and will bear interest at an annual rate
of 3.250%. The 1.900% notes due 2017, and the 3.250% notes due 202... |
| | | 08/06/12 | Celgene Announces Offering of Senior Unsecured Notes| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 6, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its intention
to offer, subject to market and other conditions, senior unsecured notes
under a shelf registration statement on Form S-3 on file with the
Securities and Exchange Commission. The interest rate, the maturity
dates and other key terms of the offering are to be determined at the
time of pricing.
Celgene expects to use the net pro... |
| | | 07/26/12 | Celgene Reports Second Quarter 2012 Operating and Financial Results|
Total Revenue of $1.37 Billion and Net Product Sales of $1.34
Billion, Increased 16 Percent Y/Y, Respectively
Non-GAAP Diluted Earnings per Share of $1.22, Increased 37 Percent
Y/Y; GAAP Earnings per Share of $0.82 Increased 39 Percent Y/Y
Raising 2012 Earnings Guidance; Revenue Guidance Reaffirmed
Key Pivotal Data for ABRAXANE®, Apremilast,
Pomalidomide and REVLIMID® Expected by Year-end
SUMMIT, N.J.--(B... |
| | | 07/20/12 | Celgene to Request Re-Examination of CHMP ISTODAX® (romidepsin) Opinion| BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 20, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced it will request a re-examination of the negative
opinion announced by the European Medicines Agency’s (EMA) Committee for
Medicinal Products for Human Use (CHMP) regarding the Marketing
Authorisation Application (MAA) submitted for ISTODAX®
(romidepsin) for the treatment of relapsed or refractory periphe... |
| | | 07/16/12 | Celgene Corporation to Announce Second Quarter 2012 Results on July 26, 2012| SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 16, 2012--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, July 26, 2012 at 9
a.m. ET to discuss the company’s second quarter 2012 financial and
operational results. The webcast will be available in the investor
relations section of the Company’s Web site at www.celgene.com.
About Celgene
Celgene Corporation, headquartered i... |
| | | 07/12/12 | Apremilast Achieves Statistical Significance for the Primary Endpoint of the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis|
Apremilast achieves clinically meaningful and statistically
significant improvement in measures of both signs and symptoms and
physical function
Safety is consistent with previous studies and tolerability improved
over phase II program
Celgene targets first apremilast NDA filing in the first half of 2013
Update on comprehensive global apremilast clinical program
BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 12, 201... |
| | | 06/21/12 | Celgene Provides Regulatory Update|
Application for new indication for REVLIMID®
(lenalidomide) in newly-diagnosed and maintenance multiple myeloma has
been withdrawn from CHMP; Plans to re-submit with more mature data
Pomalidomide NDA for patients with relapsed and refractory multiple
myeloma accepted for standard review by U.S. FDA, PDUFA date set for
Feb. 10, 2013; MAA for patients with relapsed and refractory
multiple myeloma submitted to the EMA
2012 gui... |
| | | 06/13/12 | Celgene Announces Additional $2.5 Billion Share Repurchase Program| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 13, 2012--
Celgene Corporation (NASDAQ: CELG) today announced that during its June
meeting the Company's Board of Directors authorized the repurchase of up
to an additional $2.5 billion of the Company's common stock. This
open-ended program is effective immediately. Purchases may be made in
the open market or in privately negotiated transactions from time to
time, as determined by Celgene’s management and in accord... |
| | | 06/06/12 | Celgene Advances ABRAXANE® (nab-paclitaxel) Development in Difficult-to-Treat Cancers|
Phase III randomized clinical study in metastatic pancreatic cancer
completed enrollment
sNDA submitted to U.S. FDA in non-small cell lung cancer, PDUFA date
Oct. 12, 2012
CALGB 40502 advances understanding of optimal dosing and scheduling
of nab-paclitaxel in metastatic breast cancer
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 6, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG... |
| | | 06/04/12 | Data Evaluating Clinical Potential of ABRAXANE® (Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at ASCO|
50% of patients experienced at least a 70% decrease in tumor marker
level CA19.9 after 2 cycles of neo-adjuvant treatment with ABRAXANE®
and gemcitabine
11 of 12 resected patients achieved a complete resection, and 13 of
16 patients achieved stable disease or partial response
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 4, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) today announced result... |
| | | 06/02/12 | Multiple Analyses Evaluating ABRAXANE® (Nab-Paclitaxel) in Non-Small Cell Lung Cancer Presented at ASCO|
Overall survival nearly doubled for elderly patients
Response rate significantly improved in squamous-cell histology
Trend toward overall survival demonstrated in squamous-cell compared
to non-squamous-cell disease
PDUFA date scheduled for Oct. 12, 2012
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 2, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation
(NASDAQ:CELG) today announced results from m... |
| | | 06/02/12 | Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO|
Previously-treated lymphoma patients receiving R2
regimen demonstrated 73% objective response rate
Combination therapy resulted in a median event-free survival of 2
years with a median follow-up of 1.7 years
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 2, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), today announced results from a randomized study comparing REVLIMID®
(lenalidomide) plus ri... |
| | | 05/22/12 | Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May. 22, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at Sanford C. Bernstein’s 28th Annual Strategic
Decisions Conference on Wednesday, May 30, 2012 at 3:00p.m. EST will be
webcast live and will be available in the investor relations section of
the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
About Celgene
... |
| | | 05/10/12 | New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma|
Consistent progression-free survival improvement shown with
continuous lenalidomide therapy in elderly patients not eligible for
transplant and as maintenance therapy in patients following autologous
stem cell transplant
BOUDRY, Switzerland--(BUSINESS WIRE)--May. 10, 2012--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), today announced that results from three phase III studies
evaluating the use of cont... |
| | | 05/07/12 | Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel| SUMMIT, N.J.--(BUSINESS WIRE)--May. 7, 2012--
Celgene Corporation (NASDAQ: CELG) today announced the appointment of
Thomas M. Moriarty as General Counsel and Corporate Secretary. In this
position, he will be responsible for global legal strategy at Celgene
and will serve on the company’s Management Committee.
Mr. Moriarty joins Celgene from Medco Health Solutions where he directed
all legal, regulatory, public policy and corporate governance ... |
| | | 05/04/12 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--May. 4, 2012--
Celgene Corporation (NASDAQ: CELG) announced its presentations at two
upcoming investor conferences will be webcast live and will be available
in the investor relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Tuesday, May 8, 2012 Celgene will present at the Baird 2012 Growth
Stock Conference at 12:20 p.m. ET.
... |
| | | 04/26/12 | Celgene Reports First Quarter 2012 Operating and Financial Results| -- Non-GAAP Net Product Sales of $1.25 Billion, Increased 17 Percent
Y/Y
-- Non-GAAP Total Revenue of $1.27 Billion, Increased 15
Percent Y/Y
-- Non-GAAP Diluted Earnings Per Share of $1.08, Increased 30 Percent
Y/Y
-- 2012 Revenue and Earnings Guidance Reaffirmed
SUMMIT, N.J., Apr 26, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales
... |
| | | 04/17/12 | Celgene Corporation to Announce First Quarter 2012 Results on April
26, 2012| SUMMIT, N.J., Apr 17, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, April 26, 2012 at 9
a.m. ET to discuss the company's first quarter 2012 financial and
operational results. The webcast will be available in the investor
relations section of the Company's Web site at www.celgene.com.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 03/08/12 | Celgene Completes Acquisition of Avila Therapeutics| SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 8, 2012--
Celgene Corporation (NASDAQ: CELG) today announced it has completed its
acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics
for $350 million in cash, plus up to $575 million contingent upon
certain milestones related to AVL-292 and candidates from Avila’s
discovery program.
The transaction provides Celgene with a highly-selective Bruton’s
tyrosine kinase inhibitor, curren... |
| | | 02/27/12 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 27, 2012--
Celgene Corporation (NASDAQ: CELG) announced its presentations at two
upcoming investor conferences will be webcast live and will be available
in the investor relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Tuesday, March 6, 2012 Celgene will present at the Cowen & Company 32nd
Annual Health Care Conferenc... |
| | | 02/21/12 | Celgene Corporation to Present at the Citi 2012 Global Health Care Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 21, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Citi 2012 Global Health Care Conference on Tuesday,
February 28, 2012 at 9:30 a.m. EST will be webcast live and will be
available in the investor relations section of the Company’s Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
About Celgene
Celgene Corporation, head... |
| | | 01/26/12 | Celgene Reports Record Fourth Quarter and Full Year 2011 Operating and Financial Results|
- Total Revenue of $4.8 Billion, Increased 34 Percent Y/Y
- Non-GAAP Diluted Earnings Per Share of $3.79, Increased 36 Percent
Y/Y
- Confirms 2012 Outlook
SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 26, 2012--
Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales
of $1,241 million for the fourth quarter of 2011, a 21 percent increase
from the same period in 2010. Non-GAAP net income for the fourth quart... |
| | | 01/26/12 | Celgene to Acquire Avila Therapeutics|
Oral Btk inhibitor AVL-292 offers promising potential for treatment
of B-cell diseases
Avilomics™ Platform enhances drug discovery capabilities
SUMMIT, N.J. and BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 26, 2012--
Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a
privately held biotechnology company developing targeted covalent drugs
that treat diseases through protein silencing, today announced a
definitiv... |
| | | 01/23/12 | Celgene Corporation Elects Dr. Richard W. Barker to Its Board of Directors| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 23, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government policy. He served as Director General of the Association of the British Pharmaceutical Industry (ABPI), and as a board member for the European and International pharmaceutical industry federations, addressing critical issues and working closely with govern... |
| | | 01/09/12 | Celgene Corporation Announces 2012 Financial Outlook and Reviews 2011 Achievements|
2012 Total Revenue Guidance $5.4-$5.6B, up ~15%, REVLIMID®
$3.75B to $3.85B, up ~19%, and Non-GAAP EPS $4.70 - $4.80, up ~25%
Outlook for 2012 Includes Significant Catalysts in Hematology,
Oncology, and Inflammation and Immunology
2011 Record Results with Total Revenue of Over $4.8B, up 34%, and
Non-GAAP EPS of approximately $3.79, up 36%
2015 Outlook Updated to $8-9B Total Revenue and Non-GAAP EPS of $8.00
to $9.00... |
| | | 12/28/11 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 28, 2011--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Thursday, January 5, 2012, Celgene will present at the Goldman Sachs
Healthcare CEOs Unscripted Conf... |
| | | 12/22/11 | Celgene Corporation Announces the Appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access| SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 22, 2011--
Celgene Corporation (NASDAQ: CELG) today announced the
appointment of Richard Bagger as Senior Vice President, Corporate
Affairs and Strategic Market Access, effective January 30th.
Mr. Bagger will be responsible for all government and public affairs,
strategic market access, communications and patient advocacy initiatives
and will report to Robert J. Hugin, Chairman and Chief Executive Officer
of... |
| | | 12/14/11 | Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype|
Celgene and GELA Announce Initiation of RELEVANCE® Phase III Study
in Follicular Lymphoma
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 14, 2011--
Celgene International Sàrl (Nasdaq: CELG) and the Groupe d’Etude
des Lymphomes de l’Adulte (GELA) today announced the organizations have
initiated an international, Phase III, open-label, randomized study to
evaluate the therapeutic potential of a novel chemotherapy-free approach
for the treatm... |
| | | 12/13/11 | Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia|
The Study Reported Overall Response Rate of 66%, With 12% of Patients
Achieving Complete Response
After a Median follow-up of 31 Months, Overall Survival Was 75%
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation,
(NASDAQ: CELG), announced final results from a phase II investigational
study evaluating the combination of REVLIMID® (lenalidomide)
and ritux... |
| | | 12/13/11 | Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Presented at ASH|
Three Year Overall Survival from Inclusion Was 93% for Patients
Treated with REVLIMID® and Dexamethasone
Compared to 76% for Patients under Observation Only
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation
(NASDAQ: CELG), announced that updated data evaluating continuous
treatment with REVLIMID® (lenalidomide) in patients with
high-risk asymptomatic smoldering multipl... |
| | | 12/13/11 | REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia|
Study Demonstrated Overall Response Rate of 95% for Patients under 65
Years of Age
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), announced results from an investigational study evaluating
REVLIMID (lenalidomide) in combination with rituximab in patients with
treatment-naive chronic lymphocytic leukemia (CLL). These data were
presented at the 53rd An... |
| | | 12/12/11 | Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA® and REVLIMID® in Higher-Risk MDS Patients Presented at ASH|
Patients achieving complete response had a median overall survival of
27 months
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation
(NASDAQ: CELG), today reported final results from the phase
II portion of a multi-center phase I/II study evaluating combination
therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in
patients with higher-risk myelodysplastic syndr... |
| | | 12/12/11 | Phase II Study Evaluates Clinical Benefit of Pomalidomide in Heavily Pre-Treated Patients with Multiple Myeloma|
Partial Response Rate or Better of 34% Observed in Patients Treated
With Pomalidomide plus Low-Dose Dexamethasone
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), announced that its oral therapy pomalidomide was evaluated as a
potential treatment for patients with relapsed and refractory multiple
myeloma who have received prior therapy that includes REVLIMID
... |
| | | 12/12/11 | Phase II Study of ISTODAX® in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): A Sub-Analysis of Patients with Most Common Subtypes of PTCL Presented at ASH|
46% of patients experienced disease control for at least 90 days
Median duration of response for all responders was 17 months
Similar response rates demonstrated across most common subtypes of
PTCL
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation
(Nasdaq:CELG) announced data from a sub-analysis of a Phase II,
multicenter, international, open-label stud... |
| | | 12/12/11 | Phase III Study with REVLIMID® Continuous Therapy Demonstrates Statistically Significant Improvement in Progression-Free Survival for Patients Newly Diagnosed with Multiple Myeloma|
Study Showed a Median Progression-Free Survival of 31 Months for
Patients ≤75 Years Old Receiving Lenalidomide Continuous Therapy
Compared with 12 Months for Patients not Receiving Lenalidomide
Continuous Therapy
Trend Reported for Extended Overall Survival in favor of Patients
Receiving Lenalidomide Continuous Therapy
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 12, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corp... |
| | | 12/11/11 | Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia|
Study Reported Overall Response Rate of 38%, and REVLIMID®
(Lenalidomide) Was Well Tolerated
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), announced interim results of CLL-009, a study evaluating three
starting doses of REVLIMID® (lenalidomide), followed by
step-wise dose escalation as tolerated in patients with chronic
lymphocytic leukemia ... |
| | | 12/11/11 | Results from a Comparative Analysis Show REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care|
The Study Reported Median Overall Survival of 5.2 Years for Patients
Treated with REVLIMID (Lenalidomide) Compared with 3.8 Years for
Untreated Patients
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 11, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG) announced results from a retrospective analysis to assess the risk
of acute myeloid leukemia (AML) progression and death in REVLIMID
(lenalidomide)-treat... |
| | | 12/10/11 | Phase I Study Evaluating Oral Azacitidine as Potential Treatment for Patients With Acute Myeloid Leukemia Presented at the American Society of Hematology Meeting|
Study Demonstrates that Oral Azacitidine Was Well Tolerated in
Patients with Acute Myeloid Leukemia Not Eligible for Other Therapies
and with Complex Cytogenetic Abnormalities
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation
(NASDAQ:CELG), announced results from a multi-center Phase I
study that explored multiple dosing schedules of oral azacitidine in 23
patients wit... |
| | | 11/25/11 | Celgene Corporation to Present at the Piper Jaffray Health Care
Conference 2011| SUMMIT, N.J., Nov 25, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Piper Jaffray Health Care Conference 2011 on
Tuesday, November 29, 2011 at 11 a.m. EST will be webcast live and will
be available in the investor relations section of the Company's Web site
at www.celgene.com.
Celgene management will provide an overview of the Company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 11/22/11 | Celgene Will Discontinue Phase III MAINSAIL(R) Trial in
Castrate-Resistant Prostate Cancer| BOUDRY, Switzerland, Nov 22, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a subsidiary of Celgene Corporation,
(NASDAQ: CELG) announced that based on the recommendation from the Data
Monitoring Committee (DMC) it will discontinue its pivotal
double-blinded Phase III MAINSAIL(R) trial that was designed to evaluate
the efficacy and safety of docetaxel and prednisone with or without
lenalidomide in patients with castrate-resistant prostate cancer (CRPC)... |
| | | 11/21/11 | REVLIMID(R) Granted Swissmedic Approval for Treatment of Rare Blood Cancer| BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 21, 2011--
Celgene International Sàrl, a subsidiary of Celgene Corporation,
(NASDAQ: CELG) today announced that REVLIMID (lenalidomide) has been
granted approval by the Swiss agency for Therapeutic Products
(Swissmedic) for use in patients with transfusion-dependent anemia due
to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated
with a deletion 5q cytogenic abnormality with or without add... |
| | | 11/08/11 | Phase II Study Evaluating Apremilast as an Oral Treatment for
Patients with Ankylosing Spondylitis Presented at ACR| Study Supports Clinical Potential of Apremilast; Underscores High
Unmet Medical Need for Novel Oral Therapies
Based on Results, Celgene To Initiate Phase III Study to Further
Evaluate Apremilast in Ankylosing Spondylitis
BOUDRY, Switzerland, Nov 08, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ:
CELG), today announced data from a Phase II study of apremilast, its
investigational oral immunomodulatory compound, i... |
| | | 11/03/11 | Celgene Corporation to Present at the Credit Suisse 2011 Healthcare
Conference| SUMMIT, N.J., Nov 03, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Credit Suisse 2011 Healthcare Conference on Friday,
November 11, 2011 at 11:30am ET will be webcast live and will be
available in the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
inte... |
| | | 10/27/11 | Celgene Reports Record Third Quarter 2011 Operating and Financial
Results| -Total Revenue of $1.25 Billion Increased 37 Percent Y/Y
-Non-GAAP Diluted Earnings Per Share of $1.02 Increased 36 Percent Y/Y
-REVLIMID(R) Global Net Product Sales of $820
Million Increased 28 Percent Y/Y
-RaisingNon-GAAP EPS Range to $3.78 - $3.80 from $3.45 - $3.55
SUMMIT, N.J., Oct 27, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales
of $1,218 million for the third quarter of 2011, a 38 percent increase
from the same... |
| | | 10/12/11 | Celgene Corporation to Announce Third Quarter 2011 Results on October
27, 2011| SUMMIT, N.J., Oct 12, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, October 27, 2011 at
9 a.m. ET to discuss the Company's third quarter 2011 financial and
operational results. The webcast will be available in the investor
relations section of the Company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated... |
| | | 10/06/11 | Celgene Issues Important New and Additional Information on Conclusion
of Article 20 for REVLIMID(R)| New information with regard to Article 20 procedure conclusion
supersedes the press release of September 23, 2011
BOUDRY, Switzerland, Oct 06, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a subsidiary of Celgene Corporation,
(NASDAQ: CELG) today announced, that it is rectifying information in its
press release of September 23rd, 2011 to provide more complete
information on the observed risk of cancer and recommended changes to
the product label fo... |
| | | 10/06/11 | Phase I/II Study Evaluating ABRAXANE(R) Clinical Potential in Patients with Advanced Pancreatic Cancer Published in the Journal of Clinical Oncology Online| Study reports ABRAXANE plus gemcitabine achieved a median overall survival of 12.2 months
Patients with "high-SPARC" biomarker achieved significantly higher overall survival
BOUDRY, Switzerland, Oct 06, 2011 (BUSINESS WIRE) -- Celgene International Sàrl (Nasdaq:CELG) today announced that results from a clinical study of ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer we... |
| | | 09/21/11 | Celgene Corporation to Present at JMP Securities Healthcare
Conference 2011| SUMMIT, N.J., Sep 21, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at JMP Securities Healthcare Conference 2011 on Tuesday,
September 27, 2011 at 11:30 a.m. ET will be webcast live and will be
available in the investor relations section of the Company's Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
in... |
| | | 09/14/11 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Sep 14, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced its presentations at two
upcoming investor conferences will be webcast live and will be available
in the investor relations section of the Company's Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Friday, September 16, 2011, Celgene will present at the Bank of
America Merrill Lynch Global Healthcare Conferenc... |
| | | 08/31/11 | Celgene Corporation to Present at Three Upcoming Investor Conferences| SUMMIT, N.J., Aug 31, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced its presentations at three
upcoming investor conferences will be webcast live and will be available
in the investor relations section of the Company's Web site at www.celgene.com.
Celgene management will provide an overview of the Company.
Thursday, September 8, 2011, Celgene will present at the Stifel
Nicolaus Healthcare Conference 2011 at 10:55 a.... |
| | | 08/18/11 | Celgene Announces Additional $2 Billion Share Repurchase Authorization| SUMMIT, N.J., Aug 18, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced the Company's Board of
Directors has authorized the repurchase of up to an additional $2
billion of the Company's common stock.
"The expansion of the share repurchase program reflects our confidence
in the operational and financial long-term growth of the Company and our
commitment to increase shareholder value," said Bob Hugin, Chairman and
Chief Executive Offic... |
| | | 08/04/11 | Celgene Corporation to Present at 2011 Canaccord Genuity Growth
Conference| SUMMIT, N.J., Aug 04, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 2011 Canaccord Genuity Growth Conference on
Thursday, August 11, 2011 at 11:30 a.m. ET will be webcast live and will
be available in the investor relations section of the company's Web site
at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 07/28/11 | Celgene Reports Record Second Quarter 2011 Operating and Financial
Results| - Non-GAAPTotal Revenue of $1.18 Billion Increased 38 Percent
Y/Y
- Non-GAAP Diluted Earnings Per Share of $0.89 Increased 29 Percent
Y/Y
- REVLIMID(R) Global Net Product Sales of $795
Million Increased 35 Percent Y/Y
- Increasing2011 Revenue and Non-GAAP EPS Financial Outlook
SUMMIT, N.J., Jul 28, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG):
2011 Second Quarter Financial Results
Year-Over-Year
... |
| | | 07/13/11 | Celgene Corporation to Announce Second Quarter 2011 Results on July
28, 2011| SUMMIT, N.J., Jul 13, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, July 28, 2011 at 9
a.m. ET to discuss the Company's second quarter 2011 financial and
operational results. The webcast will be available in the investor
relations section of the Company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated g... |
| | | 06/17/11 | GELA, the Premier Cooperative Group in Adult Lymphoma Research Choses
REVLIMID(R) for Major Study in Follicular Lymphoma| Celgene and GELA Announce Second Collaboration with the "RELEVANCE"
Study Evaluating REVLIMID plus Rituximab for Patients Newly-Diagnosed
with Follicular Lymphoma
BOUDRY, Switzerland & LYON, France, Jun 17, 2011 (BUSINESS WIRE) --Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene
International Sarl (Nasdaq: CELG) today announced a collaboration to
conduct an international randomized study to evaluate the therapeutic
potential of the REVLIMI... |
| | | 06/17/11 | Phase II Data Evaluating Clinical Benefit of REVLIMID(R)
Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas
Presented at International Conference on Malignant Lymphoma| Study Reports 91% Overall Response Rate and 65% Complete Remission
Rate
Study Participants with Follicular Lymphoma Achieved an 85% Complete
Remission Rate
Study Further Validates Therapeutic Potential of Antibody DependentCellular Mediated Cytotoxicity (ADCC)
BOUDRY, Switzerland, Jun 17, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data
from a Phase II study, conducted by investigators from the MD Anderson
Cancer C... |
| | | 06/16/11 | FDA Grants Accelerated Approval of ISTODAX(R)
As Treatment for Patients with Peripheral T-Cell Lymphoma Who Have
Received at Least One Prior Therapy| SUMMIT, N.J., Jun 16, 2011 (BUSINESS WIRE) --Celgene Corporation (Nasdaq:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has granted accelerated approval for its
Supplemental New Drug Application (sNDA) for an additional indication
for ISTODAX (romidepsin) for injection for the treatment of peripheral
T-cell lymphoma (PTCL) in patients who have received at least one prior
therapy. ISTODAX is also approved for the treatment of cutaneo... |
| | | 06/16/11 | Phase I/II Data Evaluating Clinical Benefit of REVLIMID(R)
in Combination with Standard R-CHOP Chemotherapy for Patients with
Untreated Diffuse Large B-Cell Lymphoma| Phase I/II Study Reports 100% Overall Response Rate and 83% Complete
Response Rate
High Complete Remission Rates and Safety in Elderly Patients
Supported by Second Phase I Study
BOUDRY, Switzerland, Jun 16, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data
from two studies evaluating the use of REVLIMID(R)
(lenalidomide) with standard R-CHOP* chemotherapy (R2CHOP) in
patients with untreated diffuse large B ce... |
| | | 06/16/11 | Phase II Study Evaluates Clinical Benefit of Combining REVLIMID(R)
with rituximab to Enhance Anti-Cancer Activity in Mantle Cell Lymphoma| Study Reports 57.8% Overall Response Rate, 32.6% Complete Remission
Rate and
Median Overall Survival of 25 Months
Study Further Validates Therapeutic Potential of Antibody Dependent
Cellular Mediated Cytotoxicity (ADCC)
BOUDRY, Switzerland, Jun 16, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data
from a Phase I/II study evaluating the combination of REVLIMID(R)
(lenalidomide) plus rituximab (R2) in relapsed/refra... |
| | | 06/06/11 | Phase II Study Evaluating Clinical Benefits of ABRAXANE(R) Plus
Gemcitabine and Bevacizumab as First-Line Treatment in Patients with
Metastatic Breast Cancer Presented at ASCO| Achieved primary endpoint of study with 81% progression free survival
rate at 6 months
BOUDRY, Switzerland, Jun 06, 2011 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that results
from an investigator-initiated phase II study of ABRAXANE (paclitaxel
albumin-bound particles for injectable suspension), gemcitabine and
bevacizumab as first-line treatment in metastatic breast cancer were
presented at the 2011 American Society of... |
| | | 06/06/11 | Two Clinical Studies Evaluating Benefits of ABRAXANE(R)
Combinations in Patients with Unresectable Melanoma Presented at ASCO| Studies report one-year survival rates of nearly 60%
BOUDRY, Switzerland, Jun 06, 2011 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that results
from two investigator initiated studies including ABRAXANE (paclitaxel
albumin-bound particles for injectable suspension), and bevacizumab in
unresectable melanoma were presented at the 2011 American Society of
Clinical Oncology Annual Meeting in Chicago, IL.
In the first study, patie... |
| | | 06/05/11 | Phase II Study Evaluates Clinical Benefit of REVLIMID(R)
in Combination Therapy for Patients with Metastatic Castration-Resistant
Prostate Cancer (MCRPC)| Study reports 86.4% of patients achieved 50% reduction of PSA or
better
BOUDRY, Switzerland, Jun 05, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results
from a phase II investigator initiated study of REVLIMID (lenalidomide)
in combination with Avastin (bevacizumab), docetaxel and prednisone in
patients with metastatic castration-resistant prostate cancer were
presented at the 2011 American Society of Clinical Oncolo... |
| | | 06/04/11 | Final Phase III Data from Study CA031 of ABRAXANE(R)
in Combination with Carboplatin in Patients with Non-Small Cell Lung
Cancer Presented at ASCO| Achieved primary endpoint with significantly improved overall
response rate for patients receiving ABRAXANE combination
Strong trends in favor of ABRAXANE combination in elderly patients
and squamous cell histology
Patients 70 years and older receiving ABRAXANE combination achieved
overall survival of 19.9 months versus 10.4 months in comparator arm
Expect to file ABRAXANE sNDA with FDA as first-line therapy for
patients with NSCLC by year-end
BOUDRY, Switze... |
| | | 05/06/11 | Multiple Phase III Studies Confirm Statistically Significant Clinical
Benefit of Continuous REVLIMID Treatment for Patients with Multiple
Myeloma at International Myeloma Workshop| CALGB Phase III newly diagnosed multiple myeloma study demonstrates
statistically significant overall survival advantage with continuous
REVLIMID versus placebo following autologous stem cell transplant
MM-015 Phase III newly diagnosed multiple myeloma study confirms
continuous treatment with REVLIMID demonstrates statistically
significant improvement in progression-free survival
IFM 0502 Phase III newly diagnosed multiple myeloma study reports
statistic... |
| | | 05/05/11 | Intergroup Phase III Study (CALGB 100104) Reports Overall Survival
Benefit with Revlimid(R) As Continuous Therapy
for Patients with Multiple Myeloma| Phase III Study Demonstrated Statistically Significant (unadjusted
p=0.018) Overall Survival Benefit for Patients Newly Diagnosed with
Multiple Myeloma Receiving Continuous Treatment with Lenalidomide
Compared to Placebo
Patients Receiving Continuous Treatment with Lenalidomide Experienced
a 56% Reduction in the Risk of Disease Progression or Death Compared to
Placebo (p<0.0001)
BOUDRY, Switzerland, May 05, 2011 (BUSINESS WIRE) --Celgene Internation... |
| | | 05/03/11 | Celgene Corporation to Webcast Investor Event During International
Myeloma Workshop| SUMMIT, N.J., May 03, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced senior
management will host a live webcast on Thursday, May 5, 2011 at 1 p.m.
ET to discuss data presented at the International Myeloma Workshop in
Paris. The webcast will be available in the investor relations section
of the company's Web site at www.celgene.com.
This release contains certain forward-looking statements which
involve known and unknown risks... |
| | | 04/28/11 | Celgene Reports Record First Quarter 2011 Operating and Financial
Results| - Non-GAAPTotal Revenue of $1.11 Billion Increased 40 Percent
Y/Y
- Non-GAAP First Quarter Diluted Earnings Per Share of $0.83
Increased 32 Percent Y/Y
- REVLIMID(R) First Quarter Global Net Product
Sales of $738 Million Increased 39 Percent Y/Y
SUMMIT, N.J., Apr 28, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG):
2011 First Quarter Financial Results
Year-Over-Year
Non-GAAP Total Revenue Increas... |
| | | 04/27/11 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Apr 27, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company's
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Monday, May 2, 2011, Celgene will present at the 2011 Deutsche Bank
Healthcare Conference at 1:30 p.m. ET.
On Tuesd... |
| | | 04/13/11 | Celgene Corporation to Announce First Quarter 2011 Results on April
28, 2011 | SUMMIT, N.J., Apr 13, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, April 28, 2011 at 9
a.m. ET to discuss the company's first quarter 2011 financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated g... |
| | | 03/10/11 | Celgene Corporation to Present at Barclays Capital 2011 Global
Healthcare Conference| SUMMIT, N.J., Mar 10, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at Barclays Capital 2011 Global Healthcare Conference on
Tuesday, March 15, 2011 at 1:30 p.m. ET will be webcast live and will be
available in the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 03/03/11 | Celgene Corporation to Present at the Cowen and Company 31st
Annual Health Care Conference| SUMMIT, N.J., Mar 03, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Cowen and Company 31st Annual Health Care
Conference on Wednesday, March 9, 2011 at 10:15 a.m. ET will be webcast
live and will be available in the investor relations section of the
company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jers... |
| | | 02/28/11 | FDA Grants Priority Review For ISTODAX(R) sNDA
For Treatment of Progressive or Relapsed PTCL| PDUFA Date of June 17, 2011 Established
SUMMIT, N.J., Feb 28, 2011 (BUSINESS WIRE) --Celgene Corporation (Nasdaq:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has granted Priority Review classification to
its Supplemental New Drug Application (sNDA) regarding ISTODAX
(romidepsin) for injection for the treatment of peripheral T-cell
lymphoma (PTCL) in patients who have received at least one prior
therapy. The Prescription Drug Us... |
| | | 02/24/11 | Celgene Corporation to Present at the Citi 2011 Global Health Care
Conference| SUMMIT, N.J., Feb 24, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Citi 2011 Global Health Care Conference on Tuesday,
March 1, 2011 at 1:30 p.m. ET will be webcast live and will be available
in the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integr... |
| | | 02/16/11 | Celgene Elects Michael A. Friedman, MD to Board of Directors| SUMMIT, N.J., Feb 16, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced the election of
Michael A. Friedman, MD, to its Board of Directors. Dr. Friedman is an
experienced healthcare leader with a distinguished career in oncology
research, regulatory strategy and public healthcare policy. He currently
serves as President and Chief Executive Officer of City of Hope, a
leading cancer research, treatment and education institution, as we... |
| | | 02/16/11 | Celgene Announces Additional $1 Billion Share Repurchase Program| SUMMIT, N.J., Feb 16, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that the company's
Board of Directors has authorized the repurchase of up to an additional
$1 billion of the Company's common stock through December 2012. This
authorization is in addition to the $500 million authorization announced
on January 10, 2011. The $500 million program announced in April of 2009
has been fully utilized.
Purchases may be made in the... |
| | | 02/16/11 | Vidaza(R) Receives Positive Final Appraisal
Determination from National Institute for Health and Clinical Excellence
(NICE) for Use in the National Health Service (NHS) in England and Wales| Definitive Appraisal Provides First Licensed Therapeutic Option for
MDS in UK
VIDAZA is the First and Only Medicine That Has Been Proven to Prolong
Survival for MDS Patients
VIDAZA is the First of an Innovative Class of Epigenetic Therapies
that Target Cause of Disease
BOUDRY, Switzerland, Feb 16, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (Nasdaq:CELG) today announced that the National Institute
... |
| | | 02/09/11 | Celgene Corporation to Present at ISI Group's 1st
Annual Global Positioning Summit| SUMMIT, N.J., Feb 09, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at ISI Group's 1st Annual Global Positioning
Summit on Monday, February 14, 2011 at 10:00 a.m. ET will be webcast
live and will be available in the investor relations section of the
company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is ... |
| | | 01/27/11 | Celgene Reports Record Non-GAAP Fourth Quarter and Full Year 2010
Operating and Financial Results| - Record Results Driven By Gains in Market Share and Duration of
Therapy, Geographic Expansion and Reimbursement Approvals
- 2010 Non-GAAP Total Revenue Increased 34 Percent Y/Y
- 2010 Non-GAAP Diluted Earnings Per Share Increased 35 Percent Y/Y
SUMMIT, N.J., Jan 27, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG):
2010 Fourth Quarter Financial Results
Year-Over-Year
Non-GAAP Total Revenue Increased 38 Percent t... |
| | | 01/19/11 | Celgene Corporation to Announce Fourth Quarter and Full Year 2010
Results on January 27, 2011| SUMMIT, N.J., Jan 19, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, January 27, 2011 at
9 a.m. ET to discuss the company's fourth quarter and full year 2010
financial and operational results. The webcast will be available in the
investor relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 01/10/11 | Celgene Corporation Reviews 2010 Achievements and Announces 2011
Financial Outlook| Record Results Driven By Gains in Market Share and Duration of
Therapy, Geographic Expansion and Reimbursement Approvals
Non-GAAP Total Revenue Increased Approximately 34 Percent Y/Y
Non-GAAP Diluted Earnings Per Share Increased Nearly 35 Percent Y/Y
Board of Directors Authorized the Repurchase of Up to An Additional
$500 Million of the Company's Common Stock
SUMMIT, N.J., Jan 10, 2011 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG):
2010 Fourth Quarter Financial ... |
| | | 01/04/11 | Celgene Provides Update on Regulatory Submissions| REVLIMID(R) (lenalidomide) Capsules Marketing
Authorisation Application Submitted to EMA for Treatment of Newly
Diagnosed Multiple Myeloma And Maintenance Therapy
ISTODAX(R) (romidepsin) for Injection
Supplemental New Drug Application Submitted to U.S. FDA for Previously
Treated Peripheral T-Cell Lymphoma
BOUDRY, Switzerland, Jan 04, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced regulatory
submissions for its blood cancer t... |
| | | 12/30/10 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Dec 30, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company's
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Thursday, January 6, 2011, Celgene will present at the Goldman Sachs
Healthcare CEOs Unscripted Conference at 3:15 p.m... |
| | | 12/13/10 | Celgene Corporation to Present at 2010 Deutsche Bank BioFEST| SUMMIT, N.J., Dec 13, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 2010 Deutsche Bank BioFEST on Wednesday, December
15, 2010 at 8:30 a.m. ET will be webcast live and will be available in
the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated gl... |
| | | 12/07/10 | Clinical Data from Two Phase II Studies Evaluating REVLIMID(R) Plus
Rituximab in Indolent Non-Hodgkin's Lymphomas Presented at ASH| BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical data
from two investigational studies evaluating the combination of REVLIMID(R)
(lenalidomide) plus rituximab in indolent non-Hodgkin's lymphoma (NHL)
were presented at the 52nd Annual Meeting of the American
Society of Hematology (ASH) in Orlando, FL.
In the first study, treatment with lenalidomide and low-dose
dexamethasone plus ritu... |
| | | 12/07/10 | Retrospective Analysis of Clinical Data from REVLIMID(R)
Phase III Study (MDS-004) Reports a Significant Improvement in Survival
and Risk Reduction in Disease Progression for Patients with del(5Q)
Myelodysplastic Syndromes| Additional Landmark Analysis Reports that Patients Achieving RBC
Transfusion Independence For At Least 26 Weeks Were Associated with
Longer AML-free Survival Times Compared with Non-responders
BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced updated
results from a retrospective analysis of a randomised, international
phase III study of REVLIMID(R) (lenalidomide) for the treatment
of patients w... |
| | | 12/07/10 | Observational Study Demonstrates No Greater Incidence of Progression
to Acute Myeloid Leukemia with REVLIMID(R) in
Patients with Lower-Risk Del(5q) Myelodysplastic Syndromes| BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced the
results of a comparative study evaluating the impact of REVLIMID(R)
(lenalidomide) on the risk of progression to acute myeloid leukaemia
(AML) in patients with low/int-1 risk myelodysplastic syndromes (MDS)
with a del(5q) chromosome abnormality. These results were presented by
investigators from the Groupe Francophone Des Myelodysplasies (GFM) ... |
| | | 12/06/10 | Data from Three Presentations Evaluating Clinical Benefit of
Pomalidomide in Previously Treated Multiple Myeloma Presented at ASH| BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that
its next IMiD(R) compound, pomalidomide, was evaluated in three
separate investigational trials of patients with multiple myeloma who
were relapsed or refractory after prior treatments including
lenalidomide, thalidomide and bortezomib. The clinical data were
presented at the 52nd Annual Meeting of the American Society
of Hematology in... |
| | | 12/06/10 | Continuous Treatment with REVLIMID(R) for
Patients with Multiple Myeloma Following Autologous Stem Cell Transplant
Evaluated by Intergroupe Francophone du Myelome (IFM) of Phase III Study
(IFM 2005 02)| Patients Receiving Continuous Daily Treatment with Lenalidomide
Experienced a 50% reduction in the Risk of Disease Progression Compared
to Placebo
Patients Receiving Continuous Lenalidomide had a Statistically
Significant Median Progression-Free Survival of 42 Months Compared to 24
Months for Patients Receiving Placebo
BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that updated
data from an... |
| | | 12/06/10 | REVLIMID(R) Data in Patients with Multiple
Myeloma Evaluating Surival Rates with Low- and High-Dose Dexamethasone
with Respect to Age| BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from
a randomised clinical study conducted by the Eastern Cooperative
Oncology Group (ECOG) were presented at the 52nd Annual
Meeting of the American Society of Hematology comparing REVLIMID(R)
(lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus
high-dose dexamethasone (RD) in both younger and older newly-diagnosed
... |
| | | 12/06/10 | Updated Clinical Results from REVLIMID(R)
Continuous Treatment Phase III Study Show Statistically Significant
Improvement in Progression-Free Survival in Patients Newly Diagnosed
with Multiple Myeloma| Patients Receiving Continuous Lenalidomide (MPR-R) Experienced a 60%
Reduction in the Risk of Disease Progression Compared to MP and a 69%
Reduction in the Risk of Disease Progression Compared to MPR
BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data
from the planned second interim analysis (median follow-up of 21 months)
of a phase III, randomised, double-blind study of continuous REVLIMID(R)
... |
| | | 12/05/10 | New Clinical Data Evaluating ISTODAX(R) in
Pivotal Open-Label Phase II Study for Patients with Peripheral T-Cell
Lymphoma (PTCL)| Study Reported Primary Endpoint Reached, as 13% of Patients Achieved
a Complete Response
Median Duration of Response Was 12 Months
BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from
a pivotal Phase II, multicenter, international, open-label study of
romidepsin (ISTODAX(R)) in progressive or relapsed PTCL
following prior systemic therapy were presented at the 52nd
American Society ... |
| | | 12/05/10 | Continuous Treatment with REVLIMID(R) for
Patients with Multiple Myeloma Following Autologous Stem Cell Transplant
Evaluated by Intergroup Phase III Study(CALGB 100104)| Patients Receiving Continuous Daily Treatment with Lenalidomide
Experienced a 60% reduction in the Risk of Disease Progression or Death
Compared to Placebo
Patients in Continuous Therapy Arm Also Had a Statistically
Significant Median Progression-Free Survival of 42.3 Months Compared to
21.8 for Placebo
BOUDRY, Switzerland, Dec 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from
a National Cancer Institut... |
| | | 12/04/10 | Clinical Data Evaluating Oral REVLIMID(R)
Either with Rituximab or Following Rituximab Combination for Patients
with Chronic Lymphocytic Leukemia (CLL) Presented at ASH| Study Evaluating REVLIMID as Consolidation Therapy in Patients with
Previously Untreated CLL Reported 91% of Patients Were Still Alive After
a Median Follow-Up of 21 Months
Second Study Evaluating Combination of REVLIMID and Rituximab in
Patients with Relapsed/Refractory CLL Reported an Overall Response Rate
of 63%
BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that clinical
data from two investi... |
| | | 12/04/10 | Phase III Study Evaluating REVLIMID(R) in
Patients with High-Risk Smoldering Multiple Myeloma Reported
Statistically Significant Reduction in Risk of Disease Progression| Study Showed Overall Response Rate of 91% for Patients Who Completed
Initial 9 Treatment Cycles
BOUDRY, Switzerland, Dec 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data
evaluating combination therapy REVLIMID(R) (lenalidomide) and
dexamethasone in patients with high-risk asymptomatic smoldering
multiple myeloma were presented during the American Society of
Hematology's annual meeting. The study reported REVLIMID ... |
| | | 11/30/10 | More Than 260 Presentations and Posters Evaluating Celgene Products to Be Highlighted at the 52nd American Society of Hematology Annual Meeting| BOUDRY, Switzerland, Nov 30, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in more than 260 posters and presentations, including more than 65 oral presentations evaluating Celgene products in blood cancers at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida from December 4-7.
For more information, please visit ... |
| | | 11/26/10 | Celgene Corporation to Present at 22nd Annual Piper Jaffray Health Care Conference| SUMMIT, N.J., Nov 26, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30, 2010 at 9:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical... |
| | | 11/09/10 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Nov 09, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company's
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Thursday, November 11, 2010, Celgene will present at the 2010 Credit
Suisse Healthcare Conference at 8:30 a.m. MT.
... |
| | | 10/29/10 | Celgene Corporation to Present at Oppenheimer's 21st
Annual Healthcare Conference| SUMMIT, N.J., Oct 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at Oppenheimer's 21st Annual Healthcare
Conference on Tuesday, November 2, 2010 at 11:25 a.m. ET will be webcast
live and will be available in the investor relations section of the
company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is a... |
| | | 10/28/10 | Celgene Reports Record Third Quarter 2010 Operating and Financial
Results| Record Third Quarter Results Driven By Share Gains Across Major
Markets
REVLIMID(R) Third Quarter Global Net Product
Sales Increased 43% Y/Y
VIDAZA(R) Third Quarter Global Net Product
Sales Increased 37% Y/Y
Non-GAAP Third Quarter Diluted Earnings Per Share Increased 34% Y/Y
SUMMIT, N.J., Oct 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG):
2010 Third Quarter Financial Results
Year-Over-Year
Non-GAAP Total Revenue Incr... |
| | | 10/18/10 | Celgene Corporation to Announce Third Quarter 2010 Results on October
28, 2010| SUMMIT, N.J., Oct 18, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, October 28, 2010 at
9 a.m. ET to discuss the company's third quarter 2010 financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated... |
| | | 10/15/10 | Celgene Completes Acquisition of Abraxis| SUMMIT, N.J., Oct 15, 2010 (BUSINESS WIRE) --
Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
The CVR's a... |
| | | 10/13/10 | Celgene and Abraxis Announce Shareholder Vote in Favor of Merger| SUMMIT, N.J. & LOS ANGELES, Oct 13, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) and Abraxis Bioscience, Inc. (NASDAQ:
ABII) today announced that Abraxis' shareholders approved the merger
agreement between the companies. The companies anticipate the closing of
the transaction will occur on October 15, 2010.
The transaction will bring Abraxis' targeted cancer therapies, led by
ABRAXANE, and its innovative nab(R) technology together with
... |
| | | 10/05/10 | Celgene Prices $1.25 Billion of Senior Unsecured Notes| Transaction Highlights Lowest Five Year Corporate Coupon and Second
Lowest Ten YearCorporate Coupon on Record for a BBB Issuer
SUMMIT, N.J., Oct 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced the successful
pricing of three series of senior unsecured notes for an aggregate
principal amount of $1.25 billion. Of these notes, $500 million will
mature in October 2015 and will bear interest at an annual rate of
2.45%, $500 mill... |
| | | 10/04/10 | Celgene Announces Offering of Senior Unsecured Notes| SUMMIT, N.J., Oct 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its intention to
offer, subject to market and other conditions, senior unsecured notes
under a shelf registration statement on Form S-3 on file with the
Securities and Exchange Commission. The interest rate, the maturity
dates and other key terms of the offering are to be determined at the
time of pricing.
Celgene expects to use the net proceeds from the of... |
| | | 09/24/10 | Celgene Corporation to Present at the JMP Securities Fifth Annual
Healthcare Conference| SUMMIT, N.J., Sep 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the JMP Securities Fifth Annual Healthcare Conference on
Tuesday, September 28, 2010 at 1:30 p.m. ET will be webcast live and
will be available in the investor relations section of the company's Web
site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jerse... |
| | | 09/15/10 | Celgene Corporation to Present at the UBS 2010 Global Life Sciences
Conference| SUMMIT, N.J., Sep 15, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the UBS 2010 Global Life Sciences Conference on Monday,
September 20, 2010 at 10:30 a.m. ET will be webcast live and will be
available in the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 09/08/10 | Celgene Corporation to Present at Four Upcoming Investor Conferences| SUMMIT, N.J., Sep 08, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at four upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at http://www.celgene.com. Celgene management will provide an overview of the company.
On Monday, September 13, 2010, Celgene will present at the Morgan Stanley Global Healthcare Conference at 8:35 a.m. ET.
On Tuesday, September 14, 2010, C... |
| | | 09/03/10 | Celgene Officially Notified of ANDA Filing for REVLIMID(R)| SUMMIT, N.J., Sep 03, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization to manufacture and market generic versions of REVLIMID(R) (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.
Celgene intends to vigorous... |
| | | 08/26/10 | Celgene Corporation Announces Appointment of Jacqualyn A. Fouse as
Senior Vice President and Chief Financial Officer| SUMMIT, N.J., Aug 26, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) todayannounced the
appointment of Jacqualyn A. Fouse as Senior Vice President and Chief
Financial Officer, effective September 27, 2010. Ms. Fouse will be
responsible for all finance operations at Celgene and will report to
Robert J. Hugin, Chief Executive Officer of Celgene Corporation. Fouse
succeeds David W. Gryska, who served as Senior Vice President and Chief
Finan... |
| | | 08/25/10 | Celgene Expects to Receive a Paragraph IV Notification of an ANDA
Filing for REVLIMID(R)| SUMMIT, N.J., Aug 25, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that information was
posted on the FDA Web site indicating that an Abbreviated New Drug
Application (ANDA) has been received by the Office of Generic Drugs
(OGD) containing a "Paragraph IV" patent certification, for REVLIMID
(lenalidomide) 25 mg capsules. Celgene has not yet received the
Paragraph IV notification letter identifying the filer.
Celgene intend... |
| | | 08/20/10 | REVLIMID(R) Approved for Treatment of Deletion
5q Myelodysplastic Syndromes in Japan| BOUDRY, Switzerland, Aug 20, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID
(lenalidomide) has been granted full marketing authorization by Japan's
Ministry of Health, Labour and Welfare (MHLW) for the treatment of
patients with myelodysplastic syndromes (MDS) associated with a deletion
5q cytogenic abnormality. REVLIMID was also approved in June 2010 in
combination with dexamethasone, for the treatment of patients... |
| | | 08/04/10 | Celgene/Abraxis Receive Verbal Confirmation of Early Termination of
Hart-Scott-Rodino (HSR) 30-Day Waiting Period| SUMMIT, N.J., Aug 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that it has received
verbal confirmation of early termination of the Hart-Scott-Rodino Act
(HSR) 30-day waiting period without the United States Federal Trade
Commission (FTC) requesting additional information with regard to
Celgene's pending acquisition of Abraxis Bioscience, Inc. (NASDAQ: ABII).
Celgene anticipates that the transaction will be completed in the th... |
| | | 07/29/10 | Celgene Reports Record Second Quarter 2010 Operating and Financial Results| Record Second Quarter Results Driven By Market Share Gains Across Major Markets
REVLIMID(R) Second Quarter Global Net Product Sales Increased 48% Y/Y
VIDAZA(R) Second Quarter Global Net Product Sales Increased 43% Y/Y
Non-GAAP Second Quarter Diluted Earnings Per Share Increased 50% Y/Y
SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) --
Celgene Corporation (NASDAQ: CELG):
2010 Second Quarter Financial Results Year-Over-Year
Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GA... |
| | | 07/19/10 | Celgene Corporation to Announce Second Quarter 2010 Results on July
29, 2010| SUMMIT, N.J., Jul 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, July 29, 2010 at 9
a.m. ET to discuss the company's second quarter 2010 financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated g... |
| | | 06/30/10 | Celgene to Acquire Abraxis BioScience Inc.| ABRAXANE(R) Approved for Second-Line Use in
Metastatic Breast Cancer, Establishes Celgene in Solid Tumors
Complementing Its Leadership Position in Blood Cancers
Recent Clinical Data Presented at ASCO and AACR for ABRAXANE in
First-Line Non-small Cell Lung Cancer and First-Line Pancreatic Cancer
Highlights Significant Growth Opportunities
Celgene Reaffirms 2010 Non-GAAP Financial Outlook; Expects
Acquisition to be Modestly Dilutive to Non-GAAP Earnings in... |
| | | 06/24/10 | Revlimid® Granted Approval for Treatment of Relapsed or Refractory Multiple Myeloma in Japan| (June 24, 2010) – Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.
Multiple myeloma is the second m... |
| | | 06/14/10 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Jun 14, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company's
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Thursday, June 17, 2010, Celgene will present at the Goldman Sachs 31st
Annual Healthcare Conference at 10:00 a.m. PT.
... |
| | | 06/12/10 | Updated Results of Phase III Study Evaluating Continuous REVLIMID(R)
Therapy in Newly Diagnosed Multiple Myeloma| BOUDRY, Switzerland, Jun 12, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data
from the planned second interim analysis (median follow-up of 21 months)
of a phase III, randomized, double-blind study of continuous REVLIMID
(lenalidomide) for the treatment of elderly patients with newly
diagnosed multiple myeloma show improvement in progression-free survival
(PFS), the primary endpoint of the study. The data were presented ... |
| | | 06/07/10 | Data from Study of Revlimid(R) in Untreated
Patients with Chronic Lymphocytic Leukemia (CLL) Presented at ASCO| BOUDRY, Switzerland, Jun 07, 2010 (BUSINESS WIRE) --ABSTRACT #6508
Celgene International Sàrl (NASDAQ:CELG) today announced thatresearchers
presented data from an investigator-initiated Phase II study of
lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic
leukemia at the annual meeting of the American Society of Clinical
Oncology.
Results of the Phase II single-arm study reported that at a median
follow-up of 23 months, the overall... |
| | | 06/06/10 | At ASCO, Oral Presentation from Intergroupe Francophone Du Myelome
(IFM) of Phase III Study (IFM 2005 02) Evaluating Continuous REVLIMID(R)
in Patients with Multiple Myeloma Following Autologous Stem Cell
Transplant| BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that
data from an Intergroupe Francophone du Myelome clinical study under the
sponsorship of the University Hospital of Toulouse were presented at the
American Society of Clinical Oncology. Results of the study (IFM 2005
02) demonstrated that patients with multiple myeloma receiving
continuous lenalidomide (REVLIMID) following a first-line autologo... |
| | | 06/06/10 | Oral Presentation at ASCO from Intergroup Phase III Study (CALGB
100104) Evaluates Continuous REVLIMID(R) in Patients with Multiple Myeloma
Following Autologous Stem Cell Transplant| BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that
data from a National Cancer Institute-sponsored clinical study were
presented by representatives of a network of researchers led by the
Cancer and Leukemia Group B (CALGB) at the annual meeting of the
American Society of Clinical Oncology.
Results of the Phase III, randomized, controlled, double-blind,
multi-center clinical study of patient... |
| | | 06/06/10 | Randomized Phase III Study Comparing REVLIMID(R)
Plus Melphalan and Prednisone (MPR) Compared to Autologous Stem Cell
Transplant Presented at ASCO| BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced clinical data
from an investigational study of patients with multiple myeloma who were
younger than 65 years old and received either lenalidomide (REVLIMID),
melphalan and prednisone (MPR) or melphalan plus autologous stem cell
transplant (MEL200) following an induction treatment of lenalidomide
plus low-dose dexamethasone (Rd) were presented at the Amer... |
| | | 06/05/10 | Data from Pomalidomide Study in Refractory Multiple Myeloma Patients
Presented at ASCO| BOUDRY, Switzerland, Jun 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results
of a Phase II study of pomalidomide and dexamethasone in multiple
myeloma patients who have failed both lenalidomide and bortezomib. Data
were presented by Dr. Martha Lacy of the Mayo Clinic during the American
Society of Clinical Oncology annual meeting.
Patients with multiple myeloma who have progressed after multiple
therapies have li... |
| | | 06/04/10 | Evaluation of REVLIMID(R) in Patients with
Either GCB or Non-GCB Diffuse Large B-Cell Lymphoma Presented at ASCO| BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced
researchersat the annual meeting of the American Society of
Clinical Oncology presented data from an evaluation of lenalidomide
(REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either
with a germinal center B-cell (GCB) or non-germinal center B-cell
(non-GCB) phenotype.
Investigators retrospectively analysed pooled patient data f... |
| | | 06/04/10 | Data from Combination of REVLIMID(R) and
Rituxan(R) in Untreated Indolent B-Cell
Non-Hodgkin's Lymphoma Presented at ASCO| BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced that
initial data from an investigator-initiated study of REVLIMID
(lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed
indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the
annual meeting of the American Society of Clinical Oncology.
Patients in the study had previously untreated indolent NHL with stage
III or IV... |
| | | 05/28/10 | Celgene Corporation to Present at Three Upcoming Investor Conferences| SUMMIT, N.J., May 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentations at three upcoming investor conferences will be webcast
live and will be available in the investor relations section of the
company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Thursday, June 3, 2010, Celgene will present at the Sanford C.
Bernstein 26th Annual Strategic Decisions Conference 20... |
| | | 05/27/10 | Celgene Announces Dismissal of Suit against Barr Laboratories
Following Withdrawal of Thalidomide ANDA| SUMMIT, N.J., May 27, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced that as a result of Barr
Laboratories, Inc., withdrawing its Abbreviated New Drug Application
(ANDA) for thalidomide with the US Food and Drug Administration, the US
District Court for the District of New Jersey has granted the requested
dismissal of all claims and counterclaims in the thalidomide patent
cases.
Celgene Corporation, headquartered in Summit, New Jers... |
| | | 05/24/10 | Celgene Corporation to Present at the 2010 Citi Global Health Care
Conference| SUMMIT, N.J., May 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Citi Global Health Care Conference on Wednesday, May
26, 2010 at 11:00 a.m. ET will be webcast live and will be available in
the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated ... |
| | | 05/21/10 | More Than 100 Presentations and Posters Evaluating Celgene Products
to Be Highlighted at Three Major Medical Meetings in June| BOUDRY, Switzerland, May 21, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that clinical
investigators from leading cancer research centers will present data
from recent and on-going clinical trials evaluating Celgene products in
blood cancers and solid tumors at the American Society of Clinical
Oncology (ASCO) Meeting in Chicago, Illinois from June 4-8.
Additionally, clinical data will be presented on Celgene products in... |
| | | 05/05/10 | Celgene Corporation to Present at the Ninth Annual JMP Securities
Research Conference| SUMMIT, N.J., May 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Ninth Annual JMP Securities Research Conference on
Monday, May 10, 2010 at 9:30 a.m. PT will be webcast live and will be
available in the investor relations section of the company's Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
in... |
| | | 04/29/10 | Celgene Reports Record First Quarter 2010 Operating and Financial
Results| Record First Quarter Results Driven By Gains in Market Share and
Duration of Therapy Across Global Markets
REVLIMID(R) First Quarter Global Net Product
Sales Increased 46% Y/Y
VIDAZA(R) First Quarter Global Net Product
Sales Increased 60% Y/Y
Non-GAAP Diluted Earnings Per Share Increased 43% Y/Y
SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG):
2010 First Quarter Financial Results
Year-Over-Year
Non-GAAP... |
| | | 04/29/10 | Celgene Corporation Announces Senior Management Succession| SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its senior management succession plan. As of the Company's annual meeting, scheduled on June 16, 2010, Dr. Sol J. Barer currently Chief Executive Officer, will be appointed Executive Chairman of the Board of Directors through December 31, 2010 and Robert J. Hugin, currently President and Chief Operating Officer, will be appointed Chief Executive Officer of Celgene Corporation.
Dr. Barer has served a... |
| | | 04/19/10 | Celgene Corporation to Announce First Quarter 2010 Results on April
29, 2010| SUMMIT, N.J., Apr 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, April 29, 2010 at 9
a.m. ET to discuss the company's first quarter 2010 financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated glo... |
| | | 03/18/10 | Celgene Corporation to Present at the Barclays Capital 2010 Global
Healthcare Conference| SUMMIT, N.J., Mar 18, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Barclays Capital 2010 Global Healthcare Conference
on Wednesday, March 24, 2010 at 10:45 a.m. ET will be webcast live and
will be available in the investor relations section of the company's Web
site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, ... |
| | | 02/25/10 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Feb 25, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company's
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Wednesday, March 3, 2010, Celgene will present at the RBC Capital
Markets 2010 Healthcare Conference at 8:00 a.m. ET.
... |
| | | 01/28/10 | Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income|
Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals
REVLIMID(R) Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q
VIDAZA(R) Fourth Quarter Global Net Product Sales Increased 68% Y/Y and 13% Q/Q
Full Year Non-GAAP Diluted Earnings Per Share Increased 33% Y/Y
SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG):
2009 Fourth Quarter Financial Results Year-Over-Y... |
| | | 01/19/10 | Celgene Corporation to Announce Fourth Quarter and Full-Year 2009
Results on January 28, 2010| SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, January 28, 2010 at
9 a.m. ET to discuss the company's fourth quarter and full-year 2009
financial and operational results. The webcast will be available in the
investor relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 01/15/10 | Celgene Completes Acquisition of Gloucester Pharmaceuticals| Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 millionCommercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its
acquisition of Gloucester Pharmaceuticals following the early
termination of the applicable waiting period u... |
| | | 01/12/10 | Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005
02) Evaluating Treatment with Continuous REVLIMID(R)
in Patients with Multiple Myeloma Following Autologous Stem Cell
Transplant Meets Primary Endpoint| BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that
the Intergroupe Francophone du Myelome and University Hospital of
Toulouse, the sponsor of the study, reported that the independent Data
and Safety Monitoring Committee, of the international Phase III,
randomized, double-blind, multi-center clinical study (IFM 2005 02)
evaluating REVLIMID(R) (lenalidomide) compared to placebo in
multi... |
| | | 01/11/10 | Celgene Corporation Reviews 2009 Achievements and Announces 2010
Financial Outlook| _ Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals î REVLIMID(R) Fourth Quarter Global Net Product Sales Increased Nearly 35% Y/Y î VIDAZA(R) Fourth Quarter Global Net Product Sales Increased Nearly 65% Y/Y î Full Year Non-GAAP Diluted Earnings Per Share Increased More Than 30 % Y/Y î Conducting 20 Phase III and Pivotal Clinical TrialsSUMMIT, N.J., Jan 11, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG)... |
| | | 01/06/10 | Celgene Corporation to Present at the 28th
Annual JPMorgan Healthcare Conference| SUMMIT, N.J., Jan 06, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 28th Annual JPMorgan Healthcare
Conference on Monday, January 11, 2010 at 8:00 AM PST (11:00 AM EST)
will be webcast live and will be available in the investor relations
section of the company's Web site at www.celgene.com.
Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide
an overview of the company.
Celgen... |
| | | 12/18/09 | Initial Data from CALGB-Led Study of Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Reported| Study showed statistically significant improvement in time to disease progressionSUMMIT, N.J., Dec 18, 2009 (BUSINESS WIRE) -- Celgene Corporation (Nasdaq:CELG) today announced the National Cancer
Institute (NCI), a part of the National Institutes of Health, reported
initial data from a Phase III, randomized, double-blind, multi-center
clinical study led by the Cancer and Leukemia Group B (CALGB). The
investigational study evaluated REVLIMID(R) compared to placebo... |
| | | 12/16/09 | Celgene Corporation Elects Carrie S. Cox to Board of Directors| SUMMIT, N.J., Dec 16, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced the election of
Carrie S. Cox to the Company's Board of Directors. Ms. Cox is an
experienced corporate director with a distinguished career in global
healthcare. She has served as executive vice president and president of
Schering-Plough's Global Pharmaceutical Business, one of the largest and
most successful multi-national healthcare companies in the world. Before
... |
| | | 12/15/09 | Positive Phase IIb Topline Clinical Data for Celgene Oral Compound
Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe
Psoriasis| Placebo-controlled, four-arm study met its primary endpoint at 16 weeksStudy demonstrates PASI-75 of 41% for apremilast 30mg twice daily compared to 6% for placebo (p<0.001) at 16 weeks; apremilast was also generally well-toleratedPivotal phase III studies evaluatingapremilast in inflammatory conditions to begin in 2010SUMMIT, N.J., Dec 15, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) announced clinical data from an
investigational Phase IIb, double-blind, placebo-control... |
| | | 12/11/09 | Celgene Corporation to Present at Deutsche Bank Securities Biotech Boston Confab Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 11, 2009--
Celgene Corporation (NASDAQ:CELG) today announced its presentation at
the Deutsche Bank Securities Biotech Boston Confab Conference on
Tuesday, December 15, 2009 at 11:00 a.m. ET will be webcast live and
will be available in the investor relations section of the company’s Web
site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquart... |
| | | 12/07/09 | Multi-Centre, Randomised, Controlled Study Results Evaluating the
Clinical Potential of REVLIMID(R) in Patients
with Smoldering Multiple Myeloma Presented at ASH| After a Median Follow-Up of 14 Months, 4% of Patients with High-Risk Smoldering Multiple Myeloma Treated with REVLIMID-Based Therapy Had Progressed to Symptomatic Myeloma Compared to 34% of Patients not Offered REVLIMID-Based TherapyIn the Study, Oral Treatment with REVLIMID Demonstrated an 81% Response Rate in Patients with High-Risk Smoldering Multiple MyelomaBOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) announced that data
evaluating com... |
| | | 12/07/09 | First Interim Analysis after Less Than 10-Months of Phase III Study
Shows That Continuous REVLIMID(R) Therapy is
Superior to Fixed Duration Regimens in Newly Diagnosed Elderly Multiple
Myeloma Patients | After less than ten months of median follow-up, elderly patients treated with MPR-R had a 50 percent reduction in the risk of disease progression or death compared to those who received MP aloneAt the first interim analysis, the median progression-free survival in the MPR-R arm was not reached, compared with a progression-free survival of 13 months in the MP arm (p<0.001)At first interim analysis, a statistically significant improvement in the overall response rate including VGPR and time to ... |
| | | 12/07/09 | Two Studies Evaluating the Clinical Potential of Pomalidomide for the
Treatment of Multiple Myeloma Patients Refractory to Novel Therapies
Presented at the American Society of Hematology Meeting| BOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) today announced that its
next-generation IMiD(R) immunomodulatory compound, pomalidomide was
evaluated in two separate investigational trials of patients with
multiple myeloma (MM) who were relapsed or refractory after treatment
with REVLIMID(R) or REVLIMID and bortezomib. Data were presented at the
51st American Society of Hematology meeting in New Orleans, LA.
... |
| | | 12/07/09 | First Randomised Study Comparing All-Oral REVLIMID(R)
Regimen Compared to Autologous Stem Cell Transplant Presented at ASH| Study Reported Patients in Both Treatment Arms Achieved a 91% Progression-Free Survival Rate at 12 MonthsBOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) announced clinical data
from an investigational study of patients with multiple myeloma who were
younger than 65 years old and received either REVLIMID (lenalidomide),
melphalan and prednisone (MPR) or melphalan plus autologous stem cell
transplant (MEL200) following a... |
| | | 12/07/09 | Phase II Data Evaluating REVLIMID(R) +
Rituximab in Relapsed Patients with Chronic Lymphocytic Leukaemia
Presented at American Society of Hematology| Combination Therapy of REVLIMID/Rituximab Achieved 64% Response Rate, in Patients Who Had Received Prior Treatments, Including RituximabBOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) announced that data
evaluating combination therapy with REVLIMID (lenalidomide) and
rituximab in patients with relapsed chronic lymphocytic leukaemia (CLL)
were presented during the 51st American Society of Hematology
annual meeting in Ne... |
| | | 12/07/09 | Celgene to Acquire Gloucester Pharmaceuticals| Commercial Launch of Novel HDAC Inhibitor, ISTODAX® (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted for Early 2010
ISTODAX Registration Special Protocol Assessment (SPA) Trial for Peripheral T-Cell Lymphoma (PTCL) - Accrual Expected to be Completed Early Next Year
Acquisition Expected to be Neutral to Non-GAAP Diluted Earnings in 2010 and Accretive in 2011
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) a... |
| | | 12/07/09 | Celgene to Acquire Gloucester Pharmaceuticals|
Commercial Launch of Novel HDAC Inhibitor, ISTODAX®
(romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Targeted for Early 2010
ISTODAX Registration Special Protocol Assessment (SPA) Trial for
Peripheral T-Cell Lymphoma (PTCL) - Accrual Expected to be
Completed Early Next Year
Acquisition Expected to be Neutral to Non-GAAP Diluted Earnings in
2010 and Accretive in 2011
SUMMIT, N.J. & C... |
| | | 11/27/09 | Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 27, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the NASDAQ OMX 23rd Investor Program on
Tuesday, December 1, 2009 at 8:30 a.m. GMT will be webcast live and will
be available in the investor relations section of the company’s Web site
at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, N... |
| | | 11/13/09 | Celgene Corporation to Present at the Lazard Capital Markets 6th Annual Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 13, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Lazard Capital Markets 6th Annual
Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will
be webcast live and will be available in the investor relations section
of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquarter... |
| | | 11/11/09 | More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 11, 2009--
Celgene Corporation (NASDAQ: CELG) today announced that clinical
investigators from leading hematology research centers around the world
will present data from more than 200 recent and on-going clinical trials
of Celgene products including REVLIMID®, VIDAZA®,
THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st
Annual American Society of Hematology Meeting and Exposition from
December 5-8, 2... |
| | | 11/06/09 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 6, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
On Tuesday, November 10, 2009, Celgene will present at the Merriman
Curhan Ford 6th Annual Inves... |
| | | 10/30/09 | Celgene Corporation to Present at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 30, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Oppenheimer & Co. Inc. 20th Annual
Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET
will be webcast live and will be available in the investor relations
section of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporati... |
| | | 10/22/09 | Celgene Reports Record Third Quarter 2009 Operating and Financial Results|
Record Third Quarter Results Driven By Gains in Global Market Share,
Duration of Therapy and Reimbursement Approvals
REVLIMID® Third Quarter Global Sales
Increased 31% Y/Y and 13% Q/Q
REVLIMID U.S. Total Share Increased to
Approximately 34%; Strong Share Gains in Second and Third Lines of
Therapy in Europe
VIDAZA® Third Quarter Global Sales Increased
62% Y/Y and 12% Q/Q
First Interim Analysis o... |
| | | 10/19/09 | Updated Data from Randomized Controlled Phase II Study Evaluating Oral Apremilast in Psoriatic Arthritis Demonstrates Sustained Response at Six Months|
Study Extension Demonstrates ACR20 of 40% and 39% for 20mg BID and
40mg QD of Apremilast, Respectively, at 24 Weeks
Activity and Safety Profile Supports Initiation of Pivotal Phase
III Studies in the First Half of 2010
SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 19, 2009--
Celgene Corporation (NASDAQ: CELG) announced that updated results of a
phase II, multi-center, randomized, double-blind, placebo-controlled,
three-arm study of a... |
| | | 10/13/09 | Celgene Corporation to Announce Third Quarter Results on October 22, 2009| SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 13, 2009--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, October 22, 2009 at
9 a.m. EDT to discuss the company’s third quarter financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, i... |
| | | 09/30/09 | Celgene Corporation to Present at the JMP Securities Fourth Annual Healthcare Focus Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 30, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the JMP Securities Fourth Annual Healthcare Focus
Conference on Monday, October 5, 2009 at 1:30 p.m. ET will be webcast
live and will be available in the investor relations section of the
company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headq... |
| | | 09/17/09 | Celgene Corporation to Present at the UBS Global Life Sciences Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 17, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the UBS Global Life Sciences Conference on Tuesday,
September 22, 2009 at 1:30 p.m. ET will be webcast live and will be
available in the investor relations section of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New ... |
| | | 09/11/09 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 11, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Monday, September 14, 2009, Celgene will present at the 2009 Morgan
Stanley Global Healthcare U... |
| | | 09/02/09 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J., Sep 02, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company's
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Wednesday, September 9, 2009, Celgene will present at the Thomas Weisel
Partners Healthcare Conference 2009 at 8:00 a.m. ET.... |
| | | 08/05/09 | Clinical Data Evaluating Amrubicin(R) as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 5, 2009--
Celgene Corporation (NASDAQ: CELG) today announced the presentation of
final results from two company-sponsored studies of Amrubicin in
relapsed small cell lung cancer (SCLC) at the 13th World
Conference on Lung Cancer in San Francisco, Calif. The presentations
included safety and efficacy data of two phase II studies of the
next-generation therapy in second-line patients with SCLC both sensitive
a... |
| | | 08/05/09 | VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network (NCCN) in Its Clinical Practice Guidelines| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 5, 2009--
Celgene Corporation (Nasdaq: CELG) today announced that the National
Comprehensive Cancer Network (NCCN) has updated its Clinical Practice
Guidelines in Oncology™ v1.2010 and has upgraded VIDAZA® to a Category 1
recommended treatment for patients with intermediate-2 and high-risk
myelodysplastic syndromes (MDS).
The NCCN consensus recommendation was based on the recent update to the
... |
| | | 08/03/09 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 3, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Wednesday, August 5, 2009, Celgene will present at the BMO Capital
Markets 9th Annual Focus on Healthcar... |
| | | 07/23/09 | Celgene Reports Record Second Quarter 2009 Operating and Financial Results| SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 23, 2009--
Celgene Corporation (NASDAQ:CELG):
REVLIMID® Pivotal MM-015 Trial Exceeds
Pre-Specified Interim Efficacy Endpoint in Newly Diagnosed Multiple
Myeloma
REVLIMID and VIDAZA® Gains in Market Share
and Duration of Therapy Drive Second Quarter Record Results
2009 Second Quarter Financial Results
Year-Over-Year:
Non-GAAP Total Revenue Increased More... |
| | | 07/09/09 | Celgene Corporation to Announce Second Quarter Results on July 23, 2009| SUMMIT, N.J., Jul 09, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, July 23, 2009 at 9
a.m. EDT to discuss the company's second quarter financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global b... |
| | | 07/07/09 | Celgene Announces New Drug Application Filing for REVLIMID(R) in Japan| BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 7, 2009--
Celgene International Sàrl (NASDAQ:CELG) today announced it has filed a
New Drug Application (NDA) with the Japanese Ministry of Health, Labour
and Welfare (MHLW) for REVLIMID (lenalidomide) in combination with
dexamethasone for the treatment of patients with multiple myeloma who
have received at least one prior therapy. Approximately 11,000 people in
Japan suffer from multiple myeloma and around 4... |
| | | 06/17/09 | Celgene Corporation to Present at Two Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 17, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at two upcoming investor conferences will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Thursday, June 18, 2009, Celgene will present at the Jefferies 3rd
Annual Healthcare Conference... |
| | | 06/15/09 | Celgene Announces Positive Top Line Data from Randomized Controlled Phase II Study of Apremilast in Psoriatic Arthritis| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 15, 2009--
Celgene Corporation (NASDAQ: CELG) announced the preliminary results of
a phase II, multi-center, randomized, double-blind, placebo-controlled,
three-arm study of apremilast - a novel, orally available small molecule
that exhibits anti- inflammatory activities through the suppression of
multiple pro-inflammatory mediators and cytokines - in adult patients
with psoriatic arthritis (CC-10004-PSA-001). The ... |
| | | 06/08/09 | Innovative Therapy Improving Responses, Survival in Multiple Myeloma Patients According to Presentations at the 14th Congress of the European Hematology Association| BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 8, 2009--
Celgene International Sàrl (NASDAQ: CELG) announced that data from
multiple studies presented at the 14th Congress of the
European Society of Hematology demonstrate that REVLIMID provides
powerful and sustained responses in patients with multiple myeloma.
These key presentations support the advantage of active long-term
disease control along with manageable safety profiles, leading to
unprec... |
| | | 06/08/09 | Presentations at the 14th Congress of the European Hematology Association Demonstrate VIDAZA(R) Benefits Patients with Myelodysplastic Syndromes| BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 8, 2009--
Celgene International Sàrl (NASDAQ: CELG) announced that data presented
at the 14th Congress of the European Society of Hematology
demonstrate that treatment with VIDAZA significantly extends overall
survival and helps patients with myelodysplastic syndromes (MDS) become
or remain red blood cell transfusion independent. Patients who benefited
included those with higher-risk MDS or acute myeloid leu... |
| | | 06/04/09 | Celgene Corporation to Present at Three Upcoming Investor Conferences| SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 4, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentations at three upcoming investor conferences will be webcast
live and will be available in the investor relations section of the
company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Tuesday, June 9, 2009, Celgene will present at the William Blair &
Company Growth Stock Conference at ... |
| | | 06/02/09 | Data From REVLIMID(R) VIDAZA(R) and Amrubicin Clinical Trials Reported in Expanded Haematology and Oncology Indications| Celgene Products Highlighted Across Multiple Diseases During 45th American Society of Clinical Oncology Meeting
BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 2, 2009--
Celgene International Sàrl (NASDAQ: CELG) announced the results of
multiple studies presented at the 45th American Society of
Clinical Oncology meeting between May 30 and June 1, 2009 in Orlando,
Florida. Key posters and presentations by clinical oncologists from
around the world included studi... |
| | | 05/26/09 | 59 Presentations and Posters Evaluating Celgene Products to Be Highlighted at the 45th American Society of Clinical Oncology Meeting| SUMMIT, N.J.--(BUSINESS WIRE)--May. 26, 2009--
Celgene Corporation (NASDAQ: CELG) today announced that clinical
investigators from leading cancer research centers will present data
from recent and on-going clinical trials of multiple Celgene products in
blood cancers and solid tumors at the 45th American Society
of Clinical Oncology (ASCO) Meeting in Orlando, Florida from May 29 –
June 2, 2009.
For more information and for complete abs... |
| | | 05/21/09 | Celgene Corporation to Present at the Sanford C. Bernstein & Co. Strategic Decisions Conference 2009| SUMMIT, N.J.--(BUSINESS WIRE)--May. 21, 2009--
Celgene Corporation (NASDAQ:CELG) today announced its
presentation at the Sanford C. Bernstein Strategic Decisions Conference
2009 on May 27, 2009 at 8:00 a.m. ET will be webcast live and will be
available in the investor relations section of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit,... |
| | | 05/18/09 | Celgene Corporation to Present at the Eighth Annual JMP Securities Research Conference| SUMMIT, NJ--(BUSINESS WIRE)--May. 18, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Eighth Annual JMP Securities Research Conference on
Wednesday, May 20, 2009 at 9:00 a.m. PT will be webcast live and will be
available in the investor relations section of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summi... |
| | | 05/15/09 | Celgene Corporation to Present at the Deutsche Bank 34th Annual Health Care Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May. 15, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Deutsche Bank 34th Annual Health Care
Conference on Tuesday, May 19, 2009 at 8:10 a.m. ET will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit... |
| | | 05/11/09 | Celgene Corporation to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May. 11, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Bank of America and Merrill Lynch 2009 Health Care
Conference on Wednesday, May 13, 2009 at 2:40 p.m. ET will be webcast
live and will be available in the investor relations section of the
company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, ... |
| | | 05/11/09 | Celgene Corporation to Present at Baird's 2009 Growth Stock Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May. 11, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at Baird’s 2009 Growth Stock Conference on Wednesday, May
13, 2009 at 8:55 a.m. CT will be webcast live and will be available in
the investor relations section of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New J... |
| | | 04/30/09 | Celgene Reports First Quarter 2009 Operating and Financial Results| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, 2009--
Celgene Corporation (NASDAQ: CELG):
REVLIMID® Continues Gains
in Multiple Myeloma Both in Market Share and Duration in US and
International Markets
REVLIMID Recommended by U.K. National Institute for Health and
Clinical Excellence in Multiple Myeloma Through Final Appraisal
Determination
VIDAZA® Market Share
Gains Cont... |
| | | 04/27/09 | Celgene Announces Share Repurchase Program| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 27, 2009--
Celgene Corporation (NASDAQ: CELG) today announced that the company's
Board of Directors has authorized the repurchase of up to $500 million
of the Company's common stock through April 2011.
Purchases may be made in the open market or in privately negotiated
transactions from time to time, as determined by Celgene’s management
and in accordance with the requirements of the Securities and ... |
| | | 04/24/09 | Celgene Corporation to Announce First Quarter Results on April 30, 2009| SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 24, 2009--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, April 30, 2009 at 9
a.m. EDT to discuss the company’s first quarter financial and
operational results. The webcast will be available in the investor
relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 04/23/09 | REVLIMID(R) Receives Positive Final Appraisal Determination from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales| BOUDRY, Switzerland--(BUSINESS WIRE)--Apr. 23, 2009--
Celgene International Sàrl (Nasdaq:CELG) today announced that the
National Institute for Health and Clinical Excellence (NICE) has issued
a Final Appraisal Determination (FAD) recommending REVLIMID, in
combination with dexamethasone, within its licensed indication, as an
option for the treatment of patients in England and Wales with multiple
myeloma who have received two or more prior therapies. N... |
| | | 03/31/09 | Celgene Corporation to Present at the 4(th) Annual Citi Biotech Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 31, 2009--
Celgene Corporation (NASDAQ: CELG) announced that Sol J. Barer, Ph.D.,
Chairman and Chief Executive Officer of Celgene will provide an overview
of corporate developments and outlook for 2009 milestones at the 4th
Annual Citi Biotech Day. During 2009, Celgene expects to advance
multiple clinical, regulatory, commercial and financial initiatives in
all areas of its global operations, underscored by the rec... |
| | | 03/25/09 | Celgene Corporation to Present at 4th Annual Citi Biotech Day| SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 25, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 4th Annual Citi Biotech Day on Wednesday,
April 1st, 2009 at 9:20 a.m. EDT will be webcast live and will be
available in the investor relations section of the company’s Web site at www.celgene.com.
Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide
an overview of the company.
Celgene Corporation... |
| | | 03/23/09 | Celgene Corporation to Present at the Needham & Company, LLC Cancer Therapeutics: Today and Tomorrow Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 23, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Needham & Company Cancer Therapeutics: Today and
Tomorrow Conference on Thursday March 26, 2009 at 8:00 a.m. EDT will be
webcast live and will be available in the investor relations section of
the company’s Web site at www.celgene.com.
David. W. Gryka, Senior Vice President and Chief Financial Officer, will
provid... |
| | | 03/13/09 | Celgene Corporation to Present at the Cowen and Company 29th Annual Health Care Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 13, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Cowen and Company 29th Annual Health Care
Conference on Tuesday, March 17, 2009 at 8 a.m. EDT will be webcast live
and will be available in the investor relations section of the company’s
Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquarter... |
| | | 03/06/09 | Celgene Corporation to Present at the Barclays Capital Global Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 6, 2009--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Barclays Capital Global Healthcare Conference on
Tuesday, March 10, 2009 at 9 a.m. EDT will be webcast live and will be
available in the investor relations section of the company’s Web site at www.celgene.com.
Celgene management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, N... |
| | | 02/26/09 | 70 Abstracts Evaluating the Potential of Celgene Products in Multiple Myeloma to Be Presented at the 12th International Myeloma Workshop| Key Clinical Data Reinforce the Importance of Overall Survival and Long-Term Disease Control to Successful Myeloma Treatment
SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 26, 2009--
Celgene Corporation (NASDAQ: CELG) today announced that clinical
investigators from leading hematology research centers around the world
will present data from recent and ongoing clinical trials of multiple
Celgene products at the 12th International Myeloma Workshop
from February 26 – Ma... |
| | | 02/17/09 | Landmark Study Published in The Lancet Oncology Shows Celgene's Vidaza(R) Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia| BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 17, 2009--
Celgene International Sàrl (Nasdaq:CELG) today announced the publication
in the journal The Lancet Oncology of the results from AZA-001,
the largest international, randomized, Phase III study ever conducted in
patients with higher-risk myelodysplastic syndromes (MDS). The data
indicate that VIDAZA (azacitidine) demonstrated a significant extension
of overall survival compared to conventional care ... |
| | | 02/06/09 | Celgene Corporation to Present at the 11th Annual BIO CEO Investor Conference| SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 11th Annual BIO CEO Investor Conference
on Monday, February 9, 2009 at 2:45 p.m. EST will be webcast live and
will be available in the investor relations section of the company’s Web
site at www.celgene.com.
Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide
an overview of the company.
Celgene C... |
| | | 01/30/09 | REVLIMID(R) Receives Preliminary Positive Recommendation from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales| BOUDRY, Switzerland--(BUSINESS WIRE)--
Celgene International Sàrl (Nasdaq:CELG):
NICE considers the benefits provided by REVLIMID to be life-extending
and a cost-effective use of NHS resources
NHS will fully fund the use of oral REVLIMID for 26 treatment cycles
of 28 days per cycle (normally two years) for patients with previously
treated multiple myeloma
Celgene will fully fund the... |
| | | 01/29/09 | Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits| SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ: CELG):
REVLIMID® #1 Therapy in Multiple
Myeloma Worldwide
European Launch of VIDAZA®
Commencing
REVLIMID U.S. Duration of Therapy Increased Greater Than 25
Percent Year-Over-Year to More Than 10 Months
Global Expansion from Nearly 30 to More Than 65 Countries
2008 Fourth Quarte... |
| | | 01/21/09 | Celgene Corporation to Announce Fourth Quarter and Full-Year 2008 Results on January 29, 2009| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 21, 2009--Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, January 29, 2009 at
9 a.m. EST to discuss the company's fourth quarter and full-year 2008
financial and operational results. The webcast will be available in the
investor relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jerse... |
| | | 01/12/09 | Celgene Corporation Reviews 2008 Achievements and Announces 2009 Financial Outlook| Significant Fourth Quarter Growth Propels REVLIMID(R) to the Global Market Leader in Multiple MyelomaSUMMIT, N.J., Jan 12, 2009 (BUSINESS WIRE) -- Exceptional 2008 Operating Performance Exceeding Annual Guidance with
Record Revenue and Profit Growth
--
Total Revenue for 2008 Increased to Approximately $2.233 Billion
(Unaudited)
--
REVLIMID Net Product Sales in 2008 Increased More Than 71 Percent
Year-Over-Year to Approximately $1.324 Billion (Una... |
| | | 01/09/09 | Celgene Corporation to Present at the 27th Annual JPMorgan Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 9, 2009--Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 27th Annual JPMorgan Healthcare
Conference on Monday, January 12, 2009 at 11 a.m. EST will be webcast
live and will be available in the investor relations section of the
company's Web site at www.celgene.com.
Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide
an overview of the company.
Celgene Co... |
| | | 12/23/08 | European Commission Grants VIDAZA(R) Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukaemia (AML)| BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 23, 2008--Celgene International Sarl (Nasdaq:CELG):
First and Only Epigenetic Cancer Therapy Proven to Significantly Extend
Survival for Patients with Intermediate-2 and Higher-Risk MDS and AML
First Approved Therapy Effective across Broad Range of MDS Subgroups, as
well as Acute Myeloid Leukaemia (AML) with 20-30 percent Blasts and
Multi-Lineage Dysplasia, as Classified by the World Health Organizat... |
| | | 12/10/08 | Promising Results from Two Trials Highlighting Developmental Oral IMiDS(R) Compound Pomalidomide Presented at the American Society of Hematology Meeting| Pomalidomide Demonstrated Significant Activity in Treatment of Refractory Multiple Myeloma and Myelofibrosis
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2008--Celgene International Sarl (Nasdaq: CELG) today announced that its next
IMiDs compound, pomalidomide, has shown promising activity with
manageable safety and tolerability for the treatment of
relapsed/refractory multiple myeloma (MM) and myelofibrosis. The data
were presented at the 50th Annual America... |
| | | 12/09/08 | Updated REVLIMID(R) Data in Newly-Diagnosed Multiple Myeloma Reports Unprecedented Three-Year Survival Rates in Phase III ECOG E4A03 Study| REVLIMID and Low-Dose Dexamethasone As Continuous Therapy in the Front Line Setting is Associated With Robust Responses and is Well Tolerated According to Study
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 9, 2008--Celgene International Sarl (Nasdaq:CELG) today announced more mature
data from clinical studies of REVLIMID (lenalidomide) in newly-diagnosed
multiple myeloma were presented at a joint symposium of the American
Society of Clinical Oncology (ASCO) and the Amer... |
| | | 12/08/08 | Landmark Analysis Shows Continuous Treatment With REVLIMID(R) Plus Dexamethasone Significantly Increases Overall Survival in Multiple Myeloma Patients| Analysis from Two Phase III REVLIMID Studies (MM-009 and MM-010) in Patients with Relapsed/Refractory Multiple Myeloma
At Two Years, in Patients with at least Stable Disease, Nearly 94 Percent who Continued Therapy for More Than Ten Months Were Alive, Compared to Less Than 50 Percent who Discontinued Treatment Early
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) announced that
data from a landmark analysis of patients with relapsed/... |
| | | 12/08/08 | Premier Cooperative Group in Adult Lymphoma Research Chooses REVLIMID(R) for Major Study in Disease's Largest Patient Population| Celgene and GELA Announce Collaboration in an International, Randomized, Double-Blind, Placebo-Controlled, Phase III Maintenance Study in Diffuse Large B-Cell LymphomaBOUDRY, Switzerland & PARIS, Dec 08, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq: CELG) and the Groupe d'Etude
des Lymphomes de l'Adulte (GELA) today announced the initiation of an
international randomized, double-blind, controlled Phase III study to
evaluate the therapeutic potential of REVLI... |
| | | 12/08/08 | ASH Presentation Shows Continued Treatment with VIDAZA(R) Improves Responses in Patients with Higher-Risk Myelodysplastic Syndromes| 51 Percent Overall Response Rate (CR + PR) with Immediate and Chronic TherapyBOUDRY, Switzerland, Dec 08, 2008 (BUSINESS WIRE) -- Celgene International Sarl (NASDAQ: CELG) reports that an analysis
presented today of a phase III international clinical trial (AZA-001) of
higher-risk patients with myelodysplastic syndromes (MDS), demonstrated
that continued treatment with VIDAZA (azacitidine) can improve patient
responses. The data were presented at the 50th Annual
... |
| | | 12/08/08 | Study Presented at the American Society of Hematology Reports REVLIMID(R) Activity in Patients with Relapsed/Refractory Mantle-Cell Lymphoma| Encouraging Response to REVLIMID Reported in International Phase II Study of Heavily Pretreated Patients with Specific Type of Non-Hodgkins Lypmhoma
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) announced updated
clinical data from the NHL-003 study, a 200 patient open label,
multi-center study of patients with relapsed/refractory mantle cell
lymphoma (MCL) who had received at least one prior therapy. The subset
ana... |
| | | 12/08/08 | Updated Data Evaluating Clinical Benefit Of REVLIMID(R) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma Presented At ASH| REVLIMID Monotherapy Demonstrates Activity, Durability and Tolerability in This Subset of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients from International Phase II Study
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) announced updated
clinical data from an ongoing REVLIMID (lenalidomide) study of patients
with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) during
the 50th Annual Meeting of the Americ... |
| | | 12/08/08 | ASH Presentation of a Phase I Study of REVLIMID(R) and VIDAZA(R) in Higher-Risk MDS Reports Combination is Well-Tolerated and has High Activity| Combination had a 39 Percent Complete Response and 72 Percent Overall Response
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) reported that results
of a Phase I study presented today combining REVLIMID and VIDAZA in
patients with higher-risk myelodysplastic syndromes (MDS) found that the
combination of these two therapies is well tolerated and has high
activity. The data were reported during the 50th Annual
... |
| | | 12/08/08 | VIDAZA(R) AZA-001 Study Reports Unprecedented Survival Benefit in Higher-Risk MDS Extends to AML Patients| Subset Analysis of the AZA-001 Study Showed the Median Overall Survival was 24.5 Months with VIDAZA Compared to 16.0 Months with CCR (p=0.005)
BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) today announced results from a
subset analysis of the international phase III trial (AZA-001)
demonstrating that the overall survival benefit observed in higher-risk
MDS patients extends to patients with acute myeloid leukemia (AML). T... |
| | | 12/07/08 | Two ASH Presentations Report REVLIMID(R) Activity and Tolerability in Patients with Previously Untreated Symptomatic Chronic Lymphocytic Leukemia| Greater Than 90 Percent Disease Control Achieved Across All Evaluable PatientsBOUDRY, Switzerland, Dec 07, 2008 (BUSINESS WIRE) -- --Based on These Data Celgene is Actively Enrolling Patients in the CONTINUUM(TM) Trial, a Phase III Global SPA Study in Maintenance Setting and Plans to Open a Global Phase III Registration Trial in Untreated Symptomatic Elderly Patients
Celgene International Sarl (NASDAQ: CELG) reported two
REVLIMID (lenalidomide) Phase II studies, presented today at the 5... |
| | | 11/17/08 | Celgene Corporation to Present at the Lazard Capital Markets 5th Annual Healthcare Conference| SUMMIT, N.J., Nov 17, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Lazard Capital Markets 5th Annual
Healthcare Conference on Wednesday, November 19, 2008 at 9:30 a.m. EST
will be webcast live and will be available in the investor relations
section of the company's Web site at www.celgene.com.
David W. Gryska, Senior Vice President and Chief Financial Officer, will
provide an overview of the com... |
| | | 11/11/08 | 128 Abstracts Evaluating Celgene Products to Be Presented at the 50th Annual American Society of Hematology Meeting| - 35 Oral Presentations Highlighting Celgene Products Across Broad
Range of Blood Cancers
BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 11, 2008--Celgene
International Sarl (NASDAQ: CELG) today announced that clinical
investigators from leading hematology research centers around the
world will present data from recent and on-going clinical trials of
multiple Celgene products at the 50th Annual American Society of
Hematology Meeting and Exposition from December 6-9,... |
| | | 11/10/08 | Celgene Cellular Therapeutics Receives FDA Clearance for First Placenta-Derived Stem Cell Clinical Study| -- Trial is First Application of Company's Proprietary Cell
Therapy Product--
WARREN, N.J.--(BUSINESS WIRE)--Nov. 10, 2008--Celgene Cellular
Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation
(NASDAQ: CELG), today announced the U.S. Food and Drug Administration
(FDA) has accepted the company's investigational new drug application
to initiate a clinical trial using PDA001, an immunomodulatory therapy
utilizing human placenta-derived stem... |
| | | 11/07/08 | Celgene Corporation to Present at the 2008 Credit Suisse Annual Health Care Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 7, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the 2008 Credit
Suisse Annual Health Care Conference on Wednesday, November 12, 2008
at 11:00 a.m. EST will be webcast live and will be available in the
investor relations section of the company's Web site at
www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer, will provide an overview of the company.
Celgene Corporation, headquartered... |
| | | 11/06/08 | Celgene Corporation to Present at the Rodman & Renshaw Annual Global Investment Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 6, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Rodman &
Renshaw Annual Global Investment Conference on Tuesday, November 11,
2008 at 9:30 a.m. EST will be webcast live and will be available in
the investor relations section of the company's Web site at
www.celgene.com. Perry Karsen, Senior Vice President of Business
Development, will provide an overview of the company.
Celgene Corporation, headquartered... |
| | | 10/31/08 | Celgene Corporation to Present at the Oppenheimer 19th Annual Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 31, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Oppenheimer
19th Annual Healthcare Conference on Monday, November 3, 2008 at 10:40
a.m. EST will be webcast live and will be available in the investor
relations section of the company's Web site at www.celgene.com. Robert
J. Hugin, President and Chief Operating Officer, will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New Je... |
| | | 10/24/08 | Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML| -- Committee for Medicinal Products for Human Use (CHMP) recommends approval of VIDAZA for treatment of MDS and AML
BOUDRY, Switzerland--(BUSINESS WIRE)--
Celgene International Sarl (Nasdaq:CELG) today announced that its
cancer drug, VIDAZA(R) (azacitidine), has received a positive opinion
from the European Medicines Agency's Committee for Medicinal Products
for Human Use (CHMP) for the treatment of adult patients who are not
eligible for haematopoietic stem cell transplantation with:
... |
| | | 10/23/08 | Celgene Reports Record Third Quarter 2008 Product Sales and Operating Profits| SUMMIT, N.J.--(BUSINESS WIRE)--
2008 Third Quarter Financial Results Year-Over-Year
Non-GAAP Total Revenue Increased 68 Percent to $587 Million;
GAAP Total Revenue $592 Million
REVLIMID(R) Net Product Sales Increased 72 Percent to $343
Million
Global THALOMID(R)/Thalidomide Net Product Sales Reached $132
Million
VIDAZA(R) Net Product Sales Achieved $64 Million, an Increase
of 50 Percent Versus $42 Million in Q3 2007 VIDAZA Sales by
... |
| | | 10/17/08 | Celgene Corporation to Announce Third Quarter Results on October 23, 2008| SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, October 23, 2008
at 9:00 a.m. EDT to discuss the Company's third quarter financial and
operational results. The webcast will be available in the investor
relations section of the Company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engage... |
| | | 10/06/08 | Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma| BOUDRY, Switzerland, Oct 06, 2008 (BUSINESS WIRE) -- Celgene International SArl (NASDAQ: CELG)
announced that its oral cancer drug REVLIMID (lenalidomide) has received
marketing authorization approval from Health Canada for use in
combination with dexamethasone as a treatment for patients with multiple
myeloma who have received at least one prior therapy. Multiple myeloma
is the second most commonly diagnosed blood cancer worldwide.
Approximately 6... |
| | | 10/03/08 | Celgene Corporation to Present at the Third Annual JMP Securities Healthcare Focus Conference| SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Third Annual JMP Securities Healthcare Focus
Conference on Tuesday, October 7, 2008 at 10:30 a.m. EDT will be
webcast live and will be available in the investor relations section
of the company's Web site at www.celgene.com. Perry Karsen, Senior
Vice President of Business Development, will provide an overview of
the company.
Celgene Corporation, headquartered in Summit, New ... |
| | | 09/19/08 | Celgene Corporation to Present at the UBS 2008 Global Life Sciences Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 19, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the UBS 2008 Global
Life Sciences Conference on Tuesday, September 23, 2008 at 8:00 a.m.
EDT will be webcast live and will be available in the investor
relations section of the company's Web site at www.celgene.com. Sol J.
Barer, Ph.D., Chairman and Chief Executive Officer, will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New J... |
| | | 09/12/08 | Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical Biotech and Medical Devices Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 12, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Merrill Lynch
Global Pharmaceutical Biotech and Medical Devices Conference on
Tuesday, September 16, 2008 at 11:10 a.m. EDT will be webcast live and
will be available in the investor relations section of the company's
Web site at www.celgene.com. David W. Gryska, Senior Vice President
and Chief Financial Officer, will provide an overview of the company.
Celgene... |
| | | 09/12/08 | Celgene Corporation to Present at the Bank of America 38th Annual Investment Conference| SUMMIT, N.J., Sep 12, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Bank of America 38th Annual
Investment Conference on Tuesday, September 16, 2008 at 7:00 p.m. EDT
will be webcast live and will be available in the investor relations
section of the company's Web site at www.celgene.com.
Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide
an overview of the company.
Celgene C... |
| | | 09/05/08 | Celgene Corporation to Present at Morgan Stanley Global Healthcare Unplugged Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 5, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Morgan Stanley
Global Healthcare Unplugged Conference on Tuesday, September 9, 2008
at 11:30 a.m. EDT will be webcast live and will be available in the
investor relations section of the company's Web site at
www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer, will provide an overview of the company.
Celgene Corporation, headquart... |
| | | 09/04/08 | Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 4, 2008--Celgene Corporation
(NASDAQ: CELG) today announced that Amrubicin has been granted Fast
Track product designation by the U.S. Food and Drug Administration
(FDA) for the treatment of small cell lung cancer after first-line
chemotherapy.
A drug designated as a Fast Track product is intended for the
treatment of a serious or life-threatening condition and demonstrates
the potential to provide a therapy where none exists or provide a
ther... |
| | | 09/03/08 | Celgene Corporation to Present at the Thomas Weisel Partners Experts in Growth Healthcare Conference 2008| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 3, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Thomas Weisel
Partners Experts in Growth Healthcare Conference 2008 on Friday,
September 5, 2008 at 9:10 a.m. EDT will be webcast live and will be
available in the investor relations section of the company's Web site
at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive
Officer, will provide an overview of the company.
Celgene Corporation, headqu... |
| | | 09/03/08 | Celgene Corporation to Present at the 3rd Annual Citi Biotech Day| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 3, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the 3rd Annual Citi
Biotech Day on Monday, September 8, 2008 at 9:00 a.m. EDT will be
webcast live and will be available in the investor relations section
of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D.,
Chairman and Chief Executive Officer, will provide an overview of the
company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 09/02/08 | Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 2, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the NewsMakers in
the Biotech Industry Conference on Thursday, September 4, 2008 at 2:00
p.m. EDT will be webcast live and will be available in the investor
relations section of the company's Web site at www.celgene.com. David
W. Gryska, Senior Vice President and Chief Financial Officer, will
provide an overview of the company.
Celgene Corporation, headquartered i... |
| | | 09/01/08 | Journal of Clinical Oncology Reports REVLIMID(R) Demonstrates Activity against Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)| BOUDRY, Switzerland--(BUSINESS WIRE)--Sept. 1, 2008--Celgene
International Sarl (Nasdaq:CELG) today announced the publication of
peer-reviewed data from a Phase II study of REVLIMID in relapsed or
refractory aggressive non-Hodgkin's lymphoma in the Journal of
Clinical Oncology. According to the data, REVLIMID, as an oral
monotherapy, demonstrated activity in patients at an advanced stage of
the disease who had received a median of four prior treatments and had
limited treatment option... |
| | | 08/21/08 | VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS| First and only drug to significantly extend survival for
patients with higher-risk MDS
First drug approved by FDA for treatment of all MDS risk
categories
First drug to achieve a transfusion independence rate of greater
than 40 percent across all MDS risk categories
First MDS drug approved with multiple routes of administration
(SC and IV)
SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 21, 2008--Celgene Corporation
(Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded
U.S. Foo... |
| | | 08/05/08 | Celgene Corporation to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 5, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Bank of America
2008 Specialty Pharmaceuticals Conference on Friday, August 8, 2008 at
8:45 a.m. EDT will be webcast live and will be available in the
investor relations section of the company's Web site at
www.celgene.com. Perry Karsen, Senior Vice President of Business
Development, will provide an overview of the company.
Celgene Corporation, headquartered in S... |
| | | 08/01/08 | Celgene Corporation to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference| SUMMIT, N.J., Aug 01, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the BMO Capital Markets 2008 Focus on Healthcare
Conference on Tuesday, August 5, 2008 at 8:30 a.m. EDT will be webcast
live and will be available in the investor relations section of the
company's website at www.celgene.com. Sol J. Barer, Ph.D., Chairman
and Chief Executive Officer, will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New J... |
| | | 07/24/08 | Celgene Reports Record Second Quarter 2008 Product Sales and Operating Profits|
SUMMIT, N.J.--(BUSINESS WIRE)--July 24, 2008--
2008 Second Quarter Financial Results Year-Over-Year
Non-GAAP Total Revenues Increased 63 Percent to $566.6
Million; GAAP Total Revenues $571.5 Million
REVLIMID(R) Net Product Sales Increased 80 Percent to $325.8
Million
Global THALOMID(R)/Thalidomide Net Product Sales Reached
$131.6 Million
VIDAZA(R) Net Product Sales Achieved $59.7 Million
Non-GAAP Operating Income Increased 60 ... |
| | | 07/18/08 | Celgene Corporation to Announce Second Quarter 2008 Results| SUMMIT, N.J.--(BUSINESS WIRE)--July 18, 2008--Celgene Corporation
(NASDAQ: CELG) senior management will host a conference call and live
audio webcast on Thursday, July 24, 2008 at 9:00am EDT to discuss the
company's second quarter financial and operational results. The
webcast will be available in the investor relations section of the
company's website at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company en... |
| | | 06/19/08 | Celgene Corporation to Present at Jefferies 2nd Annual Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--June 19, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at Jefferies 2nd
Annual Healthcare Conference on Wednesday, June 25, 2008 at 9:30 a.m.
EDT will be webcast live and will be available in the investor
relations section of the company's website at www.celgene.com. David
W. Gryska, Senior Vice President and Chief Financial Officer, will
provide an overview of the company.
Celgene Corporation, headquartered in Summit, New... |
| | | 06/17/08 | Celgene Corporation to Present at William Blair & Company's 28th Annual Growth Stock Conference| SUMMIT, N.J.--(BUSINESS WIRE)--June 17, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at William Blair &
Company's 28th Annual Growth Stock Conference on Thursday, June 19,
2008 at 7:30 a.m. CDT will be webcast live and will be available in
the investor relations section of the company's website at
www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer, will provide an overview of the company.
Celgene Corporation, headquarte... |
| | | 06/17/08 | Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology Association Congress| BOUDRY, Switzerland, Jun 17, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq: CELG):
-- Study of VIDAZA in Higher-Risk MDS Patients Reports Improved
Overall Survival
-- New Analysis of Phase III Studies Shows REVLIMID Plus
Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life
Years for Patients with Multiple Myeloma
-- Health Economic Analysis Reports that REVLIMID is a Cost
Effective Treatment for Multiple Myeloma
-- Preliminar... |
| | | 06/16/08 | REVLIMID(R) Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress| COPENHAGEN, Denmark--(BUSINESS WIRE)--June 16, 2008--Data from the
ECOG E4A03 and SWOG 0232 studies were reported at a Satellite
Symposium and showed that newly diagnosed multiple myeloma patients
who are eligible for a transplant, obtain better outcomes when treated
with REVLIMID (lenalidomide) plus dexamethasone. The data were
presented by Dr A. Stewart, from the Mayo Clinic at the 13th European
Hematology Association (EHA) congress in Copenhagen, Denmark.
These data from the ... |
| | | 06/14/08 | Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma| COPENHAGEN, Denmark--(BUSINESS WIRE)--June 14, 2008--Celgene
International Sarl (Nasdaq:CELG) today announced that preliminary data
from an international study of single agent REVLIMID (lenalidomide) in
relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) were
presented at the 13th Congress of the European Hematology Association
(EHA) in Copenhagen, Denmark.
In this study of heavily pretreated patients, 83 were eligible for
response evaluation. An objective response was obs... |
| | | 06/14/08 | New Analysis of Phase III Studies Shows That REVLIMID(R) Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma| Longer Survival Than Previously DemonstratedCOPENHAGEN, Denmark, Jun 14, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq:CELG) today announced that
according to data from a pooled study presented at the 13th European
Hematology Association (EHA) congress in Copenhagen, Denmark, multiple
myeloma patients taking REVLIMID(R) (lenalidomide) plus dexamethasone
significantly increased their survival rates. A lifetime simulation
yielded an estimated mean survival of 5.6 life-years with ... |
| | | 06/14/08 | Health Economic Analysis Reports That Revlimid is a Cost Effective Treatment for Multiple Myeloma| COPENHAGEN, Denmark--(BUSINESS WIRE)--June 14, 2008--Celgene
International Sarl (Nasdaq:CELG) announced that data presented today
at the 13th Congress of the European Hematology Association (EHA) in
Copenhagen, Denmark found that patients previously treated for
multiple myeloma receiving REVLIMID (lenalidomide) in combination with
dexamethasone experienced a significant survival gain regardless of
the number of prior therapies they had received.
The results showed that not only wa... |
| | | 06/13/08 | Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival| COPENHAGEN, Denmark--(BUSINESS WIRE)--June 13, 2008--Celgene
International Sarl (Nasdaq:CELG) today announced results from a
sub-analysis of a previously reported large, randomized phase III
study (AZA-001), which showed that treatment with VIDAZA (azacitidine)
prolonged overall survival for patients with high-risk myelodysplastic
syndromes (MDS) when compared to conventional care regimens (CCR).
This analysis evaluated a sub-group of patients (n=94) who were
pre-selected to receive l... |
| | | 06/13/08 | VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU| Survival analysis pooled results from France, Germany, Italy,
Spain, UK, Sweden, Greece and the Netherlands
COPENHAGEN, Denmark--(BUSINESS WIRE)--June 13, 2008--Celgene
International Sarl (Nasdaq:CELG) today announced that data showed
VIDAZA (azacitidine) provides a significant overall survival benefit
for patients with higher-risk myelodysplastic syndromes (MDS)
regardless of whether patients were treated with low-dose Ara-C or
best supportive care in the control arm... |
| | | 06/10/08 | Key Presentations of Celgene Products to Be Highlighted at the 13th European Hematology Association Congress| BOUDRY, Switzerland, Jun 10, 2008 (BUSINESS WIRE) -- Celgene International Sarl (NASDAQ: CELG) today announced that
clinical investigators from leading hematology research centers will
present data from recent and on-going clinical trials of multiple
Celgene products at the 13th European Hematology Association Congress
in Copenhagen, Denmark from June 12 - 15, 2008. These presentations
will highlight new efficacy and survival results, with important
studies highlighting new health economic... |
| | | 06/09/08 | Celgene Corporation to Present at Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference| SUMMIT, N.J.--(BUSINESS WIRE)--June 9, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the Seventh Annual
Needham & Company, LLC Biotechnology and Medical Technology Conference
on Wednesday, June 11, 2008 at 10:00 a.m. EDT will be webcast live and
will be available in the investor relations section of the Company's
Web site at www.celgene.com. David W. Gryska, Senior Vice President
and Chief Financial Officer, will provide an overview of the company.
C... |
| | | 06/09/08 | Celgene Corporation to Present at Goldman Sachs 29th Annual Global Healthcare Conference| SUMMIT, N.J., Jun 09, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the Goldman Sachs 29th Annual Global Healthcare
Conference on Wednesday, June 11th, 2008 at 10:00 a.m. PDT will be
webcast live and will be available in the investor relations section
of the Company's Web site at www.celgene.com. Sol Barer, Ph.D.,
Chairman and Chief Executive Officer, will provide an overview of the
company.
Celgene Corporation, headquartered in Summit, New... |
| | | 06/03/08 | Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival| SUMMIT, N.J.--(BUSINESS WIRE)--June 3, 2008--Celgene Corporation
(Nasdaq:CELG) today announced updated results from a Phase III
international clinical trial of VIDAZA in patients with
myelodysplastic syndromes demonstrated an extension of overall
survival compared to conventional care regimens (CCR). The data were
presented at the 44th Annual American Society of Clinical Oncology
meeting in Chicago, IL.
In the study, the two-year survival rate for patients treated with
VIDAZA was... |
| | | 06/02/08 | Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes| BOUDRY, Switzerland--(BUSINESS WIRE)--June 2, 2008--Celgene
International Sarl (NASDAQ: CELG) announced that, following
discussions with the European Medicines Agency (EMEA) and the EMEA's
Committee for Medicinal Products for Human use (CHMP), it has
withdrawn its Marketing Authorization Application (MAA) for
Lenalidomide - Celgene Europe (lenalidomide), which was intended for
the treatment of patients with transfusion-dependent anemia due to
low- or intermediate-1-risk myelodysplasti... |
| | | 06/02/08 | Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population| SUMMIT, N.J.--(BUSINESS WIRE)--June 2, 2008--Celgene Corporation
(Nasdaq:CELG) today announced physicians from leading medical centers
presented data from two Phase II clinical studies of amrubicin in
patients with extensive-disease small-cell lung cancer (SCLC) either
sensitive to platinum-based first-line therapy or refractory to
platinum-based first-line therapy. Results of the studies demonstrated
improved overall response rates that compare favorably with topotecan,
as well as no... |
| | | 06/01/08 | Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting|
In a four-month landmark analysis of ECOG Phase III study
E4A03, patients who continued on treatment of REVLIMID plus
low-dose dexamethasone (Rd) achieved a two-year overall
survival rate of 93 percent
In the same landmark analysis, patients who went on to
autologous stem cell transplant achieved the same two-year
survival rate of 93 percent
Patients in the landmark analysis who received Rd achieved an
overall response rate of ... |
| | | 06/01/08 | Updated REVLIMID(R) Results Presented In Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO| BOUDRY, Switzerland, Jun 01, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq:CELG) today announced
preliminary data were presented from an international study of single
agent REVLIMID in relapsed/refractory non-Hodgkin's lymphoma (NHL-003,
Abstract #8509). The data was presented at the 44th Annual American
Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
In this study of heavily pretreated patients, 83 were eligible for
response evaluation. An objective response was o... |
| | | 05/26/08 | Celgene Corporation to Present at FBR Capital Markets Spring Investor Conference| SUMMIT, N.J., May 26, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the FBR Capital Markets Spring Investor Conference on
Wednesday, May 28, 2008 at 11:15 a.m. EDT will be webcast live and
will be available in the investor relations section of the Company's
Web site at www.celgene.com. Perry Karsen, Senior Vice President of
Business Development, will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey... |
| | | 05/20/08 | Celgene Corporation to Present at 2008 Citi Investment Research Global Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May 20, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the 2008 Citi
Investment Research Global Healthcare Conference on Thursday, May 22,
2008 at 3:30pm EDT will be webcast live and will be available in the
investor relations section of the Company's website at
www.celgene.com. Robert J. Hugin, President and Chief Operating
Officer, will provide an overview of the company.
Celgene Corporation, headquartered in Summit, N... |
| | | 05/19/08 | Celgene Corporation to Present at NASDAQ OMX 21st Investor Program| SUMMIT, N.J.--(BUSINESS WIRE)--May 19, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at the NASDAQ OMX 21st
Investor Program on Wednesday, May 21, 2008 at 8:30am BST will be
webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. David W. Gryska, Senior
Vice President and Chief Financial Officer, will provide an overview
of the company.
Celgene Corporation, headquartered in Summit, New Jersey, ... |
| | | 05/19/08 | Celgene Corporation to Present at The Seventh Annual JMP Securities Research Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May 19, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at The Seventh Annual
JMP Securities Research Conference on Wednesday, May 21, 2008 at
10:30am PDT will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. Perry
Karsen, Senior Vice President of Business Development, will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, N... |
| | | 05/16/08 | 75 Abstracts Evaluating Celgene Products to Be Presented at The 44th American Society of Clinical Oncology Meeting| SUMMIT, N.J.--(BUSINESS WIRE)--May 16, 2008--Celgene Corporation
(NASDAQ: CELG) today announced that clinical investigators from
leading cancer research centers will present data from recent and
on-going clinical trials of multiple Celgene products in blood cancers
and solid tumors at the 44th American Society of Clinical Oncology
(ASCO) Meeting in Chicago, Illinois from May 31 - June 3, 2008.
For more information and for complete abstracts, please visit
www.asco.org.
Celgene... |
| | | 05/12/08 | Celgene Corporation to Present at Bank of America's 2008 Healthcare Conference| SUMMIT, N.J., May 12, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at Bank of America's 2008 Healthcare Conference on
Wednesday, May 14, 2008 at 4:40 p.m. PDT will be webcast live and will
be available in the investor relations section of the Company's
website at www.celgene.com. Robert J. Hugin, President and Chief
Operating Officer will provide an overview of the Company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integ... |
| | | 05/09/08 | Celgene Corporation to Present at Baird's 2008 Growth Stock Conference| SUMMIT, N.J.--(BUSINESS WIRE)--May 9, 2008--Celgene Corporation
(NASDAQ: CELG) today announced its presentation at Baird's 2008 Growth
Stock Conference on Tuesday, May 13, 2008 at 11:50 a.m. CDT will be
webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. David W. Gryska, Senior
Vice President and Chief Financial Officer will provide an overview of
the company.
Celgene Corporation, headquartered in Summit, New Jersey, is... |
| | | 05/08/08 | Celgene Reports Record First Quarter 2008 Product Sales and Operating Profits|
SUMMIT, N.J.--(BUSINESS WIRE)--May 8, 2008--
2008 First Quarter Financial Results Year-Over-Year
Non-GAAP Total Revenues Increased 57 Percent to $461.0
Million; GAAP Total Revenues $462.6 Million
REVLIMID(R) Net Product Sales Increased 96 Percent to $286.8
Million
THALOMID(R) Net Product Sales Reached $113.9 Million
Non-GAAP Operating Income Increased 96 Percent to $188.4
Million; GAAP Operating Loss $1.63 Billion due to Acquisition
... |
| | | 05/02/08 | Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells|
-- First Application is Pediatric Patient with Acute Lymphoblastic
Leukemia (ALL) --
-- Study in Collaboration with Louisiana State University
Children's Hospital and Morgan Stanley Children's Hospital of
NewYork-Presbyterian and Columbia University Medical Center
WARREN, N.J.--(BUSINESS WIRE)--May 2, 2008--Celgene Cellular
Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation
(NASDAQ: CELG), today announced the cli... |
| | | 04/30/08 | Celgene Corporation to Announce First Quarter Results on May 8, 2008| SUMMIT, N.J.--(BUSINESS WIRE)--April 30, 2008--Celgene Corporation
(NASDAQ: CELG) senior management will host a conference call and live
audio webcast on Thursday, May 8, 2008 at 9:00 am EDT to discuss the
Company's first quarter financial and operational results. The webcast
will be available in the investor relations section of the Company's
website at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company eng... |
| | | 04/29/08 | Celgene Corporation to Present at Morgan Stanley Healthcare Unplugged Conference| SUMMIT, N.J.--(BUSINESS WIRE)--April 29, 2008--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Morgan
Stanley Healthcare Unplugged Conference on Thursday, May 1, 2008 at
3:40 pm EDT will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. Robert
J. Hugin, President and Chief Operating Officer will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New J... |
| | | 04/21/08 | Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union| BOUDRY, Switzerland--(BUSINESS WIRE)--April 21, 2008--Celgene
International Sarl (NASDAQ: CELG) announced that Thalidomide Pharmion
has been granted full marketing authorization by the European
Commission for use in combination with melphalan and prednisone as a
treatment for patients with newly diagnosed multiple myeloma. In June
2007, the European Commission granted the Company's REVLIMID(R) full
marketing authorization as the first oral treatment in more than 40
years for patients ... |
| | | 04/11/08 | Amrubicinis Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer| BOUDRY, Switzerland--(BUSINESS WIRE)--April 11, 2008--Celgene
International Sarl (NASDAQ: CELG) today announced that amrubicin
hydrochloride has been designated as an orphan medicinal product by
the European Commission (EC) for the treatment of small cell lung
cancer following the favorable opinion of the European Medicines
Agency's (EMEA) Committee for Orphan Medicinal Products (COMP).
Criteria for designation of orphan medicinal product require that
the product be intended for... |
| | | 04/07/08 | Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma| BOUDRY, Switzerland, Apr 07, 2008 (BUSINESS WIRE) -- Celgene International Sarl (NASDAQ: CELG) today announced the
Australian Therapeutic Goods Administration (TGA) approved a
supplemental filing granting Thalidomide Pharmion marketing approval
for use in combination with melphalan and prednisone for patients with
untreated multiple myeloma or ineligible for high dose chemotherapy.
Additionally, Thalidomide Pharmion was granted marketing approval in
combination with dexamethasone for induc... |
| | | 03/25/08 | Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer| SUMMIT, N.J.--(BUSINESS WIRE)--March 25, 2008--Celgene Corporation
(NASDAQ: CELG) today announced that Amrubicin has been granted orphan
drug designation by the U.S. Food and Drug Administration (FDA) for
the treatment of small cell lung cancer.
FDA's Orphan Drug Act was designed to encourage the development of
products that demonstrate promise for the diagnosis, prevention and/or
treatment of life-threatening or very serious conditions that are rare
and affect 200,000 persons or ... |
| | | 03/14/08 | Celgene Corporation to Present at Lehman Brothers Global Healthcare Conference| SUMMIT, N.J., Mar 14, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the Lehman Brothers Global Healthcare Conference on
Tuesday, March 18, 2008 at 5:15 pm EDT will be webcast live and will
be available in the investor relations section of the Company's
website at www.celgene.com. Robert J. Hugin, President and Chief
Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an... |
| | | 03/13/08 | Celgene Corporation to Present at Cowen Health Care Conference| SUMMIT, N.J.--(BUSINESS WIRE)--March 13, 2008--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Cowen
Health Care Conference on Monday, March 17, 2008 at 1:45 pm EDT will
be webcast live and will be available in the investor relations
section of the Company's website at www.celgene.com. David W. Gryska,
Senior Vice President and Chief Financial Officer will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, ... |
| | | 03/10/08 | Celgene Corporation to Present at Bear Stearns London Healthcare Conference| SUMMIT, N.J., Mar 10, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the Bear Stearns London Healthcare Conference on
Thursday, March 13, 2008 at 8:45 am GMT will be webcast live and will
be available in the investor relations section of the Company's
website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive
Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
inte... |
| | | 03/07/08 | Celgene Completes $2.9 Billion Acquisition of Pharmion|
Acquisition moves Celgene closer to becoming a leading global
hematology/oncology company
Combined company will bring together three innovative
disease-altering therapies and a deep pipeline in cancer and
inflammation
SUMMIT, N.J.--(BUSINESS WIRE)--March 7, 2008--Celgene Corporation
(NASDAQ: CELG) today announced it has closed its $2.9 billion
acquisition of Pharmion Corporation. Pharmion shareholders will
rec... |
| | | 03/06/08 | Celgene and Pharmion Announce Shareholder Vote in Favor of Acquisition of Pharmion|
Acquisition moves Celgene closer to becoming a leading global
hematology/oncology company
Combined company will bring together three innovative
disease-altering therapies and a deep pipeline in cancer and
inflammation
SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--March 6,
2008--Celgene Corporation (NASDAQ: CELG) and Pharmion Corporation
(NASDAQ: PHRM) today announced that Pharmion's shareholders approved
the... |
| | | 02/19/08 | Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications| Ministry of Health, Labour and Welfare grants designation in both
deletion 5q MDS and previously treated multiple myeloma
BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 19, 2008--Celgene
International Sarl (NASDAQ: CELG) announced that lenalidomide
(CC-5013) has been granted orphan drug status by Japan's Ministry of
Health, Labour and Welfare (MHLW) for two different indications: the
treatment of both anemia due to low- or intermediate-1-risk
myelodysplastic syndromes (MDS) as... |
| | | 02/04/08 | Clinical Data Reported on Celgene Compound Apremilast (CC-10004) Evaluating Efficacy, Safety and Quality of Life Improvement for Psoriasis Patients| Updated results presented at 66th American Academy of Dermatology
Meeting
SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 4, 2008--Celgene Corporation
(NASDAQ: CELG) announced that clinical data from a completed Phase II
study of apremilast (CC-10004) in patients with moderate-to-severe
plaque-type psoriasis were presented for the first time at the 66th
American Academy of Dermatology meeting in San Antonio, Texas on
Saturday, Feb. 2, 2008.
Kim Papp, M.D.,... |
| | | 02/04/08 | Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference| SUMMIT, N.J., Feb 04, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced that its
presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology
and Medical Device Conference on Wednesday, Feb. 6, 2008 at 8:40 am
EST will be webcast live and will be available in the investor
relations section of the Company's Web site at www.celgene.com. Sol J.
Barer, Chairman and Chief Executive Officer will provide an overview
of the company.
Celgene Corporation, headquar... |
| | | 01/31/08 | Celgene Reports Record Fourth Quarter and Full Year 2007 Product Sales and Operating Profits| 2007 Fourth Quarter Financial Results Year-Over-Year:
Total Revenue Increased 51 Percent to $414.6 Million
REVLIMID® Net Product Sales Increased 100 Percent to $247.4 Million
THALOMID® Net Product Sales Increased to $112.6 Million
Adjusted Operating Income Increased 97 Percent to $156.5 Million
Adjusted Net Income Increased 78 Percent to $132.8 Million
Adjusted Earnings Per Share Increased 72 Percent to $0.31 Per Diluted
Share
2007 Full Year Financial Re... |
| | | 01/28/08 | German Federal Cartel Office Clears Celgene to Acquire Pharmion| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 28, 2008--Celgene Corporation
(NASDAQ: CELG) and Pharmion Corporation (NASDAQ: PHRM) announced that
the Bundeskartellamt, Germany's Federal Cartel Office in charge of
reviewing the antitrust aspects of mergers and acquisitions, has
cleared Celgene's pending acquisition of Pharmion Corporation.
As previously announced on January 3, 2008, the 30-day waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended, expired ... |
| | | 01/28/08 | Celgene Corporation to Present at Wachovia Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 28, 2008--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Wachovia
Healthcare Conference on Thursday, January 31, 2008 at 1:30 pm EST
will be available in the investor relations section of the Company's
website at www.celgene.com. David W. Gryska, Senior Vice President and
Chief Financial Officer, will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated gl... |
| | | 01/25/08 | Celgene Corporation to Announce Fourth Quarter and Year-End 2007 Results on January 31, 2008| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 25, 2008--Celgene Corporation
(NASDAQ: CELG) senior management will host a conference call and live
audio webcast on Thursday, January 31, 2008 at 9:00 am EST to discuss
the Company's fourth quarter and year-end operational results. The
webcast will be available in the investor relations section of the
Company's website at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company... |
| | | 01/24/08 | Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes|
REVLIMID in combination with dexamethasone receives Marketing
Authorisation Approval for relapsed/refractory multiple myeloma in
Australia
REVLIMID receives conditional Marketing Authorisation Approval for
deletion 5q MDS in Canada
Lenalidomide - Celgene Europe receives Negative Opinion on
Marketing Authorisation Application for deletion 5q MDS in European
Union (EU)
BOUDRY, Sw... |
| | | 01/06/08 | Celgene Corporation Reviews 2007 Achievements and Announces 2008 Financial Outlook| SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 6, 2008--
Company Reports Record Operating Performance in 2007 Driven by
Extraordinary Revenue and Profit Growth
Total Revenue for 2007 Increased More Than 50 Percent
Year-Over-Year to Approximately $1.4 Billion (Unaudited)
REVLIMID(R) Net Product Sales in 2007 Increased More Than 140
Percent Year-Over-Year to a Range of $770-775 Million
(Unaudited)
REVLIMID Net Product Sales in Fourth Quarter 2007 Incre... |
| | | 01/03/08 | Celgene/Pharmion Hart-Scott-Rodino (HSR) Thirty Day Waiting Period Expires| SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3,
2008--Celgene Corporation (NASDAQ: CELG) and Pharmion Corporation
(NASDAQ: PHRM) today jointly announced that the waiting period under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
has expired without the United States Federal Trade Commission
requesting additional information with regard to Celgene's pending
acquisition of Pharmion.
The Companies anticipate that the transaction will close in April
of... |
| | | 12/20/07 | Celgene Will Provide Fourth Quarter and Full-Year 2007 Guidance at the 26th Annual JP Morgan Healthcare Conference| Company will provide full-year 2008 guidanceSUMMIT, N.J., Dec 20, 2007 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced Chief Executive
Officer Sol J. Barer, Ph.D., will present fourth quarter and full-year
2007 and 2008 guidance during a presentation at the JP Morgan
Healthcare Conference on Monday, January 7, 2008 at 11:30 am EST. The
event will be webcast live and will be available in the investor
relations section of the Company's Web site at www.celgene.com.
Celge... |
| | | 12/05/07 | 113 Abstracts Evaluating Celgene Products to Be Presented at the 49th American Society of Hematology Meeting| Sixty-five Abstracts Investigating REVLIMID(R) in a Broad Range of
Hematological Cancers
SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 5, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that clinical investigators from
leading cancer research centers will present data from recent and
on-going clinical trials of REVLIMID (lenalidomide) at the American
Society of Hematology 49th Annual Meeting, considered the premier
educational and scientific event in the hema... |
| | | 11/30/07 | Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia| BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 30, 2007--Celgene
International Sarl (NASDAQ: CELG) announced that lenalidomide
(REVLIMID) has been granted orphan medicinal product designation by
the European Commission (EC) for treatment of chronic lymphocytic
leukemia (CLL) following the favorable opinion of the European
Medicines Agency's (EMEA) Committee for Orphan Medicinal Products
(COMP).
Orphan medicinal product designation is granted by the EC to
promote development of drugs ... |
| | | 11/30/07 | Celgene Corporation to Present at BMO Capital Markets Focus on Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 30, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the BMO
Capital Markets Focus on Healthcare Conference on Tuesday, December 4,
2007 at 9:00 am EST will be webcast live and will be available in the
investor relations section of the Company's website at
www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer
will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New ... |
| | | 11/21/07 | Celgene Corporation to Present at Lazard Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 21, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Lazard
Capital Markets 4th Annual Healthcare Conference on Tuesday, November
27, 2007 at 1:30 pm EST will be webcast live and will be available in
the investor relations section of the Company's website at
www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer,
will provide an overview of the company.
Celgene Corporation, headquartered in Summi... |
| | | 11/21/07 | Two Major Phase III Studies Report Oral REVLIMID(R) (Lenalidomide) Plus Dexamethasone Shows Increased Overall Survival Advantage to Dexamethasone Plus Placebo in Previously Treated Multiple Myeloma Patients in The New England Journal of Medicine| BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 21, 2007--The New
England Journal of Medicine today published updated clinical data from
two Celgene Corporation (NASDAQ: CELG)-sponsored multi-centered,
randomized, double-blind, placebo-controlled Phase III pivotal studies
evaluating lenalidomide plus dexamethasone in previously treated
multiple myeloma patients.
The updated clinical data from the pivotal International Phase III
trial reported median time to disease progression in patie... |
| | | 11/21/07 | Updated REVLIMID(R) (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in The New England Journal of Medicine|
Major Phase III Studies Report Oral REVLIMID Plus Dexamethasone
Shows Time to Disease Progression and Overall Survival in Patients
with Relapsed or Refractory Multiple Myeloma
SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 21, 2007--The New England
Journal of Medicine today published updated clinical data from a
Celgene Corporation (NASDAQ: CELG)-sponsored multi-centered,
randomized, double-blind, placebo-controlled Phase III pivotal study
evaluating lenalidomide plus dexa... |
| | | 11/20/07 | Celgene Corporation to Present at Piper Jaffray Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 20, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Piper
Jaffray 19th Annual Healthcare Conference on Tuesday, November 27,
2007 at 12:00 pm EST will be webcast live and will be available in the
investor relations section of the Company's website at
www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered ... |
| | | 11/19/07 | REPEAT/Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock| Pharmion's Oncology Portfolio Further Strengthens Celgene's
Pipeline
Accelerates Celgene's Revenue and Earnings Growth, Accretive in
2009 and Beyond
SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--Nov. 19,
2007--Celgene Corporation (Nasdaq: CELG) and Pharmion Corporation
(Nasdaq: PHRM) today jointly announced the signing of a definitive
merger agreement pursuant to which Celgene has agreed to acquire
Pharmion. Under the terms of the merger agreement, Celgene will
acquire all... |
| | | 11/12/07 | Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma| NEUCHATEL, Switzerland--(BUSINESS WIRE)--Nov. 12, 2007--Celgene
International Sarl (NASDAQ: CELG) announced that its oral cancer drug
REVLIMID (lenalidomide) has received recommendation for approval from
the Australian Drug Evaluation Committee (ADEC) for use in combination
with dexamethasone as a treatment for patients with multiple myeloma
whose disease has progressed after one therapy. Multiple myeloma is
the second most commonly diagnosed blood cancer.
ADEC's recommendation fo... |
| | | 11/09/07 | Celgene Corporation to Present at Citibank Biotech Day| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 9, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Citibank
Biotech Day on Monday, November 12, 2007 at 11:30 am EST will be
webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. Sol J. Barer, Chairman
and Chief Executive Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated globa... |
| | | 11/08/07 | Celgene Corporation to Present at JMP Securities Healthcare Focus Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 8, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the JMP
Securities Healthcare Focus Conference on Tuesday, November 13, 2007
at 9:00 am EST will be webcast live and will be available in the
investor relations section of the Company's website at
www.celgene.com. Robert J. Hugin, President and Chief Operating
Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jers... |
| | | 11/07/07 | Celgene Corporation to Present at Credit Suisse Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 7, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Credit
Suisse Annual Healthcare Conference on Tuesday, November 13, 2007 at
2:00 pm MST (12:00 pm EST) will be webcast live and will be available
in the investor relations section of the Company's website at
www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, headqu... |
| | | 11/01/07 | Celgene Corporation to Present at Rodman & Renshaw Global Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 1, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Acumen
BioFin Rodman & Renshaw 9th Annual Global Healthcare Conference on
Monday, November 5, 2007 at 11:40 am EDT will be webcast live and will
be available in the investor relations section of the Company's
website at www.celgene.com. Celgene senior management will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey... |
| | | 10/25/07 | Celgene Reports Record Third Quarter Product Sales and Operating Profits|
SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 25, 2007--
2007 Third Quarter Financial Results Year-Over-Year:
Total Revenue Increased 43 Percent to $350 Million
Product Sales Increased 48 Percent to $331 Million
REVLIMID(R) Net Product Sales Increased 97 Percent to $199
Million
THALOMID(R) Net Product Sales Increased to $111 Million
Adjusted Operating Income Increased 84 Percent to $146 Million
Adjusted Net Income Increased 109 Percent to ... |
| | | 10/19/07 | Celgene Corporation to Announce Third Quarter Results on October 25, 2007| SUMMIT, N.J., Oct 19, 2007 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, October 25, 2007
at 9:00 am EDT to discuss the Company's third quarter financial and
operational results. The webcast will be available in the investor
relations section of the Company's website at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged ... |
| | | 09/20/07 | Celgene Corporation to Present at UBS Global Life Sciences Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 20, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the UBS 2007
Global Life Sciences Conference on Tuesday, September 25, 2007 at 2:30
pm EDT will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. David
W. Gryska, Senior Vice President and Chief Financial Officer will
provide an overview of the company.
Celgene Corporation, headquartered in Sum... |
| | | 09/18/07 | Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical Biotech & Medtech Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 18, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Merrill
Lynch Global Pharmaceutical, Biotech and Medtech Conference on
Thursday, September 20, 2007 at 11:20 am BST (6:20 am EDT) will be
webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. Robert J. Hugin,
President and Chief Operating Officer will provide an overview of the
company.
Celgene C... |
| | | 09/17/07 | Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia| Clinical Data from Ongoing Studies Evaluate REVLIMID in Relapsed or Refractory Chronic Lymphocytic Leukemia
BOUDRY, Switzerland--(BUSINESS WIRE)--Sept. 17, 2007--Celgene
Corporation (NASDAQ: CELG) announced that clinical data from two
ongoing REVLIMID studies in Chronic Lymphocytic Leukemia (CLL) were
reported during the 12th International Workshop on Chronic Lymphocytic
Leukemia in London on Saturday, September 15, 2007. Chronic
Lymphocytic Leukemia is a hematological... |
| | | 09/06/07 | Celgene Corporation Will Present at the Bear Stearns 20th Annual Healthcare Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 6, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the Bear
Stearns & Co. Inc. 20th Annual Healthcare Conference on Monday,
September 10, 2007 at 4:30pm EDT will be webcast live and will be
available in the investor relations section of the Company's website
at www.celgene.com. Sol. J. Barer, Chairman and Chief Executive
Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summ... |
| | | 09/04/07 | Oral Cancer Drug REVLIMID® Receives Swissmedic Approval in Switzerland For Treatment of Multiple Myeloma| SUMMIT, NJ – (September 4, 2007) – Celgene International Sàrl (NASDAQ: CELG) announced today that it's oral cancer drug, REVLIMID (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. This approval represents the first regulatory approval for Celgene in Switzerland, and REVLIMID represents the first oral ther... |
| | | 08/31/07 | Celgene Corporation to Present at Thomas Weisel Partners Healthcare Conference| SUMMIT, N.J., Aug 31, 2007 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the Thomas Weisel Partners Healthcare Conference on
Thursday, September 6, 2007 at 1:30 pm EDT will be webcast live and
will be available in the investor relations section of the Company's
website at www.celgene.com. Robert J. Hugin, President and Chief
Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, i... |
| | | 08/31/07 | Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 31, 2007--Celgene Corporation
(NASDAQ: CELG) announced today that its presentation at the NewsMakers
in the Biotech Industry Conference on Thursday, September 6, 2007 at
3:00 pm EDT will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. Sol J.
Barer, Chief Executive Officer will provide an overview of the
company.
Celgene Corporation, headquartered in Summit, New Jersey, is an
i... |
| | | 08/23/07 | Celgene Corporation Elects Ernest Mario to Board of Directors| SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 23, 2007--Celgene Corporation
(NASDAQ: CELG) announced the election of Ernest Mario, Ph.D. to the
Company's Board of Directors. Dr. Mario is an experienced corporate
director with a distinguished career in global healthcare. Dr. Mario
has served as Deputy Chairman and Chief Executive of Glaxo Holdings
plc., one of the largest and most successful multi-national healthcare
companies in the world. Also, Dr. Mario served as Chairman and Chief
Executive ... |
| | | 07/26/07 | Celgene Reports Record Second Quarter Product Sales and Operating Profits|
2007 Second Quarter Financial Results Year-Over-Year:
Total Revenue Increased 76 Percent To $348 Million
Product Sales Increased 81 Percent To $319 Million
REVLIMID(R) Net Product Sales Increased 187 Percent To $181
Million
THALOMID(R) Net Product Sales Totaled $118 Million
Adjusted Operating Income Increased 143 Percent To $130
Million
Adjusted Net Income Increased 160 Percent To $110 Million
Adjusted Earnings Per... |
| | | 07/10/07 | Celgene Corporation to Announce Second Quarter Results on July 26, 2007| SUMMIT, N.J.--(BUSINESS WIRE)--July 10, 2007--Celgene Corporation
(NASDAQ: CELG) senior management will host a conference call and live
audio webcast on Thursday, July 26, 2007 at 9:00 am EDT to discuss the
Company's second quarter financial and operational results. The
webcast will be available in the investor relations section of the
Company's website at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company e... |
| | | 06/15/07 | REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union| SUMMIT, N.J., June 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that REVLIMID (lenalidomide) has been granted full
marketing authorization by the European Commission for use in combination with
dexamethasone as a treatment for patients with multiple myeloma who have
received at least one prior therapy. This approval represents the first
regulatory approval for Celgene in Europe, and REVLIMID represents the first
breakthrough oral cancer therapy in Europe fo... |
| | | 06/08/07 | Celgene Corporation Will Present at the Goldman Sachs Global Healthcare Conference| SUMMIT, N.J., June 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Goldman Sachs 28th
Annual Global Healthcare Conference on Wednesday, June 13, 2007 at 2:00 pm PT
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com. Sol. J. Barer, Chairman
and Chief Executive Officer will provide an overview of the company.
Celgene Corporation, headquartered in Su... |
| | | 06/07/07 | Celgene Corporation Will Present at the Needham Biotechnology & Medical Technology Conference| SUMMIT, N.J., June 7 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Needham
Biotechnology & Medical Technology Conference on Wednesday, June 13, 2007 at
8:30 am ET will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. David W.
Gryska, Senior Vice President and Chief Financial Officer will provide an
overview of the company.
Celgene Corporation, headquarter... |
| | | 05/22/07 | Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases| Celgene to Advance Clinical and Regulatory Development of Oral
Anti-Inflammatory Franchise
SUMMIT, N.J., May 22 -- Celgene Corporation
(Nasdaq: CELG) announced its plans to advance the development of leading oral
anti-inflammatory candidates across a broad range of inflammatory diseases.
CC-10004 (apremilast), an oral TNF antagonist and anti-inflammatory agent has
demonstrated significant activity and an excellent side effect profile in a
placebo contr... |
| | | 05/15/07 | SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone| SWOG Action Based on Results from ECOG Phase III Study (E4A03)
SUMMIT, N.J., May 15 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the Southwest Oncology Group (SWOG) has
permanently closed enrollment in a federally funded clinical trial. The Phase
III randomized controlled study (S0232) compared a standard drug therapy,
dexamethasone, with a combined therapy of dexamethasone plus REVLIMID
(lenalidomide) for patients newly diagnosed with multiple my... |
| | | 05/14/07 | Celgene Corporation Will Present at the Citigroup Global Healthcare Conference| SUMMIT, N.J., May 14 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Citigroup Global
Healthcare Conference on Tuesday, May 22, 2007 at 1:30 pm ET will be webcast
live and will be available in the investor relations section of the Company's
website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer
will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an int... |
| | | 05/10/07 | Celgene Corporation Will Present at the JMP Securities Research Conference| SUMMIT, N.J., May 10 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JMP Securities
Research Conference on Monday, May 21, 2007 at 3:30 pm PDT will be webcast
live and will be available in the investor relations section of the Company's
website at www.celgene.com. Celgene senior management will provide an overview
of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceut... |
| | | 05/08/07 | Celgene Corporation Will Present at the Acumen BioFin Rodman & Renshaw Global Healthcare Conference| SUMMIT, N.J. May 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Acumen BioFin
Rodman & Renshaw Global Healthcare Conference on Tuesday, May 15, 2007 at
12:35 pm CEST will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. Robert J.
Hugin, President and Chief Operating Officer will provide an overview of the
company.
Celgene Corporation, headquartered in S... |
| | | 05/03/07 | Celgene Reports First Quarter Record Operating Performance and Significant Global Clinical and Regulatory Progress|
2007 First Quarter Financial Results Year-Over-Year:
-- Total Revenue Increased 61 Percent To $293 Million
-- Product Sales Increased 68 Percent To $270 Million
-- REVLIMID(R) Net Product Sales Increased 351 Percent To $146 Million
-- THALOMID(R) Net Product Sales Totaled $106 Million
-- Adjusted Operating Income Increased 103 Percent To $96 Million
-- Adjusted Net Income Increased 154 Percent To $86 Million
-- Adjusted Earnings Per Share In... |
| | | 04/26/07 | Celgene Corporation Will Present at the UBS Global Generic and Specialty Pharmaceuticals Conference| SUMMIT, N.J., April 26 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the UBS Global Generic
and Specialty Pharmaceuticals Conference on Wednesday, May 9, 2007 at 11:30 am
ET will be webcast live and will be available in the investor relations
section of the Company's website at www.celgene.com. Robert J. Hugin,
President and Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in... |
| | | 04/25/07 | Celgene Corporation Will Present at the Baird Growth Stock Conference| SUMMIT, N.J., April 25 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at Baird's 2007 Growth
Stock Conference on Tuesday, May 8, 2007 at 10:40 am CT will be webcast live
and will be available in the investor relations section of the Company's
website at www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jerse... |
| | | 04/24/07 | Celgene Corporation Will Present at the Morgan Stanley Global Healthcare Unplugged Conference| SUMMIT, N.J., April 24 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Morgan Stanley
Global Healthcare Unplugged Conference on Friday, May 4, 2007 at 11:00 a.m. ET
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com. Robert J. Hugin,
President and Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in... |
| | | 04/16/07 | Celgene Corporation to Announce First Quarter Results on May 3, 2007| SUMMIT, N.J., April 16 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on Thursday, May 3, 2007 at 9:00 am EDT to discuss the Company's first
quarter financial and operational results. The webcast will be available in
the investor relations section of the Company's website at
http://www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceutical c... |
| | | 04/04/07 | ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma| SUMMIT, N.J., April 4 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the Eastern Cooperative Oncology Group (ECOG)
has reported that its Data Monitoring Committee's (DMC) review of preliminary
results from a large, randomized clinical trial for patients with newly
diagnosed multiple myeloma has found that the use of a low dose of
dexamethasone (Decadron) in combination with lenalidomide suggests survival
advantage for patients when compared to the higher, s... |
| | | 03/23/07 | Oral Cancer Drug REVLIMID® Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency| SUMMIT, N.J., March 23 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its innovative oral cancer drug REVLIMID
(lenalidomide) has received a positive opinion from the European Medicines
Agency (EMEA) for use in combination with dexamethasone as a treatment for
patients with multiple myeloma who have received at least one prior therapy.
The EMEA's Committee for Medicinal Products for Human Use (CHMP), which
reviews applications for all 27 Member States... |
| | | 03/07/07 | Celgene Corporation Will Present at the Cowen and Company 27th Annual Healthcare Conference| SUMMIT, N.J., March 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Cowen and Company
Healthcare Conference on Monday, March 12, 2007 at 2:25 pm ET will be webcast
live and will be available in the investor relations section of the Company's
website at www.celgene.com. David W. Gryska, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, head... |
| | | 02/16/07 | Celgene Corporation Will Present at The Bear Stearns London Healthcare Conference| SUMMIT, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bear Stearns
London Healthcare Conference on Tuesday, February 27, 2007 at 9:20 am GMT will
be webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. Aart Brouwer, President of Celgene
International will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, ... |
| | | 02/08/07 | Celgene Corporation Will Present at the BIO CEO & Investor Conference| SUMMIT, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the BIO CEO & Investor
Conference 2007 on Monday, February 12, 2007 at 11:00 am ET will be webcast
live and will be available in the investor relations section of the Company's
website at http://www.celgene.com. Sol J. Barer, Chairman and Chief Executive
Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, ... |
| | | 02/01/07 | Celgene Reported Exceptional Operating Performance Driven by Record Revenue and Profits| 2006 Fourth Quarter Financial Results: * Total Revenue Increased 84 Percent to $275 Million * Product Sales Increased 96 Percent to $252 Million * REVLIMID(R) Net Product Sales Reached $124 Million * THALOMID(R) Net Product Sales Increased to $110 Million * Adjusted Earnings Per Share Increased 500 Percent to $0.18 Per Diluted Share 2006 Full-Year Financial Results: * Total Revenue Increased 67 Percent to $899 Million * Net Product Sales Increased 82 Percent to $812 Million * REVLIMID Net Produc... |
| | | 01/30/07 | Celgene Corporation Will Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference| SUMMIT, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Merrill Lynch
Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday,
February 6, 2007 at 8:40 am ET will be webcast live and will be available in
the investor relations section of the Company's website at www.celgene.com.
Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of
the company.
Celgene Corporation... |
| | | 01/19/07 | Celgene Corporation to Announce Fourth Quarter and Year-End 2006 Results on February 1, 2007| SUMMIT, N.J., Jan 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on February 1, 2007 at 9:00 am ET to discuss the Company's fourth
quarter and year-end 2006 financial and operational results. The webcast will
be available in the investor relations section of the Company's website at
www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
... |
| | | 01/08/07 | Celgene Corporation Reviews 2006 Achievements and Announces 2007 Financial Outlook|
- Company Reports Exceptional Operating Performance in 2006 Driven by
Record Revenue And Profits
- Total Revenue for 2006 Increased Approximately 60 Percent to $890
Million Range (Unaudited)
- REVLIMID(R) Net Product Sales Reached a Range of $315 to $320 Million
(Unaudited)
- THALOMID(R) Net Product Sales Reached a Range of $425 to $430 Million
(Unaudited)
- Adjusted Diluted Earnings Per Share Expected to Nearly... |
| | | 01/08/07 | Celgene Corporation Elects James J. Loughlin to Board of Directors| SUMMIT, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced the election of James J. Loughlin to the Company's
Board of Directors. Mr. Loughlin is an experienced corporate director with a
distinguished 40-year career with one of the world's leading professional
accounting and business consulting firms where he reached the highest levels
of corporate management and governance from entry level in 1964 to National
Director of the Pharmaceuticals Practice, i... |
| | | 01/02/07 | Celgene Corporation Elects Sol J. Barer, Ph.D. to Chairman of the Board| SUMMIT, N.J., Jan 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that its Board of Directors elected Sol J. Barer,
Ph.D., Chief Executive Officer, to the additional position of Chairman of the
Board, effective immediately. Dr. Barer has been our Chief Executive Officer
since May 1, 2006, one of our Directors since March 1994, and is a member of
the Executive Committee of our Board of Directors. Dr. Barer served as
President from Octo... |
| | | 12/27/06 | Celgene Will Present at JP Morgan 25th Annual Healthcare Conference| SUMMIT, N.J., Dec 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JP Morgan
Healthcare Conference on Monday, January 8, 2007 at 4:30 pm PST will be
webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. Sol J. Barer, Chief Executive Officer
will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is ... |
| | | 12/26/06 | Celgene Notified of ANDA Filing for Thalidomide| SUMMIT, N.J., Dec. 26 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the Company has been notified of an Abbreviated
New Drug Application (ANDA) filed with the U.S. Food and Drug Administration
(FDA), with a Paragraph IV certification, by Barr Pharmaceuticals, Inc. This
applicant is seeking authorization to market a generic version of thalidomide
100 mg and 50 mg tablets in the United States for the acute treatment of
cutaneous manifestations of moderate to... |
| | | 12/13/06 | Celgene Notified of ANDA Filing for Thalidomide| SUMMIT, N.J., Dec. 13 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the Company has been notified of an Abbreviated
New Drug Application (ANDA) filed with the U.S. Food and Drug Administration
(FDA), with a Paragraph IV certification, by Barr Pharmaceuticals, Inc. This
applicant is seeking authorization to market a generic version of thalidomide
200 mg tablets in the United States for the acute treatment of cutaneous
manifestations of moderate to severe er... |
| | | 12/11/06 | Celgene Acquires API Manufacturing Facility in Europe| SUMMIT, N.J., Dec 11, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that it has acquired active pharmaceutical ingredient
(API) manufacturing facility from Siegfried Ltd. (SWX: SFZN), a manufacturer
of high-quality pharmaceutical products located in Zofingen, Switzerland.
Celgene is purchasing the assets for approximately a total of $46.5 million in
cash, with an initial payment of $12.5 million. The manufacturing facility has
the capab... |
| | | 12/08/06 | 49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting| 131 Abstracts Investigating Celgene Products in Single and Combination
Therapies in a Broad Range of Hematological Cancers
SUMMIT, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
REVLIMID (lenalidomide) at the American Society of Hematology 48TH Annual
Meeting, considered the premier educational and sci... |
| | | 12/07/06 | 131 Abstracts Evaluating Celgene Products to Be Presented at the 48th American Society of Hematology Meeting| Seventy-Three Abstracts Investigating THALOMID(R) in Single and Combination
Therapies in a Broad Range of Hematological Cancers
SUMMIT, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
THALOMID (thalidomide) at the American Society of Hematology 48th Annual
Meeting, one of the largest oncology meetings in t... |
| | | 12/07/06 | Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research| SUMMIT, N.J., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that Thomas O. Daniel, M.D. has joined the Company as
President of Celgene Research. Dr. Daniel brings to Celgene more than two
decades of medical and pharmaceutical research experience, having most
recently served as the Chief Scientific Officer at Ambryx, Inc., a
biotechnology company focused on discovering and developing protein-based
therapeutics. Prior to that, Dr.... |
| | | 12/07/06 | Celgene Names David W. Gryska Chief Financial Officer| SUMMIT, N.J., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that David W. Gryska has joined the company as Chief
Financial Officer. Mr. Gryska brings with him extensive business experience as
having served as a Chief Financial Officer of public companies for more than
ten years, most recently at SCIOS Inc., a biopharmaceutical company that was
acquired by Johnson & Johnson. Earlier in his career, Mr. Gryska spent eleven
years at... |
| | | 11/03/06 | Celgene Announces Pricing of Common Stock Offering| SUMMIT, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG), announced the pricing of its public offering of 20,000,000
shares of its common stock at a public offering price of $51.60 per share.
The gross proceeds of the offering will be $1.032 billion.
This offering of the shares of Celgene common stock may be made only by
means of a prospectus. A copy of the prospectus relating to the securities can
be obtained from: J.P. Morgan Securities Inc., 277 Park Ave... |
| | | 11/01/06 | Celgene Intends to Issue Up to Approximately 20 Million Shares of Common Stock in S&P 500 Inclusion Transaction| SUMMIT, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG), announced that as a result of the decision by Standard and
Poor's Corporation to include Celgene Corporation in the S&P 500 Index, the
Company intends to issue up to approximately 20 million shares of its common
stock.
The purpose of the offering is to partially meet the anticipated demand of
index funds to purchase Celgene common stock when the Company is added to the
S&P 500 Index, curre... |
| | | 10/26/06 | Celgene Corporation Reports Record Third Quarter Revenue and Operating Profits|
Product Sales Drive Record Third Quarter Revenue and Profits:
* Record Net Product Sales of $223.1 Million
- REVLIMID Achieved $101.3 Million in Net Product Sales
- THALOMID Net Product Sales Totaled $108.4 Million
* Record Adjusted Net Income of $59.4 Million with Adjusted Diluted
Earnings Per Share of $0.15
Financial Highlights of Third Quarter Performance Year-Over-Year:
* Total Revenue Increased 89.1% to a Record $244.8 Million
... |
| | | 10/19/06 | Celgene Corporation to Announce Third Quarter Results on October 26, 2006| SUMMIT, N.J., Oct. 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on October 26, 2006 at 9:00 a.m. ET to discuss the Company's third
quarter financial and operational results. The webcast will be available in
the investor relations section of the Company's website at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pharmaceutical company engaged p... |
| | | 10/04/06 | Clinical Data From REVLIMID(R) Study in Myelodysplastic Syndromes Reported in New England Journal of Medicine| SUMMIT, N.J., Oct. 4 /PRNewswire-FirstCall/ -- The New England Journal of
Medicine today published final results of a Celgene Corporation (Nasdaq: CELG)
sponsored Phase II trial evaluating REVLIMID(R) (lenalidomide) as an oral
therapy for patients with myelodysplastic syndromes (MDS) with transfusion-
dependent anemia and deletion 5q cytogenetic abnormality with or without
additional cytogenetic abnormalities. MDS is a malignant disorder of blood
cell production that affects approximat... |
| | | 10/02/06 | Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies| Preliminary Phase II Data Evaluate REVLIMID Oral Therapy in Patients with
Aggressive Non-Hodgkin's Lymphoma
PALERMO, Italy, Oct. 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced clinical data from a multi-center, single arm open
label Phase II clinical study evaluating and investigating single agent
REVLIMID (lenalidomide) in patients with relapsed and refractory aggressive
non-Hodgkins lymphoma (NHL) were reported at the 3rd Internationa... |
| | | 09/20/06 | Celgene Will Present at UBS Global Life Sciences Conference| SUMMIT, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the UBS Global Life
Sciences Conference on Wednesday, September 27, 2006 at 9:30 a.m. EDT will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, Chief Executive
Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is a... |
| | | 09/18/06 | Celgene Will Present at Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference| SUMMIT, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Merrill Lynch
Global Pharmaceutical, Biotech and Medtech Conference on Wednesday, September
20, 2006 at 4:00 pm BST will be webcast live and will be available in the
investor relations section of the Company's website at http://www.celgene.com.
Robert J. Hugin, President and Chief Operating Officer will provide an
overview of the company.
Celgene Corpora... |
| | | 09/01/06 | Celgene Will Present at NewsMakers in the Biotech Industry Conference| SUMMIT, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the NewsMakers in the
Biotech Industry Conference on Thursday, September 7, 2006 at 11:30 am EDT
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com. Celgene senior management
will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an inte... |
| | | 08/04/06 | Celgene Will Present at Bank of America Specialty Pharmaceutical Conference| SUMMIT, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bank of America
Specialty Pharmaceuticals Conference on Thursday, August 10, 2006 at 3:45 pm
EDT will be webcast live and will be available in the investor relations
section of the Company's website at www.celgene.com . Celgene senior
management will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integra... |
| | | 07/27/06 | Celgene Corporation Reports Record Revenue and Operating Profits|
REVLIMID(R) and THALOMID(R) Regulatory Approvals Highlight Second Quarter Performance
Product Sales Drive Record Second Quarter Revenue and Profits:
- Total Net Product Sales Reached a Record $176.4 Million
- REVLIMID Achieved $63.0 Million in Net Product Sales
- THALOMID Net Product Sales Attained $107.2 Million
- Adjusted Second Quarter Earnings Per Diluted Share Increased to $0.11
Financial Highlights of Second Quarter Performance:
... |
| | | 07/19/06 | Celgene Corporation to Announce Second Quarter Results on July 27, 2006| SUMMIT, N.J., July 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on July 27, 2006 at 9:00 am ET to discuss the Company's second quarter
financial and operational results. The webcast will be available in the
investor relations section of the Company's website at http://www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pharmaceutical company engage... |
| | | 06/29/06 | REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma| Third FDA Approval for Celgene Corporation in Six Months
SUMMIT, N.J., June 29 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG)
announced that the U.S. Food and Drug Administration (FDA) has granted
approval for its Supplemental New Drug Application (sNDA) for an additional
indication for REVLIMID (lenalidomide), for use in combination with
dexamethasone as a treatment for patients with multiple myeloma who have
received at least one prior therapy. REVLIMID is also approve... |
| | | 06/20/06 | Celgene Will Present at NASDAQ Investor Program| SUMMIT, N.J., June 20 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the NASDAQ 17th
Investor Program on Wednesday, June 21, 2006 at 8:30 am BST will be webcast
live and will be available in the investor relations section of the Company's
website at http://www.celgene.com . Celgene senior management will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pharma... |
| | | 06/05/06 | REVLIMID(R) (Lenalidomide) Evaluated as Combination Oral Treatment Regimen in Elderly Newly Diagnosed Multiple Myeloma| Updated Clinical Data Evaluating Lenalidomide in Newly Diagnosed Multiple
Myeloma reported at 42nd American Society of Clinical Oncology Oral Session
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that clinical data from a study with combination
therapy lenalidomide, melphalan and prednisone (R-MP) in elderly newly
diagnosed multiple myeloma patients were reported at an oral presentation
during the 42nd American Society of Clinical Oncology (A... |
| | | 06/05/06 | THALOMID(R) (Thalidomide) Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma| Updated Clinical Data Evaluating THALOMID in Multiple Myeloma Reported at the 42nd American Society of Clinical Oncology Oral Session ATLANTA, June 5, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that updated clinical data from an ongoing multi-
centered, randomized, placebo-controlled phase III study (MM-003) of oral
combination therapy thalidomide plus dexamethasone versus dexamethasone alone
as induction therapy for previously unt... |
| | | 06/05/06 | Thalidomide Survival Data Evaluated in Newly Diagnosed Multiple Myeloma| Clinical Data Evaluating THALOMID in Newly Diagnosed Multiple Myeloma
Presented at the 42nd American Society of Clinical Oncology Plenary Session
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced results from an ongoing randomized trial evaluating
the treatment of newly diagnosed, multiple myeloma patients with oral
combination therapy thalidomide, melphalan and prednisone. The clinical data
evaluating thalidomide in newly diagnosed multiple m... |
| | | 06/05/06 | REVLIMID(R) (Lenalidomide) Survival Data Evaluated In Previously Treated Multiple Myeloma| Updated Clinical Data Evaluating Lenalidomide in Multiple Myeloma Reported at
42nd American Society of Clinical Oncology Oral Session
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq:
CELG) announced updated clinical data from two multi-centered, randomized,
double-blind, placebo-controlled Phase III pivotal studies evaluating
lenalidomide plus dexamethasone in previously treated multiple myeloma
patients were presented at the 42nd American Society of Cl... |
| | | 05/25/06 | Thalomid(R) sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma| SUMMIT, N.J., May 25 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has
granted accelerated approval to its Supplemental New Drug Application (sNDA)
for THALOMID (thalidomide) in combination with dexamethasone for the treatment
of newly diagnosed multiple myeloma. The effectiveness of THALOMID is based
upon response rates. There are no controlled trials demonstrating a clinical
benefit, such as an improvement in ... |
| | | 05/16/06 | Celgene Cellular Therapeutics Strengthens Intellectual Property Estate in the Field of Placental-Derived Stem Cells| Patent Issued to Protect Proprietary Methodologies of Celgene Cellular Therapeutics for Recovering Placental-Derived Stem CellsSUMMIT, N.J., May 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Cellular
Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation
(Nasdaq: CELG) announced that its intellectual property estate was
strengthened by the issuance of United States Patent No. 7,045,148 by the
United States Patent & Trademark Office (USPTO). This patent is t... |
| | | 05/11/06 | Celgene Will Present at Bank of America Healthcare Conference| SUMMIT, N.J., May 11 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bank of America
Healthcare Conference on Tuesday, May 16, 2006 at 8:00 am PDT will be webcast
live and will be available in the investor relations section of the Company's
website at http://www.celgene.com. Robert J. Hugin, President and Chief
Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jerse... |
| | | 04/28/06 | Celgene Will Present at Deutsche Bank Securities Annual Healthcare Conference| SUMMIT, N.J., April 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Deutsche Bank
Securities 31st Annual Healthcare Conference on Tuesday, May 2, 2006 at 11:15
am EDT will be webcast live and will be available in the investor relations
section of the Company's website at http://www.celgene.com. Sol J. Barer,
Chief Executive Officer will provide an overview of the company.
Celgene Corporation, head... |
| | | 04/28/06 | Celgene Will Present at Morgan Stanley Global Healthcare Unplugged Conference| SUMMIT, N.J., April 28 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Morgan Stanley
Global Healthcare Unplugged Conference on Wednesday, May 3, 2006 at 2:15 pm
EDT will be webcast live and will be available in the investor relations
section of the Company's website at http://www.celgene.com . Robert J. Hugin,
President and Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered ... |
| | | 04/27/06 | Celgene Corporation Reports Record Revenue and Operating Profits|
Product Sales Drive Record First Quarter Revenue and Profits:
Strong REVLIMID(R) Launch Achieved $32.4 Million in Net Product Sales
Record THALOMID(R) Net Product Sales Increased 21.3% to $107.2 Million Versus
First Quarter 2005
Market Share Gains Drive Ritalin(R)/Focalin(TM) Revenue Increase of 84.4%
to $19.4 Million Versus Prior Year Quarter
Financial Highlights of First Quarter Performance:
Total Revenue Increased 61.8% to a Record $181... |
| | | 04/26/06 | Celgene Will Present at Baird Growth Stock Conference| SUMMIT, N.J. April 26 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Baird 2006 Growth
Stock Conference on Wednesday, May 10, 2006 at 9:40 am CDT will be webcast
live and will be available in the investor relations section of the Company's
website at http://www.celgene.com . Perry Karsen, Senior Vice President,
Business Development will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New J... |
| | | 04/20/06 | Celgene Corporation Elects Rodman L. Drake To Board of Directors| SUMMIT, N.J., April 20 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced Thursday, April 20th, the election of Rodman L. Drake
to the Company's Board of Directors. Mr. Drake is an experienced corporate
director and former CEO with more than 30 years of diverse consulting and
executive management experience. He will serve as a member of the Nominating
and Audit Committees of the Celgene Board of Directors. Mr. Drake has spent
most of his career in executive level p... |
| | | 04/19/06 | Celgene Corporation to Announce First Quarter Results on April 27, 2006| SUMMIT, N.J., April 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on April 27, 2006 at 9:00 AM ET to discuss the Company's first quarter
financial and operational results. The webcast will be available in the
investor relations section of the Company's website at http://www.celgene.com.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pharmaceu... |
| | | 04/18/06 | LifebankUSA(TM) Announces New Service to Bank Placental-Derived Stem Cells|
New Technology Available to Expecting Families
Builds on Celgene Cellular Therapeutics Deep Experience and Patented
Procedures
CEDAR KNOLLS, N.J., April 18 /PRNewswire-FirstCall/ -- LifebankUSA, a
subsidiary of Celgene Cellular Therapeutics (CCT), today announced plans for a
new service to bank stem cells derived from the placenta. Placental-derived
stem cells (PDSCs), which have different characteristics from those isolated... |
| | | 04/07/06 | REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review| REVLIMID is Being Evaluated by the EMEA as Oral Therapy for Treatment
for Patients with Relapsed or Refractory Multiple Myeloma
SUMMIT, N.J., April 7 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG), announced that the European Medicines Agency (EMEA) has
accepted for review the Company's Marketing Authorization Application (MAA)
for LENALIDOMIDE - CELGENE EUROPE (lenalidomide), submitted in February 2006.
The application is based upon the safety and efficacy results of... |
| | | 03/06/06 | Clinical Data Evaluating CC-10004 as New Oral Therapy in Severe Psoriasis| Data Presented at the American Academy of Dermatology Meeting
SAN FRANCISCO, March 6 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that phase II data, evaluating CC-10004 - a novel
compound with anti-inflammatory activities - as a potential oral-therapy for
patients with severe plaque-type psoriasis, were reported at the 64th Annual
American Academy of Dermatology meeting in San Francisco, Calif on Sunday,
March 5, 2006.
Psoriasis is a lifelong ski... |
| | | 03/03/06 | FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma|
June 30, 2006 PDUFA Date Established
Expanded Access Program to Remain Open Through FDA Action on REVLIMID sNDA
SUMMIT, N.J., March 3 /PRNewswire-FirstCall/ - Celgene Corporation
(Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has
granted a Priority Review designation to its Supplemental New Drug Application
(sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory
multiple myeloma. The Prescription Drug User F... |
| | | 02/23/06 | Celgene Will Present at Lehman Brothers Global Healthcare Conference| SUMMIT, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Lehman Brothers
Global Healthcare Conference on Wednesday, March 8, 2006 at 5:15 pm EST will
be webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. Robert J. Hugin, Senior Vice President
and Chief Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Su... |
| | | 02/22/06 | Celgene Will Present at JMP Securities Research Conference| SUMMIT, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JMP Securities
Research Conference on Tuesday, March 7, 2006 at 7:30 am PST will be webcast
live and will be available in the investor relations section of the Company's
website at http://www.celgene.com. Celgene senior management will provide an
overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global pha... |
| | | 02/21/06 | Celgene Will Present at Bear Stearns London Healthcare Conference| Feb 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bear Stearns
London Healthcare Conference on Wednesday, March 1, 2006 at 9:20 am GMT will
be webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com . Celgene senior management will
provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an int... |
| | | 02/17/06 | Celgene Shareholders Approve Increase in Authorized Shares|
Friday, February 17, 2006 Record Date for Two-for-One Stock Split
Celgene Share Price Expected to be Reported on
Split-Adjusted Basis on Monday, February 27, 2006
SUMMIT, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that its shareholders approved an increase in the
number of authorized shares of stock from 280,000,000 to 580,000,000 at a
Special Meeting of the Stockholders on February 16, 2006. The record... |
| | | 02/02/06 | Celgene Will Present at Citigroup Healthcare Conference| SUMMIT, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the 2006 Citigroup
Healthcare Conference on Monday, February 27, 2006 at 1:20 pm EST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and Chief
Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey... |
| | | 02/01/06 | Celgene Will Present at BIO CEO and Investor Conference| SUMMIT, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the BIO CEO and
Investor Conference on Tuesday, February 14, 2006 at 2:00 pm EST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and Chief
Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is... |
| | | 01/31/06 | Celgene Will Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Conference| SUMMIT, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the 17th Annual
Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device
Conference on Tuesday, February 7, 2006 at 11:00 am EST will be webcast live
and will be available in the investor relations section of the Company's
website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and
Chief Financial Officer will provide an overview of... |
| | | 01/26/06 | Celgene Corporation Reports Record Operating Performance for 2005|
42% Increase in Total Revenue For 2005 Versus Prior Year
35% Annual Increase in Total Product Sales For 2005
100% Increase in Adjusted Operating Income Year-Over-Year
Fourth Quarter Highlights:
REVLIMID(R) NDA Granted FDA Approval for MDS Deletion 5q
REVLIMID sNDA Submitted to FDA for Relapsed or Refractory Multiple Myeloma
REVLIMID MAA Filing Under Review at EMEA for MDS Deletion 5q
REVLIMID MAA Submitted to Switz... |
| | | 01/09/06 | THALOMID(R) Pivotal Phase III Multiple Myeloma Trial Reaches Pre-Specified Interim Endpoint|
Independent Data Monitoring Committee review determines that the Phase III
pivotal trial (MM-003) meets the pre-established efficacy-stopping rule of
p
SUMMIT, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that an external Independent Data Monitoring
Committee analysis of the multi-centered, randomized, placebo-controlled phase
III study of combination thalidomide plus dexamethasone versus dexamethasone
alone as induction therapy for ... |
| | | 01/09/06 | Celgene Corporation Reviews Recent Highlights and Outlines 2006 Milestones|
- Recent Highlights
* REVLIMID(R) NDA Granted FDA Approval for MDS Deletion 5q
* REVLIMID sNDA Submitted to FDA for Relapsed or Refractory Multiple
Myeloma Indication
* REVLIMID MAA Filing Under Review at EMEA for MDS/Deletion
5q Indication
* REVLIMID MAA Submitted to Switzerland for MDS/Deletion 5q Indication
* More Than 100 Abstracts at ASH 2005; 23 Oral Presentations Including
Survival Data for REVLIMID
... |
| | | 01/06/06 | Celgene Corporation to Announce Fourth Quarter and Year-End 2005 Results On January 26, 2006| SUMMIT, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on January 26, 2006 at 9:00 AM ET to discuss the Company's fourth
quarter and year-end 2005 financial and operational results. The webcast will
be available in the investor relations section of the Company's website at
http://www.celgene.com.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrat... |
| | | 01/04/06 | Celgene Will Present at JP Morgan 24th Annual Healthcare Conference| SUMMIT, N.J., Jan. 4 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JP Morgan
Healthcare Conference on Monday, January 9, 2006 at 9:30 am PST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and
Chief Operating Officer will provide an overview of the company.
About Celgene
Celgene Corporation, headquartered in Summi... |
| | | 12/27/05 | Celgene Corporation Announces Two-For-One Stock Split| SUMMIT, N.J., Dec 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that its Board of Directors has approved a
two-for-one stock split, payable in the form of a 100 percent stock dividend.
The stock split is subject to stockholder's approval to increase the number of
authorized shares of common stock from 280,000,000 to 580,000,000, an action
that will be voted on at a Special Meeting of the Stockholders on February 16,
2006. If approve... |
| | | 12/27/05 | Celgene Corporation Announces Senior Management Transition Plan| Changes to be Effective May 1, 2006
SUMMIT, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) Celgene Corporation announced today that its Chairman and Chief
Executive Officer John W. Jackson will retire as Chief Executive Officer on
May 1, 2006. Mr. Jackson will continue as Chairman of the Board of Directors
and stand for re-election at the Company's annual meeting on June 15, 2006. On
May 1st, Sol J. Barer will assume responsibility as th... |
| | | 12/27/05 | FDA Grants REVLIMID(R) NDA Approval| SUMMIT, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA)
granted approval of REVLIMID (lenalidomide) which is indicated for the
treatment of patients with transfusion-dependent anemia due to low- or
intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion
5q cytogenetic abnormality with or without additional cytogenetic
abnormalities. REVLIMID will be available through a REVLIMID... |
| | | 12/13/05 | REVLIMID(R) Clinical Results as Oral Treatment Regimen in Newly Diagnosed Multiple Myeloma Presented at the 47th American Society of Hematology Meeting| ATLANTA, Dec. 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq:
CELG) announced that new data evaluating clinical results on the treatment of
newly diagnosed multiple myeloma patients with REVLIMID (lenalidomide) and
dexamethasone as an oral combination therapy were reported at the 47th
American Society of Hematology (ASH) Meeting in Atlanta, GA. Multiple myeloma
(MM) is the second most common cancer of the blood, representing approximately
one percent of all cancers and two pe... |
| | | 12/13/05 | REVLIMID(R) Clinical Results as Oral Treatment Regimen in Myelofibrosis Presented at the 47th American Society of Hematology Meeting| ATLANTA, Dec. 13 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that clinical data from a REVLIMID (lenalidomide)
study in myelofibrosis (MF) were reported at an oral presentation during the
47th American Society of Hematology (ASH) Meeting in Atlanta, GA. The Phase II
study evaluated previously treated patients with myelofibrosis, a rare blood
disorder that can be fatal if untreated. To date, there are no drugs approved
for the treatment of this disease.
A... |
| | | 12/12/05 | REVLIMID(R) Clinical Results as Oral Treatment Regimen in Chronic Lymphocytic Leukemia Presented at the 47th American Society of Hematology Meeting|
ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG)
announced that clinical data from a REVLIMID study in Chronic Lymphocytic Leukemia
(CLL) were reported at an oral presentation during the 47th American Society
of Hematology (ASH) Meeting in Atlanta, GA on Monday, December 12, 2005. The
study reported that sixteen out of nineteen evaluable patients achieved stable
disease or better after treatment with REVLIMID, and experienced a median decrease ... |
| | | 12/11/05 | Revlimid(R) Improves Overall Survival and Delays Time to Disease Progression in Previously Treated Multiple Myeloma Patients| Updated Clinical Data Evaluating REVLIMID in Multiple Myeloma Reported at the 47th American Society of Hematology Meeting Plenary SessionATLANTA, Dec 11, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced updated clinical data from two Phase III pivotal
studies evaluating REVLIMID (lenalidomide) plus dexamethasone in previously
treated multiple myeloma patients. The updated clinical data from the pivotal
International Phase III trial (MM-010),... |
| | | 12/08/05 | 107 Abstracts on Clinical Data Evaluating REVLIMID(R) and Thalidomide To Be Presented at The 47th American Society of Hematology Meeting| SUMMIT, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
thalidomide, and REVLIMID in multiple indications at The 47th American Society
of Hematology Meeting, one of the largest oncology meetings in the world, in
Atlanta, GA from December 10-13, 2005.
The presentations will include 30 abstracts clinically evaluating ... |
| | | 11/15/05 | Celgene Receives Approvable Letter From FDA for THALOMID(R) in Treatment of Newly Diagnosed Multiple Myeloma| SUMMIT, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) today announced the U.S. Food and Drug Administration (FDA)
issued an approvable letter in response to the Company's sNDA for multiple
myeloma (MM). The FDA has requested revised product labeling with the specific
indication of newly diagnosed multiple myeloma and updated safety information,
as well as some additional patient information to finalize its review.
The THALOMID sNDA is based on results f... |
| | | 11/03/05 | Celgene Corporation Reports Strong Operating, Regulatory and Clinical Results with Record Product Sales|
Third Quarter Highlights:
Total Product Sales for the Third Quarter Reached a Record $113.9 Million,
36% Increase Year-Over-Year
Commercial Team Finalized Preparations for REVLIMID(R) Launch As First Oral
Targeted Therapy For Low To Intermediate-1-Risk MDS Patients With Deletion
5q Chromosomal Abnormality
FDA Oncologic Drugs Advisory Committee Recommended REVLIMID for Full Approval,
by a 10-5 vote, As Oral Targeted Therapy For Low To Intermediat... |
| | | 11/03/05 | Clinical Data on Thalidomide Reported in Recurrent Epithelial Ovarian Cancer| Oral Presentation at the Chemotherapy Foundation Symposium Reported 50% of
Patients Achieved Overall Response in Median Progression Free Survival
SUMMIT, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that preliminary clinical data was reported at
the XXIII Chemotherapy Foundation Symposium in New York City, New York on
Thursday, November 3, 2005 comparing the efficacy and safety of the
combination of thalidomide and topotecan vs. topote... |
| | | 10/28/05 | Celgene Corporation to Announce Third Quarter Results on November 3, 2005| SUMMIT, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management team plans to report its third quarter
financial and operational results on Thursday, November 3, 2005 at 8:00 am
EST, before the open of the financial markets. The webcast will be available
in the investor relations section of the Company's website at
http://www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceutical company... |
| | | 10/26/05 | REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review| REVLIMID Being Evaluated by the EMEA as Oral Targeted Therapy for Treatment of
Patients with Myelodysplastic Syndromes (MDS) with
Deletion 5q Chromosomal Abnormality
SUMMIT, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that the European Medicines Agency (EMEA) has
accepted for review the Company's Marketing Authorization Application (MAA)
for REVLIMID (lenalidomide), submitted in August 2005. The application is
... |
| | | 10/03/05 | REVLIMID(R) PDUFA Date Extended Three Months By FDA|
Extension to Allow for Completion of Review of REVLIMID Risk-Management
Program
Celgene Prepared for REVLIMID Launch As First Oral Targeted Therapy For
Low To Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality
Celgene Expects November Filing of REVLIMID application for Multiple Myeloma
SUMMIT, N.J., Oct. 3 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that they received notification late Friday
... |
| | | 09/14/05 | FDA Oncologic Drugs Advisory Committee Recommends REVLIMID(R) for Full Approval| By a 10-5 Vote, ODAC Recommends REVLIMID as Oral Targeted Therapy for Low to Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality WASHINGTON, Sept 14, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that the Oncologic Drugs Advisory Committee (ODAC) of
the U.S. Food and Drug Administration (FDA) recommended full approval of
REVLIMID (lenalidomide) for the treatment of patients with transfusion-
dependent anemia due to ... |
| | | 09/13/05 | FDA and Celgene Revlimid(R) Briefing Documents for Advisory Committee Meeting Available Online| WASHINGTON, Sept 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced that the Oncologic Drugs Advisory Committee (ODAC) of
the U.S. Food and Drug Administration (FDA) has posted on its website briefing
documents for the ODAC meeting scheduled to review the REVLIMID(R)
(lenalidomide) New Drug Application (NDA) seeking approval for REVLIMID for
the treatment of patients with transfusion-dependent anemia due to low- or
intermediate-1-risk ... |
| | | 09/09/05 | Celgene Will Present at Bear Stearns Healthcare Conference| SUMMIT, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bear Stearns
Healthcare Conference on Monday, September 12, 2005 at 9:30 am EDT will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. John W. Jackson, Chairman and CEO
will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
... |
| | | 09/08/05 | Celgene Will Present at Thomas Weisel Healthcare Tailwinds Conference| SUMMIT, N.J., Sept 08, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Thomas Weisel
Healthcare Tailwinds on Friday, September 9, 2005 at 11:00 am EDT will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice
President and Chief Financial Officer will provide an overview of the company.
Celgene Corpor... |
| | | 09/07/05 | Celgene Will Present at NewsMakers in the Biotech Industry Conference| SUMMIT, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at NewsMakers in the
Biotech Industry Conference on Friday, September 9, 2005 at 11:00 am EDT will
be webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. John W. Jackson, Chairman and CEO will
provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
... |
| | | 07/28/05 | Celgene Corporation Reports Record Operating Performance and Key Clinical and Regulatory Progress|
Record Second Quarter Revenue and Profits:
Total Revenue Increased 66 Percent Year-Over-Year
Net Operating Profits Increased More Than 300 Percent Year-Over-Year
Earnings Per Diluted Share More Than Doubled Year-Over-Year
Company Affirms 2005 Financial Targets
REVLIMID(R), THALOMID(R) and FOCALIN XR(TM) Clinical and Regulatory
Programs Advanced:
FDA Granted Priority Review for REVLIMID NDA for Treatment of Low and Intermediate
R... |
| | | 07/20/05 | Celgene Corporation to Announce Second Quarter Results on July 28, 2005| SUMMIT, N.J., July 20 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that it plans to report its second quarter results on
Thursday, July 28, 2005 before the open of the financial markets. Following
the announcement senior management will host a conference call and live audio
webcast at 9:00 am EDT to discuss the Company's second quarter financial and
operational results. The webcast will be available in the investor relations
section of the Company's website at ht... |
| | | 07/18/05 | Celgene Corporation Second Quarter 2005 Earnings Conference Call| SUMMIT, N.J.--(BUSINESS WIRE)--July 18, 2005--Celgene Corporation
(NASDAQ:CELG) will announce second quarter operational and financial
results on Thursday, July 28, 2005. Celgene's management team will
host a conference call and live audio webcast to discuss the financial
and operational results.
The webcast will be available in the investor relations sections
of the Company's website at www.celgene.com and will be archived for
two weeks.
The webcast is also being distributed... |
| | | 06/24/05 | Celgene Added to the Nasdaq-100 Index| Effective Prior to Market Open on Tuesday, July 5, 2005
SUMMIT, N.J., June 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG), a leading global biopharmaceutical company, announced that it
will be added to the Nasdaq-100 Index(R), effective prior to market open on
Tuesday, July 5, 2005. Shares of CELG will also be included in the Nasdaq-100
Index Tracking Stock (Nasdaq: QQQQ).
"Our addition to the Nasdaq-100 Index is a result of the outstanding
perfor... |
| | | 06/21/05 | FDA Grants Priority Review for REVLIMID(R) NDA for Treatment of Low- and Intermediate- Risk MDS With Deletion 5q Chromosomal Abnormality| SUMMIT, N.J., June 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has
granted a Priority Review designation to its New Drug Application (NDA) for
REVLIMID with a Prescription Drug User Fee Act (PDUFA) date by October 7,
2005. The Company is seeking approval to market REVLIMID as a targeted
treatment for transfusion-dependent patients with low- and intermediate-risk
myelodysplastic syndromes (MDS) w... |
| | | 06/16/05 | Celgene Will Present at FBR European Investor Conference| SUMMIT, N.J., June 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the FBR European
Investor Conference on Wednesday, June 29, 2005 at 10:10 am BST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice
President and Chief Financial Officer will provide an overview of the company.
Celgene Corporation, headquart... |
| | | 06/15/05 | Celgene Will Present At Goldman Sachs Global Healthcare Conference| SUMMIT, N.J., June 15 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the 26th Annual
Goldman Sachs Global Healthcare Conference on Thursday, June 16, 2005 at 11:00
am PDT will be webcast live and will be available in the investor relations
section of the Company's website at http://www.celgene.com. Robert J. Hugin,
Senior Vice President and Chief Financial Officer will provide an overview of
the company.
Celgene Corporation, he... |
| | | 06/07/05 | REVLIMID® (lenalidomide) New Drug Application Accepted for Review by FDA| New Drug Application Based on Phase II Trial (MDS-003) in Myelodysplastic Syndromes Patients with Deletion 5q Chromosomal Abnormality
SUMMIT, NJ – (June 7, 2005) –Celgene Corporation (NASDAQ: CELG) announced
that the U.S. Food and Drug Administration (FDA) has formally accepted for review the Company's New Drug Application (NDA) for REVLIMID. The REVLIMID NDA is seeking approval as a targeted treatment for transfusion-dependent myelodysplastic syndromes (MDS) patients with deletion 5q ch... |
| | | 06/06/05 | REVLIMID(R) (lenalidomide) Study in Low and Intermediate-1 Risk Myelodysplastic Syndromes Presented at the 10th Congress of the European Hematology Association|
51% of Eligible Low and Intermediate-1 Risk Transfusion Dependent
Myelodysplastic Syndromes (MDS) Patients Without Deletion 5q Chromosomal
Abnormality Achieve Hematologic Improvement, with 33% Achieving
Transfusion Independence
Transfusion Independence Maintained for a Median of 41 Weeks in
Responders
Median Hemoglobin Increased 3.2 g/dl From a Baseline of 8.0 g/dl in
Responders
45% of Evaluable Patients Experience Cytogenetic ... |
| | | 05/27/05 | FDA Grants Approval to Market FOCALIN XR(TM) for the Treatment of ADHD in Adults, Adolescents and Children| SUMMIT, N.J., May 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced that Novartis Pharma AG, its partner in the
development and commercialization of FOCALIN XR, was granted U.S. Food and
Drug Administration (FDA) approval for FOCALIN XR (dexmethylphenidate HCl)
extended-release capsules for the treatment of Attention-Deficit/Hyperactivity
Disorder (ADHD) in adults, adolescents and children. The approval of
FOCALIN XR for the treatment of ADHD was ba... |
| | | 05/20/05 | Celgene Will Present at Needham & Company Fourth Annual Biotechnology Conference| SUMMIT, N.J., May 20 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Needham and
Company Biotechnology Conference on Wednesday, May 25, 2005 at 10:00 am EDT,
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com . Perry Karsen, Senior VP
Business Development, will provide an overview of the Company.
Celgene Corporation, headquartered in Summit, New Jers... |
| | | 05/19/05 | Celgene Will Present at UBS 2005 Global Pharmaceuticals Conference| SUMMIT, N.J., May 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the UBS Global
Pharmaceuticals Conference on Tuesday, May 24, 2005 at 10:00 am EDT, will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. John W. Jackson, Chairman and
CEO, will provide an overview of the Company.
Celgene Corporation, headquartered in Summit, New Jersey, is... |
| | | 05/15/05 | REVLIMID(R) (lenalidomide) Significantly Delays Time to Disease Progression in Previously Treated Multiple Myeloma Patients Presented at 2005 ASCO|
- Overwhelmingly Positive Statistically Significant Difference in The
Primary Endpoint of Time-To-Progression (TTP) Demonstrated in Two
Pivotal Phase III Special Protocol Assessment Trials (SPA)
- Updated Clinical Data Presented at ASCO Scientific Symposium
- The median time-to-disease progression in the North American Phase III
Trial (MM-009) with REVLIMID plus dexamethasone was 60.1 weeks,
compared with the median time-to-disease progr... |
| | | 05/15/05 | REVLIMID(R) Study in Myelodysplastic Syndromes With Deletion 5Q Chromosomal Abnormality Presented at ASCO Plenary Session|
66% of Transfusion-Dependent Myelodysplastic Syndromes (MDS) Patients
Achieved Transfusion Independence and a Median Hemoglobin Increase
5.3g/dl, on an Intent-To-Treat Basis
73% of Responders have Remained Transfusion Independent with a Median
Duration of 58 Weeks of Follow-Up; Median Duration of Transfusion
Independence Not Yet Reached
Cytogenetic Response Achieved in 70% of Patients Evaluated; Complete
Cytogenetic Response in 63... |
| | | 05/15/05 | REVLIMID(R)(Lenalidomide) Study in Chronic Lymphocytic Leukemia Presented at 2005 ASCO| ORLANDO, Fla., May 15 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that clinical data from a REVLIMID study in Chronic
Lymphocytic Leukemia (CLL) were presented at the 2005 American Society
Clinical Oncology (ASCO) Meeting in Orlando, Florida, at a poster session, on
Saturday, May 14. Clinical results were presented on REVLIMID as a potential
new approach for treating patients with relapsed or refractory CLL.
Chronic Lymphocytic Leukemia is a hematological c... |
| | | 05/06/05 | Celgene Will Present at Baird Growth Stock Conference| SUMMIT, N.J., May 6 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Baird Growth Stock
Conference on Wednesday, May 11, 2005 at 11:25 am CDT will be webcast live and
will be available in the investor relations section of the Company's website
at http://www.celgene.com. Alan Lewis, President of Celgene Signal Research
will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an integ... |
| | | 05/02/05 | Celgene Will Present at Bear Stearns Healthcare Conference in London| SUMMIT, N.J., May 2, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bear Stearns
London Healthcare Conference on Tuesday, May 10, 2005 at 11:00 am UKT will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and
Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Sum... |
| | | 04/28/05 | Celgene Corporation First Quarter Results Deliver Record Operating Performance and Key Clinical and Regulatory Progress|
Product Sales Drive Record First Quarter Revenue and Profits:
Total Revenue Increased Approximately 36 Percent Year-Over-Year
Adjusted Earnings Per Diluted Share More Than Doubled Versus Prior Year
Company Affirms 2005 Financial Targets
REVLIMID(R)(lenalidomide) Clinical and Regulatory Programs Advanced:
REVLIMID Pivotal Phase III Special Protocol Assessment (SPA) Multiple
Myeloma (MM) Trials Reported Overwhelming Statistically S... |
| | | 04/21/05 | Celgene Corporation to Announce First Quarter Results on April 28, 2005| SUMMIT, N.J., April 21 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on April 28, 2005 at 9:00 am EDT to discuss the Company's first
quarter financial and operational results. The webcast will be available in
the investor relations section of the Company's website at
http://www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceutical company en... |
| | | 04/19/05 | Celgene Will Present at Rodman & Renshaw Global Healthcare Conference in Paris| SUMMIT, N.J., April 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Rodman & Renshaw
Global Healthcare Conference on Thursday, May 5, 2005 at 12:40 pm CEST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and
Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, Ne... |
| | | 04/13/05 | International Stem Cell Meeting Reports Pluripotent Stem Cells Isolated From Placenta| Ethically Non-Controversial Stem Cells Can Be Obtained from Placenta
SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that human placenta-derived stem cells that are
"pluripotent", or have the ability to become different types of tissue, can be
isolated with a proprietary perfusion technology from placentas so they are
available for potential treatment applications, according to an oral
presentation yesterday at the International Conference... |
| | | 04/11/05 | Revlimid(R) (Lenalidomide) Clinical Data From Interim Analysis of Pivotal Phase III Special Protocol Assessment Trials in Previously Treated Myeloma Presented at the 10th International Multiple Myeloma Workshop| Overwhelming Statistically Significant Difference (p is less-than 0.00001) In
Time-To-Progression (TTP) Rates Validated by Two Pivotal Phase III Special
Protocol Assessment Trials (SPA)
After more than 15 months of follow-up, the primary endpoint of
time-to-disease progression in the REVLIMID plus dexamethasone arm of
U.S. Phase III Trial (MM-009) not reached, compared with median
time-to-disease progression of 5 months for the dexam... |
| | | 04/08/05 | REVLIMID(R) New Drug Application Submitted to FDA for Review| Clinical Data From Phase II Trial (MDS-003) in Patients With Myelodysplastic
Syndromes With 5q Deletion Chromosomal Abnormality Submitted
SUMMIT, N.J., April 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that it has completed the rolling submission of its
New Drug Application (NDA) for REVLIMID (lenalidomide), an investigational
drug, to the Division of Oncology Drug Products at the U.S. Food and Drug
Administration (FDA) for review. The Company'... |
| | | 03/24/05 | Celgene Licenses Rights To EntreMed For Tubulin Inhibitor Program| SUMMIT, N.J., March 24 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that it has signed a licensing agreement with
EntreMed Corporation (ENMD) whereby EntreMed has been granted rights to the
development and commercialization of Celgene's tubulin inhibitor compounds, a
class of orally available, anti-proliferative compounds that have
demonstrated, in preclinical models, activity against drug-resistant cancer
cells, inhibition of inflammatory cytokines and anti-angio... |
| | | 03/10/05 | Celgene Will Present at Lehman Brothers Global Healthcare Conference| SUMMIT, N.J., March 10 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Lehman Brothers
Annual Global Healthcare Conference on Thursday, March 31, 2005 at 10:15 a.m.
EST will be webcast live and will be available in the investor relations
section of the Company's website at http://www.celgene.com. Robert J. Hugin,
Senior Vice President and Chief Financial Officer will provide an overview of
the company.
Celgene Corporation, he... |
| | | 03/09/05 | Celgene Will Present at Smith Barney Citigroup Healthcare Conference| SUMMIT, N.J., March 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Smith Barney
Citigroup Healthcare Conference on Wednesday, March 30, 2005 at 10:20 am EST
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com. John W. Jackson, Chairman
and CEO will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, is an i... |
| | | 03/07/05 | REVLIMID(R) Pivotal Phase III Multiple Myeloma Trials Both Exceed Pre-Specified Interim Efficacy Endpoint|
Independent Data Monitoring Committee review determines that both Phase III Special Protocol Assessment pivotal trials overwhelmingly exceeded the pre-established efficacy stopping rule of p
Celgene will unblind the studies and allow all patients in these studies access to REVLIMID
Discussions with FDA and international regulatory agencies are ongoing
Plans being formulated to create expanded access programs for patients with previously treated myeloma
SUMMIT, N.... |
| | | 02/11/05 | Celgene Will Present at Leerink Swann Healthcare Conference| SUMMIT, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Leerink Swann
Healthcare Conference on Tuesday, March 1, 2005 at 10:00 am EST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and
Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summit, New Jersey, i... |
| | | 02/10/05 | Celgene Will Present at Wells Fargo Annual Healthcare Conference| SUMMIT, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Wells Fargo Annual
Healthcare Conference on Tuesday, March 1, 2005 at 10:30 am EST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice
President and Chief Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in S... |
| | | 02/09/05 | Celgene Will Present at JMP Fourth Annual Research Conference| SUMMIT, N.J., Feb 09, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JMP Securities
Fourth Annual Research Conference on Wednesday, March 2, 2005 at 9:30 am EST
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com. Alan Lewis, President of
Celgene Signal Research will provide an overview of the company.
Celgene Corporation, headquartered... |
| | | 02/09/05 | Clinical Data From Initial REVLIMID(TM) Study in Myelodysplastic Syndromes Reported in New England Journal of Medicine|
63% of Transfusion Dependent Patients, On An Intent-To-Treat-Basis,
Achieved Transfusion Independence
At 81 Weeks, Median Duration of Transfusion Independence Had Not Been
Reached
75% of Patients On An Intent-To-Treat Basis with 5q Deletion
Chromosomal Abnormality Achieved Major Response of Whom 83% Became
Transfusion Independent
SUMMIT, N.J., Feb. 9 /PRNewswire-FirstCall/ -- The New England Journal of
Medicine today pu... |
| | | 02/04/05 | Celgene Will Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference| SUMMIT, N.J., Feb 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Merrill Lynch
Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday,
February 8, 2005 at 9:30am EST will be webcast live and will be available in
the investor relations section of the Company's website at
http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief
Financial Officer will provide an overview of t... |
| | | 01/27/05 | Celgene Corporation Delivers Record Operating Performance in Fourth Quarter and Full-Year 2004 With Strong Revenue Growth and Profits| 39% Increase in Total Revenue For 2004 Versus Prior Year
35% Increase in Total Product Sales For 2004 Year Over Year
2004 Net Income Triples Over Prior Year
Fourth Quarter Results:
REVLIMID(TM) On Track For First Quarter NDA Submission for Treatment of
MDS Patients with 5q Deletion Chromosomal Abnormality
FDA Agreed to Request for Rolling NDA
Non-Clinical (Preclinical, Toxicology) Section Submitted
... |
| | | 01/24/05 | Celgene Corporation to Announce Fourth Quarter and Year-End 2004 Results on January 27, 2005| SUMMIT, N.J., Jan. 24 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on January 27, 2005 at 9:00 AM ET to discuss the Company's fourth
quarter and year-end 2004 financial and operational results. The webcast will
be available in the investor relations section of the Company's website at
http://www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharm... |
| | | 01/10/05 | Celgene Corporation Reviews 2004 Achievements and Announces 2005 Financial Outlook| SUMMIT, N.J., Jan 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) today reviewed its clinical and commercial progress in 2004 and
provided its initial outlook for 2005 at the J.P. Morgan 23rd Annual
Healthcare Conference.
In 2004, Celgene achieved outstanding results in its commercial
operations, financial performance, and clinical performance advancing
REVLIMID(R) in key clinical trials.
"We expect to continue to build on our solid foundation of a... |
| | | 01/06/05 | Celgene Will Present at Piper Jaffray Healthcare Conference| SUMMIT, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Piper Jaffray
Healthcare Conference on Thursday, January 27, 2005 at 2:00 pm EST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice
President and Chief Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Summ... |
| | | 01/04/05 | Celgene Will Present At JPMorgan 23rd Annual Healthcare Conference| WARREN, N.J., Jan. 4 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JPMorgan
Healthcare Conference on Monday, January 10, 2005 at 8:30 am PST will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. Sol J. Barer, President and
Chief Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is an ... |
| | | 12/07/04 | REVLIMID(TM) Clinical Data in Newly Diagnosed Multiple Myeloma Presented at the American Society of Hematology 46th Annual Meeting| SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that data evaluating clinical results on
REVLIMID (lenalidomide) as a new therapeutic approach for patients with newly
diagnosed multiple myeloma (MM) was presented at the American Society of
Hematology 46th Annual Meeting in San Diego, one of the world's largest
oncology meetings. Multiple myeloma is the second most common blood cancer in
the United States affecting approximately 50,000 people. ... |
| | | 12/06/04 | Clinical Data on Combination Oral Treatment Regimen Thalidomide, Melphalan and Prednisone in Newly Diagnosed Multiple Myeloma Patients| SAN DIEGO, Dec 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced that data evaluating clinical results on the
treatment of newly diagnosed multiple myeloma patients with an oral
combination therapy consisting of melphalan, prednisone and thalidomide (MPT)
were presented at the American Society of Hematology 46TH Annual Meeting, one
of the largest oncology meetings in the world, in San Diego, CA from December
3-7, 2004. The study reported a statistica... |
| | | 12/06/04 | ECOG Phase III Study on Thalomid(R) (Thalidomide) Plus Dexamethasone Reports Final Results for Newly Diagnosed Multiple Myeloma| SAN DIEGO, Dec 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that the Eastern Cooperative Oncology Group
(ECOG) reported final clinical results in a Phase III study (E1A00) using
thalidomide plus dexamethasone as therapy in multiple myeloma in comparison to
dexamethasone monotherapy. The clinical data were presented at the American
Society of Hematology 46TH Annual Meeting, one of the largest oncology
meetings in the world, in San Diego, CA... |
| | | 12/05/04 | Preliminary Clinical Data Presented On REVLIMID(TM) in Malignant Blood Disorders|
Transfusion Independence (64%) and Median Hemoglobin Increase (3.9g/dl) Achieved in MDS 5q Deletion Patients
Completed Trial Data To Be Presented After NDA Filing
To Initiate Phase III Trial in 5q Deletion in 2005 for Potential EMEA Regulatory Approval
SAN DIEGO, Dec 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced that clinical data presented during the American
Association of Hematology 46th Annual Meeting in San Diego on Saturday and
... |
| | | 12/03/04 | Celgene and Pharmion Extend Strategic Collaboration for Worldwide Development of THALOMID(R) (Thalidomide)| * Celgene and Pharmion Modify Thalidomide Product Supply Agreement * Pharmion License Amended to Include Expanded Marketing Territory * Collaborative Thalidomide Development Agreement Extended Three Years * Celgene to Receive $88 Million for Multiple Transactions WARREN, N.J. and BOULDER, Colo., Dec 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) and Pharmion Corporation (Nasdaq: PHRM) announced
an expansion of their thalidomide development and commercializa... |
| | | 12/01/04 | Clinical Data on REVLIMID(TM) in Multiple Myeloma and Myelodysplastic Syndromes to be Presented at The American Society of Hematology 46th Annual Meeting| WARREN, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
REVLIMID in multiple myeloma, myelodysplastic syndromes, other malignant blood
disorders, as well as its mechanism of action at the American Society of
Hematology 46TH Annual Meeting, one of the largest oncology meetings in the
world, in San Diego, CA from December 2-7... |
| | | 11/30/04 | 113 Abstracts on Recent Clinical Data for Thalomid(R), Revlimid(TM), Actimid(TM) and Alkeran(R) to be Presented at the American Society of Hematology 46th Annual Meeting| Forty-Nine Abstracts on Thalidomide in Single and Combination Therapies in
Newly Diagnosed Multiple Myeloma and Other Hematological Cancers
WARREN, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
thalidomide in newly diagnosed as well as all stages of multiple myeloma at
the American Society of Hematology 46... |
| | | 11/24/04 | Celgene Will Present at Lazard Life Sciences Conference| WARREN, NJ, Nov. 24, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the Lazard Life Sciences Conference on Tuesday,
November 30, 2004 at 8:00 am EST will be webcast live and will be
available in the investor relations section of the Company's website
at www.celgene.com. Sol J. Barer, President and Chief Operating
Officer, will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is a... |
| | | 11/23/04 | Celgene Licenses S.T.E.P.S.(R) Use Patents to Isotretinoin Manufacturers for Safe Distribution of Isotretinoin for Treatment of Severe Recalcitrant Nodular Acne| WARREN, N.J., Nov. 23 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced an agreement providing Barr Pharmaceuticals, Inc.
(NYSE: BRL), Mylan/Bertek (NYSE: MYL) on behalf of Genpharm, Ranbaxy, and
Roche (OTC: RHHBY) with a non- exclusive license to its patent portfolio
directed to methods of safely delivering drugs in potentially high risk
patient populations. The manufacturers of isotretinoin have licensed these
patents with the intention of implementing a new pregnan... |
| | | 11/09/04 | Clinical Data on THALOMID(R) and REVLIMID(TM) to be Presented at XXII Chemotherapy Foundation Symposium| Presentations on Clinical Studies Using Thalidomide in Solid Tumors
and REVLIMID in Myelodysplastic Syndromes
WARREN, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that clinical investigators from leading cancer
research centers will present clinical data from ongoing trials of THALOMID
(thalidomide) and REVLIMID at the XXII Chemotherapy Foundation Symposium in
New York City, New York from November 10-13, 2004.
The fol... |
| | | 10/25/04 | Focalin XR(TM) Clinical Studies Suggest Investigational Once-Daily ADHD Treatment is Safe and Effective in Both Children and Adults|
Focalin XR New Drug Application Accepted by FDA for Review as Treatment for
Pediatric and Adult ADHD Indications
Focalin XR Helps Manage ADHD Symptoms for 12 Hours
WARREN, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that its investigational drug Focalin XR (formerly
known as Focalin LA) may help adults and children manage Attention-
Deficit/Hyperactivity Disorder (ADHD) symptoms, according to three s... |
| | | 10/22/04 | Celgene Receives FDA Approvable Letter for Thalomid sNDA| WARREN, N.J., Oct 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) -- announced that the Company received an approvable letter
from the FDA for its THALOMID multiple myeloma sNDA late this afternoon.
The FDA letter stated that sufficient support for an accelerated approval
could be provided by the results of the completed study E1A100, a large
randomized Eastern Cooperative Oncology Group (ECOG) study comparing
thalidomide plus dexamethasone to dexametha... |
| | | 10/21/04 | Celgene Corporation Reports Record Operating Performance in Third Quarter With Strong Revenue and Profit Growth| Third Quarter Highlights:
Record Revenue Exceeds $100 Million First Time; Third Quarter Revenue Performance Driven by 36.7% Growth in THALOMID(R) Net Product Sales
Quarterly Diluted Earnings Per Share Increased 383% to $0.24 (pre-split basis) from $0.05 (pre-split basis) in the Year-Ago Quarter; 7th Consecutive Quarter of Increasing Profitability
Celgene Corporation Acquires THALOMID(R) Manufacturing Entity in UK -- Accretive Transaction Increases Economic Participation in Potenti... |
| | | 10/19/04 | Celgene Will Present at C.E. Unterberg Specialty Pharmaceutical Conference| WARREN, NJ, Oct. 19, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the C.E. Unterberg Specialty Pharmaceutical
Conference on Thursday, October 28, 2004 at 3:00 pm ET will be
webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. Robert J. Hugin, Senior
Vice President and Chief Financial Officer, will provide an overview
of the company.
Celgene Corporation, headqua... |
| | | 10/18/04 | Celgene Will Present at JPMorgan Small Cap Conference| WARREN, NJ, Oct. 18, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the JPMorgan Small Cap Conference on Tuesday, October
26, 2004 at 4:10 pm ET will be webcast live and will be available in
the investor relations section of the Company's website at
www.celgene.com. Robert J. Hugin, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Je... |
| | | 10/15/04 | Celgene Corporation Third Quarter 2004 Earnings Conference Call| WARREN, N.J., Oct 15, 2004 (BUSINESS WIRE) -- Celgene Corporation
(NASDAQ:CELG) will announce third quarter financial and operations
results on Thursday, October 21, 2004. Celgene's management team will
host a conference call and live audio webcast to discuss the financial
and operational results.
The webcast will be available in the investor relations sections
of the Company's website at www.celgene.com and will be archived for
two weeks.
The webcast is also being distributed th... |
| | | 10/14/04 | Celgene Corporation to Announce Third Quarter Results on October 21, 2004| WARREN, NJ, Oct. 14, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on October 21, 2004 at 9:00 AM
EDT to discuss the Company's third quarter financial and operational
results. The webcast will be available in the investor relations
section of the Company's website at www.celgene.com.
Celgene Corporation, headquartered in Warren, New Jersey, is an
integrated biopharmaceutical company engaged prim... |
| | | 09/21/04 | Celgene Will Present at UBS Global Life Sciences Conference| WARREN, NJ, Sep. 21, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the UBS Global Life Sciences Conference in New York
on Monday, September 27, 2004 at 8:00 am ET will be webcast live and
will be available in the investor relations section of the Company's
website at www.celgene.com. John W. Jackson, Chairman and CEO will
provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is an
i... |
| | | 09/10/04 | Celgene Will Present at Bear Stearns Healthcare Conference| WARREN, NJ, Sep. 10, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the Bear Stearns Healthcare Conference on Tuesday,
September 14, 2004 at 10:30 am ET will be webcast live and will be
available in the investor relations section of the Company's website
at www.celgene.com. John W. Jackson, Chairman and CEO will provide an
overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is an
integrated b... |
| | | 09/09/04 | Celgene Updates Corporate and Regulatory Developments at BioCentury Newsmakers Conference|
Clinical/Regulatory Update on THALOMID(R) and REVLIMID(TM)
Financial Guidance Reaffirmed
Company Announced Timeline for 2-for-1 Stock Split
WARREN, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) provided a corporate update at the BioCentury Newsmakers
Conference. The presentation updated the company's key clinical, regulatory
and commercial programs. The company reaffirmed its plans to seek regulatory
approval for REVLIM... |
| | | 09/07/04 | Celgene Will Present at Thomas Weisel Healthcare Tailwinds Conference| WARREN, NJ, Sep. 07, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the Thomas Weisel Healthcare Tailwinds Conference on
Friday, September 10, 2004 at 11:45 am EDT will be webcast live and
will be available in the investor relations section of the Company's
website at www.celgene.com. Robert J. Hugin, Senior Vice President
and Chief Financial Officer will provide an overview of the company.
Celgene Corporation, headquartere... |
| | | 09/03/04 | Celgene Will Present at NewsMakers in the Biotech Industry Conference| WARREN, NJ, Sep. 03, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) announced today that its
presentation at the NewsMakers in the Biotech Industry Conference on
Thursday, September 9, 2004 at 11:30 am EDT will be webcast live and
will be available in the investor relations section of the Company's
website at www.celgene.com. Celgene senior management will provide
an overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is an
integrat... |
| | | 07/22/04 | Celgene Corporation Reports Record Operating Performance in Second Quarter With Strong Revenue and Profit Growth|
Second Quarter Revenue Performance Driven by 36% Growth in THALOMID(R)
Net Product Sales
Quarterly Diluted Earnings Per Share Increased to $0.14 from $0.03 in
the Year-Ago Quarter
Raising 2004 Revenue and Earnings Guidance Based on Second Quarter
Results and Positive Developments in 2004
Total Revenue Target Increased to $370 to $390 Million from $365 to
$385
THALOMID Sales Target Increased to $295 to $305 Million from $285 to
$295
... |
| | | 07/15/04 | Celgene Corporation to Announce Second Quarter Financial and Operational Results on July 22, 2004| WARREN, N.J.--(BUSINESS WIRE)--July 15, 2004--Celgene Corporation
(NASDAQ:CELG) will announce second quarter financial and operational
results on Thursday, July 22, 2004. Celgene's management team will
host a conference call and live audio webcast at 9:00 AM EDT to
discuss the financial and operational results.
The webcast will be available to in the investor relations section
of the Company's website at www.celgene.com and will be archived for
two weeks.
The webcast is also ... |
| | | 07/15/04 | Celgene Corporation to Announce Second Quarter Results| WARREN, NJ, Jul. 15, 2004 (MARKET WIRE via COMTEX) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on July 22, 2004 at 9:00 AM ET
to discuss the Company's second quarter financial and operational
results. The webcast will be available in the investor relations
section of the Company's website at www.celgene.com.
Celgene Corporation, headquartered in Warren, New Jersey, is an
integrated biopharmaceutical company engaged primari... |
| | | 07/01/04 | Thalomid(R) in Major Peer-Reviewed Journal Publication of Clinical Data From Randomized Phase II Trial in Androgen-Independent Prostate Cancer| Thalidomide/Docetaxel Regimen Reported Results in PSA Decline, and Clinical Improvement Both in Overall Survival and Time to Progression, in Patients With Androgen-Independent Prostate Cancer
WARREN, NJ--(MARKET WIRE)--Jul 1, 2004 -- Celgene Corporation (NasdaqNM:CELG - News) today announced the results of a randomized Phase II trial conducted by the National Cancer Institute (NCI). This trial used thalidomide in combination with docetaxel (taxotere) versus docetaxel alone in patients wit... |
| | | 06/11/04 | Celgene Will Present At Needham Biotechnology Conference| WARREN, N.J., June 11 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Needham
Biotechnology Conference on Wednesday, June 16, 2004 at 2:30 pm ET will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. John W. Jackson, Chairman and CEO
will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is an integrated
bioph... |
| | | 06/08/04 | Clinical Study Presented on THALOMID(R) Plus Temozolomide Oral Regimen as Adjuvant Therapy for Treating Patients With High Risk Advanced-Stage Metastatic Melanoma| NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) today announced results of an ongoing clinical study using
thalidomide in combination with temozolomide as an oral regimen for the
adjuvant treatment of high-risk metastatic melanoma patients reported at the
American Society of Clinical Oncology (ASCO), the largest oncology meeting in
the world. This clinical study investigated the combination of a low-dose
daily schedule of temozolomide with thalidomide (100 ... |
| | | 06/08/04 | Clinical Data On Combination Oral Treatment Regimen Thalomid(R), Melphalan And Prednisone In Newly Diagnosed Multiple Myeloma Patients| 93 Percent of Evaluable Patients Achieved A Partial Response or Better in Newly Diagnosed Multiple Myeloma 45 Percent of Patients Achieved Complete/Near Complete Response
NEW ORLEANS, Jun 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced that data evaluating clinical results on the
treatment of newly diagnosed multiple myeloma patients with an oral
combination therapy consisting of melphalan, and prednisone and thalidomide
were presented at the A... |
| | | 06/07/04 | ECOG Phase III Study on Thalomid(R) Plus Dexamethasone Reports Clinical Benefit for Newly Diagnosed Multiple Myeloma| NEW ORLEANS, Jun 7, 2004 (PRNewswire-FirstCall via COMTEX) -- Celgene Corporation announced today that the Eastern Cooperative Oncology Group (ECOG) reported a clinical benefit in a Phase III study (E1A00) using thalidomide plus dexamethasone as therapy in multiple myeloma in comparison to dexamethasone monotherapy, a common conditioning regimen for this indication. The clinical data, which were presented at the American Society of Clinical Oncology (ASCO), the largest oncology meeting in the wo... |
| | | 06/02/04 | Clinical Data on THALOMID(R), REVLIMID(TM), ACTIMID(TM) and ALKERAN(R) in Hematological and Solid Tumor Cancers at The American Society of Clinical Oncology| Phase III ECOG Clinical Study of THALOMID plus Dexamethasone Oral Regimen
Reports Clinical Statistical Significance in Newly Diagnosed Multiple Myeloma
Patients
Forty-one Abstracts on THALOMID, REVLIMID, ACTIMID and ALKERAN as Single
Agents and in Combination Therapies
WARREN, N.J., June 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from cancer
research centers w... |
| | | 05/28/04 | Celgene Will Present at Friedman Billings Ramsey Growth Investor Conference| WARREN, N.J., May 28 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Friedman Billings
Ramsey Growth Investor Conference on Wednesday, June 2, 2004 at 10:40 am ET
will be webcast live and will be available in the investor relations section
of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior
Vice President and Chief Financial Officer will provide an overview of the
company.
Celgene Corporation, headqua... |
| | | 05/12/04 | Celgene Will Present at Banc of America Healthcare Conference| WARREN, N.J., May 12 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Banc of America
Healthcare Conference on Wednesday, May 19, 2004 at 8:00 am PT will be webcast
live and will be available in the investor relations section of the Company's
website at www.celgene.com. Robert J. Hugin, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New J... |
| | | 05/11/04 | Celgene Will Present at Rodman & Renshaw Global Healthcare Conference| WARREN, N.J., May 11 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Rodman & Renshaw
Techvest Global Healthcare Conference in London on Thursday, May 13, 2004 at
11:35 am GMT will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. Robert J.
Hugin, Senior Vice President and Chief Financial Officer will provide an
overview of the company.
Celgene Corporation, he... |
| | | 05/05/04 | Study Suggests Focalin(TM) LA Capsules (d-MPH-ER) are Safe and Effective for ADHD in Adults| WARREN, N.J., May 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) -- Results from data presented today support the safety and
efficacy of Focalin LA (dexmethylphenidate extended release) capsules, an
investigational treatment for Attention-Deficit/Hyperactivity Disorder (ADHD),
in managing symptoms of the disorder in adults. In the study, patients taking
Focalin LA showed significant improvements in ADHD symptoms compared to
patients taking placebo and Foca... |
| | | 04/30/04 | Celgene Will Present at Morgan Stanley Global Healthcare Conference| WARREN, N.J., Apr 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Morgan Stanley 2nd
Annual Global Healthcare Unplugged Conference on Thursday, May 6, 2004 at
11:15 am ET will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. John W.
Jackson, CEO and Chairman of the Board will provide an overview of the
company.
Celgene Corporation, headquart... |
| | | 04/29/04 | Celgene Will Present at R.W. Baird Growth Stock Conference| WARREN, N.J., Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the R.W. Baird Growth
Stock Conference on Wednesday May 5, 2004 at 7:45 am CT will be webcast live
and will be available in the investor relations section of the Company's
website at www.celgene.com. Alan Lewis, President of Celgene Signal Research
will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Jersey, is... |
| | | 04/28/04 | Celgene Announces Plans to Stop Phase III Trials In Melanoma Due to Lack of Efficacy| WARREN, N.J., Apr 28, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) today announced that it plans to stop its pivotal Phase III
REVLIMID(R) trial based on the verbal recommendation of the Data Monitoring
Committee (DMC). The DMC yesterday afternoon reviewed the unblinded interim
results of our Phase III monotherapy REVLIMID melanoma trials and has
determined that the trials would not demonstrate a statistically significant
treatment effect and therefore reco... |
| | | 04/28/04 | Celgene Will Present at Deutsche Bank Healthcare Conference| WARREN, N.J., April 28 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Deutsche Bank 29th
Annual Healthcare Conference on Tuesday, May 4, 2004 at 3:30 pm ET will be
webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. Robert J. Hugin, Senior Vice President
and Chief Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warre... |
| | | 04/22/04 | Celgene Corporation Reports Record Operating Performance in First Quarter With Strong Revenue Growth and Profits|
First Quarter Results:
First Quarter Revenues Increased 68.8% Versus The Year Ago Quarter,
Driven by Strong THALOMID(R) and ALKERAN(R) Performance
Quarterly Diluted Earnings Per Share Increased to $0.10 from $0.01 in
the Year-Ago Quarter.
Key REVLIMID(TM) Multiple Myeloma Regulatory Trial Enrollment
Accelerated
Accelerated Phase II Trial Target Enrollment Completed
Pivotal Phase III SPA Trial Target Enro... |
| | | 04/15/04 | Celgene Corporation to Announce First Quarter Results on April 22, 2004| WARREN, N.J., April 15 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on April 22, 2004 at 9:00 AM ET to discuss the Company's first quarter
financial and operational results. The webcast will be available in the
investor relations section of the Company's website at www.celgene.com.
Celgene Corporation, headquartered in Warren, New Jersey, is an integrated
biopharmaceutical company engaged primarily ... |
| | | 04/14/04 | Celgene Corporation to Announce First Quarter Financial and Operational Results on April 22, 2004| WARREN, N.J.--(BUSINESS WIRE)--April 14, 2004--Celgene Corporation
(NASDAQ:CELG) will announce first quarter financial and operational
results on Thursday, April 22, 2004. Celgene's management team will
host a conference call and live audio webcast at 9:00 AM EDT to
discuss the financial and operational results.
The webcast will be available to in the investor relations section
of the Company's website at www.celgene.com and will be archived for
two weeks.
The webcast is also... |
| | | 03/09/04 | Celgene Will Present At Bear Stearns London Healthcare Conference| WARREN, N.J., March 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Bear Stearns 2004
London Healthcare Conference on Tuesday, March 16, 2004 at 2:15 pm GMT will be
webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. Sol J. Barer, Ph.D., President and Chief
Operating Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New... |
| | | 03/03/04 | REVLIMID(TM) Receives Orphan Drug Designation From the European Commission for Myelodysplastic Syndromes| WARREN, N.J., March 3 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that REVLIMID has been granted orphan drug
designation for myelodysplastic syndromes (MDS) by the European Commission
(EC) following the favorable opinion of the European Agency for the Evaluation
of Medicinal Products (EMEA). REVLIMID is the lead development compound of a
new class of novel immunomodulatory drugs, or IMiDs (TM). Clinical trials,
ongoing or soon to be initiated, are evaluatin... |
| | | 03/02/04 | Celgene Will Present at JMP Securities Research Conference| WARREN, N.J., March 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JMP Securities
Research Conference on Tuesday, March 9, 2004 at 8:10 a.m. PT will be webcast
live and will be available in the investor relations section of the Company's
website at www.celgene.com . Robert J. Hugin, Senior Vice President and Chief
Financial Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New Je... |
| | | 03/02/04 | Celgene Will Present at Lehman Brothers Global Healthcare Conference| WARREN, N.J., March 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the 7th Annual Lehman
Brothers Healthcare Conference on Wednesday, March 3, 2004 at 4:15 p.m. ET
will be webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. John W. Jackson, Chairman and
Chief Executive Officer will provide an overview of the company.
Celgene Corporation, headquartered in Warren, New... |
| | | 02/23/04 | Thalomid(R) Supplemental New Drug Application Accepted by FDA for Review As Treatment for Multiple Myeloma| WARREN, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that the Division of Oncology Drug Products at
the U.S. Food and Drug Administration (FDA) has accepted for review the
company's Supplemental New Drug Application (sNDA) seeking approval to market
THALOMID for the treatment of multiple myeloma. Multiple myeloma is the second
most common blood cancer in the United States affecting approximately 50,000
people. About 14,600 new cases of multiple... |
| | | 02/19/04 | REVLIMID(TM) Receives Orphan Drug Designation From the European Commission For Multiple Myeloma| WARREN, N.J., Feb 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that REVLIMID(TM) (formerly known as REVIMID),
has been granted orphan drug designation by the European Commission (EC) for
multiple myeloma (MM) following the favorable opinion of the European Agency
for the Evaluation of Medicinal Products (EMEA). REVLIMID is the lead
development compound of a new class of novel immunomodulatory drugs, or IMiDs
(TM). Ongoing clinical trials ... |
| | | 01/29/04 | Celgene Corporation Reports Record Operating Performance in Fourth Quarter And Full-Year 2003 With Strong Revenue Growth and Profits| Fourth Quarter Results:
* Fourth Quarter Revenues Increased 117% Versus The Year Ago Quarter, Driven by Strong THALOMID(R) and ALKERAN(R) Performance
* Quarterly Diluted Earnings Per Share Increased to $0.06
* Quarterly Diluted Earnings Per Share Increased to $0.06
* Key REVIMID(TM) Regulatory Trials Accelerated; Targeted Enrollment Completed in Pivotal Phase III Melanoma Trials, and Both Phase II MDS Regulatory Trials
* SWOG Selects REVIMID For Evaluation in Major Phase III Trial... |
| | | 01/29/04 | Celgene Corporation to Present at the 11th Annual Emerald Groundhog Day Investment Forum| LANCASTER, Pa.--(BUSINESS WIRE)--Jan. 29, 2004--Emerald Asset Management has announced that Celgene Corporation (NASDAQ:CELG - News) will be presenting at the Eleventh Annual Emerald Groundhog Day Investment Forum, scheduled for Tuesday, February 3, 2004 at the Wyndham Franklin Plaza Hotel in Philadelphia. The Forum will showcase investment opportunities in some of the Mid-Atlantic region's fastest growing companies, as well as industry leaders from across the country. Senior management from ove... |
| | | 01/21/04 | Celgene Corporation to Announce Fourth Quarter and Year-End 2003 Results On January 29, 2004| WARREN, N.J., Jan 21, 2004 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on January 29, 2004 at 9:00 AM ET to discuss the Company's fourth
quarter and year-end 2003 financial and operational results. The webcast will
be available in the investor relations section of the Company's website at
www.celgene.com.
Celgene Corporation, headquartered in Warren, New Jersey, is an integrated
biopharma... |
| | | 01/12/04 | Celgene Corporation Reviews 2003 Achievements and Announces 2004 Financial Outlook|
Company Reports Excellent Operating Performance in 2003 Accelerating
Product Revenues And Increasing Profits
Key REVIMID(TM) Regulatory Trials Accelerated; Enrollment Completed in
Pivotal Phase III Melanoma Trials, Phase II MDS Trial and Second Cohort
of Phase II MDS/5Q minus Trial
R&D Investments Increased In 2003 To Advance Pipeline and Support
Strategic Regulatory Initiative For Immunomodulatory Drugs (IMiDs)(TM)
Celgene For... |
| | | 01/06/04 | Celgene Will Present at the JP Morgan 22nd Annual Healthcare Conference| WARREN, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JP Morgan 22nd
Annual Healthcare Conference will be webcast live and will be available in the
investor relations section of the Company's website at www.celgene.com.
Sol J. Barer, Ph.D., President and Chief Operating Officer will provide an
overview of the company. The presentation will take place at 8:30 a.m. PT on
Monday, January 12, 2004 from the Westin St... |
| | | 12/09/03 | Clinical Data on REVIMID(TM) in Relapsed or Refractory Multiple Myeloma Presented at the American Society of Hematology 45th Annual Meeting| * 91 Percent of Evaluable Patients Achieved Stabilization of Disease or Better
in Relapsed/Refractory Myeloma
* 10 Percent of Patients Achieved a Complete Response
SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that data evaluating clinical results on
REVIMID
(CC-5013) as a therapeutic approach for patients with refractory or relapsed
multiple myeloma (MM) were presented at the American Associati... |
| | | 12/09/03 | Clinical Data on ACTIMID(TM) in Multiple Myeloma at The American Society of Hematology 45th Annual Meeting| 93% of Evaluable Patients Achieved Stabilization of
Disease or Better in Relapsed/Refractory Myeloma
SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that data evaluating clinical results on
ACTIMID (CC-4047) as a therapeutic approach for patients with
relapsed/refractory multiple myeloma was presented at the American Association
of Hematology 45th Annual Meeting in San Diego, one of the world's largest
oncology meetings.... |
| | | 12/08/03 | Additional Clinical Data Presented on REVIMID(TM) in Myelodysplastic Syndromes At the American Society of Hematology 45th Annual Meeting|
* Red Blood Cell Production Restored in 67 Percent of Evaluable Patients
* Transfusion Independence Achieved in 90 Percent of Responders
* 10 of 11 Patients with Abnormal Chromosomal Abnormality, 5q minus,
Achieve Complete Response as Chromosomal Abnormality Disappears
SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that data evaluating clinical results on
REVIMID (CC-5013) as a therapeutic approach for ... |
| | | 12/04/03 | Clinical Data on ACTIMID(TM) in Multiple Myeloma to be Presented at the American Society of Hematology 45th Annual Meeting| Multiple Abstracts on Immunomodulatory Drugs (IMiDs(TM)) as Single Agents and Combination Therapy in Hematological Cancers and Malignant Blood Disorders
WARREN, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
ACTIMID in multiple myeloma and its mechanism of action at the American
Society of Hematology 45th Annual Meet... |
| | | 12/03/03 | Clinical Data on REVIMID(TM) in Multiple Myeloma and Myelodysplastic Syndromes To be Presented at the American Society of Hematology 45th Annual Meeting| Multiple Abstracts on Immunomodulatory Drugs (IMiDs(TM)) as Single and
Combination Therapies in Hematological Cancers and Blood Disorders
WARREN, N.J., Dec. 3 /PRNewswire-FirstCall/ - Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
REVIMID in multiple myeloma, myelodysplastic syndromes, malignant blood
disorders, as well as its mechanism of action at... |
| | | 12/02/03 | Clinical Data on Alkeran(R) (Melphalan) in Hematological Cancers to be Presented at The American Society of Hematology 45th Annual Meeting| Sixty Abstracts on ALKERAN in Combination Therapy for Hematological Cancers
and Malignant Blood Disorders
WARREN, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present clinical data from recent and on-going trials of
ALKERAN (melphalan) at the American Society of Hematology 45TH Annual Meeting,
one of the largest oncology meetings in the world, in San Di... |
| | | 12/01/03 | One Hundred and Twenty-Eight Abstracts on Recent Clinical Data for THALOMID(R), Revimid(TM), Actimid(TM) and Alkeran(R) to be Presented at the American Society of Hematology 45th Annual Meeting| Fifty-Six Abstracts on THALOMID in Single and Combination Therapies in Newly
Diagnosed Multiple Myeloma and Other Hematological Cancers
WARREN, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading cancer
research centers will present data from recent and on-going clinical trials of
THALOMID in newly diagnosed as well as all stages of multiple myeloma at the
American Society of Hematology 45th Annua... |
| | | 11/13/03 | Data On Combination Thalomid(R) Regimens In Refractory Solid Tumors To Be Presented At The Chemotherapy Foundation Symposium XXI| NEW YORK, Nov. 13 /PRNewswire-FirstCall/ -- (Nasdaq: CELG) Interim data
from three studies assessing thalidomide in combination regimens for certain
solid tumors will be presented at the annual Chemotherapy Foundation Symposium
XXI in New York.
Dr. Paul Mathew from M.D. Anderson Cancer Center will update findings of
data that was presented at the European Cancer Conference (ECCO) in
Copenhagen, Denmark. The trial, headed by Dr. Danai Daliani, investigated
THALOMID in combination wit... |
| | | 11/12/03 | Additional Data Presented on REVIMID(TM)in Malignant Blood Disorders At Chemotherapy Foundation Symposium XXI| 10 of 11 Patients with 5q- Abnormal Chromosome Achieve Complete Response
Two Multicenter Phase II Trials Underway To Further Evaluate REVIMID in
Myelodysplastic (MDS) and 5Q minus Syndromes
WARREN, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that data to be presented at the annual
Chemotherapy Foundation Symposium XXI in New York on Wednesday, November 12,
2003 and at the American Association of Hematology Me... |
| | | 11/07/03 | Celgene Will Present at JP Morgan Small Cap Conference| WARREN, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the JP Morgan Small
Cap Conference on Thursday, November 13, 2003 at 10:45 am ET will be webcast
live and will be available in the investor relations section of the Company's
website at www.celgene.com. Robert J. Hugin, Senior Vice President and Chief
Financial Officer will present a company overview.
Celgene Corporation, headquartered in Warren, New Jersey, is ... |
| | | 11/06/03 | Celgene Will Present at Credit Suisse First Boston Healthcare Conference| WARREN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Credit Suisse
First Boston 2003 Healthcare Conference on Thursday, November 13, 2003 at
10:00 am MT will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. John W.
Jackson, Chairman and Chief Executive Officer will present a company overview.
Celgene Corporation, headquartered in Warren, New J... |
| | | 11/05/03 | Clinical Data on THALOMID(R) and REVIMID(TM) to Be Presented at XXI Chemotherapy Foundation Symposium| Presentations on THALOMID in Combination Therapy for Solid Tumors
And REVIMID in Myelodysplastic Syndromes
WARREN, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators from leading
cancer research centers will present data from clinical trials of THALOMID
(thalidomide) and REVIMID at the XXI Chemotherapy Foundation Symposium in New
York City, New York from November 12-15, 2003. The investigators will disc... |
| | | 10/31/03 | Celgene Corporation and The National Cancer Institute Initiate Clinical Trial In Brain Cancer With New Anti-Cancer Compounds| WARREN, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) and the National Cancer Institute (NCI) announced today the
initiation of a clinical trial with CC-8490, a new anti-cancer compound from
Celgene's proprietary class of benzopyrans, being evaluated as a potential
therapy for brain cancer. Recently, Celgene signed a cooperative research and
development agreement (CRADA) with The National Cancer Institute (NCI), a
component of the National Institutes of Health... |
| | | 10/30/03 | Celgene Corporation Advances ACTIMID(TM) (CC-4047) Into Phase II Trial For Prostate Cancer| WARREN, N.J., Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that it advanced the development of one of its
leading clinical candidates, ACTIMID (CC-4047). ACTIMID, a proprietary
immunomodulatory drug (IMiD), is being evaluated as a potential therapy for
prostate cancer. This recently initiated multi-center Phase II; two-stage,
open-label trial will investigate the safety and efficacy of ACTIMID, as a
single agent, in hormone-refractory... |
| | | 10/23/03 | Celgene Corporation Reports Record Operating Performance in Third Quarter As Total Revenue Increases 117% and Profits Rise|
Third Quarter Product Sales Increase 112%, versus the year ago quarter, driven by strong THALOMID(R) performance
Quarterly Diluted Earnings Per Share of $0.05 Exceeds Earnings Consensus
Progress in Key REVIMID(TM) Regulatory Trials On-Track; Enrollment of First Cohort Completed in Phase II MDS/5Q minus Trials
Recent Highlights:
THALOMID Phase I/II Clinical Data Presented on Combination Therapy For Treating Prostate Cancer
Major Peer-Reviewed Journal Publication of a Cli... |
| | | 10/13/03 | Celgene Corporation to Announce Third Quarter Financial Results On October 23, 2003| WARREN, N.J., Oct. 13 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) senior management will host a conference call and live audio
webcast on October 23, 2003 at 9:00 AM EDT to discuss the Company's third
quarter and nine month financial and operational results. The webcast will be
available in the investor relations section of the Company's website at
www.celgene.com and will be archived for one week.
Celgene Corporation, headquartered in Warren, New Jersey, is an inte... |
| | | 09/25/03 | Thalomid(R) Phase I/II Clinical Data Presented as Combination Therapy For Treating Prostate Cancer| 76% of evaluable patients demonstrated prostate-specific antigen response
in second line therapy
COPENHAGEN, Denmark, Sept. 25 /PRNewswire-FirstCall/ -- Celgene
Corporation (Nasdaq: CELG) announced today the results of data presented at
the European Cancer Conference (ECCO) in Copenhagen, Denmark which used
THALOMID(R) in combination with chemotherapy androgen-independent prostate
carcinoma (AIPCa). The Phase I/II study results demonstrated that 18 of 33
... |
| | | 09/22/03 | Celgene Will Present at Morgan Stanley Convertible Conference| WARREN, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the Morgan Stanley
2003 Convertible Conference on Thursday, September 25, 2003 at 11:20 am MT
will be webcast live and will be available in the investor relations section
of the Company's website at www.celgene.com. Robert J. Hugin, Senior Vice
President and Chief Financial Officer will present a company overview.
Celgene Corporation, headquartered in Warren, ... |
| | | 09/19/03 | Celgene Will Present at UBS Global Life Sciences Conference| WARREN, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its presentation at the UBS Global Life
Sciences Conference on Thursday, September 25, 2003 at 9:30 am ET will be
webcast live and will be available in the Conferences section of the UBS
website at www.ibb.ubs.com. John W. Jackson, Chairman and Chief Executive
Officer will present a company overview.
Celgene Corporation, headquartered in Warren, New Jersey, is an
independent bio... |
| | | 09/10/03 | New Patent Broadens Celgene JNK Intellectual Property Estate| New U.S. Patent With Broad Claims Directed to Polypeptides That Regulate JNK
Activity
JNK Targets Offer Potential for Innovative Approach in Treatment of Cancer,
Diabetes, Immune and Inflammatory Diseases
WARREN, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that its extensive intellectual property estate
for the JNK patent program has been further strengthened with the recently
iss... |
| | | 09/08/03 | Major Peer-Reviewed Journal Publication of a Clinical Study of THALOMID(R) Plus Temozolomide as Oral Regimen for Treating Patients with Advanced-Stage Metastatic Melanoma| Objective of Clinical Trial to Determine Antitumor Response by Combining Immunomodulatory and Antiangiogenic Agents Overall Objective Response Rate of 32 Percent
WARREN, N.J., Sep 8, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) today announced the results of a clinical study using
THALOMID(R) in combination with temozolomide as an oral regimen for metastatic
melanoma, published in the September 1, 2003 issue of the Journal of Clinical
Oncology (JCO). Thi... |
| | | 09/02/03 | Celgene Corporation Will Present at Healthcare Conferences| WARREN, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that Celgene Senior Management will present a
company overview at three major healthcare conferences. The presentations will
be webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com
John W. Jackson, Chairman and Chief Executive Officer will present at the
Bear Stearns 16th Annual Healthcare Conference at 4:30 p.m. ET on M... |
| | | 08/26/03 | New Patent Broadens Celgene JNK Intellectual Property Estate| - New U.S. Patent With Broad Claims Directed to Identifying Compounds
Affecting JNK Protein Kinase
- JNK Targets Offer Potential for Innovative Approach in Treatment of Cancer,
Diabetes Immune and Inflammatory Diseases
WARREN, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced that its JNK patent portfolio now includes U.S.
Patent No. 6,610,505 which issued today and contains broad claims to methods
for... |
| | | 08/19/03 | Thalidomide Receives Australian Recommendation for Approval For the Treatment of Relapsed and Refractory Multiple Myeloma|
Thalidomide also received an approval recommendation for
Acute Manifestations of Inflammatory
Complications of Leprosy
WARREN, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced today that the Australian Drug Evaluation Committee
has recommended for approval Pharmion's thalidomide for the treatment of both
patients with relapsed and refractory multiple myeloma (MM) and for the
treatment... |
| | | 07/24/03 | Celgene Corporation Reports Strong Operating Performance in Second Quarter as Total Sales Increase 100 Percent and Profits Rise|
Product Sales Driven by Increase of 93.4 Percent, year-over-year, in
THALOMID(R) Revenues and Reintroduction of ALKERAN(R)
Quarterly Earnings of $0.03 per Diluted Share Exceeds Earnings
Consensus
2003 Full Year Financial Guidance Raised
R&D Investment Increased to Accelerate REVIMID(TM) Regulatory Approval
Recent Highlights:
Additional Clinical Data Demonstrated REVIMID Potential in Treating -
Myelodysplastic Syndrome... |
| | | 07/18/03 | Celgene Corporation to Announce Second Quarter and Six Months Financial and Operational Results on July 24, 2003| WARREN, N.J., Jul 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) will announce second quarter and six month financial and
operational results on Thursday, July 24, 2003. Celgene's management team
will host a conference call and live audio webcast at 9:00 AM EDT to discuss
the financial and operational results. The webcast will be available to in the
investor relations section of the Company's website at www.celgene.com and
will be archived for two weeks.
... |
| | | 07/08/03 | Celgene Corporation Announces New Additions to Senior Management Team| Dr. Graham Burton Appointed Senior VP of Regulatory Affairs, Pharmacovigilence
and Project Management
Dr. Michael Vander Zwan Appointed VP of Quality Assurance and Compliance
WARREN, N.J., July 8 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today the appointment of Graham
Burton, M.D., Ph.D. as Senior Vice President of Regulatory Affairs,
Pharmacovigilence and Project Management and Michael Vander Zwan, Ph.D. as
Vice Pre... |
| | | 07/02/03 | Focalin(TM) LA Pivotal Clinical Trial Initiated in Adults With ADD/ADHD| WARREN, N.J., Jul 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that a pivotal clinical
trial of Focalin(TM) LA (dexmethylphenidate hydrochloride extended-release
capsules) in adults with attention deficit disorder / attention deficit
hyperactivity disorder (ADD/ADHD) has been initiated. Novartis
Pharmaceuticals Corporation has marketing rights to Focalin LA in the United
States and will conduct the multi-center, controlled pivotal trial to... |
| | | 06/05/03 | Celgene Corporation Announces the Appointment of Mr. Francis Brown As Senior Vice President of Sales and Marketing| Senior Management Capabilities Enhanced
WARREN, N.J., June 5 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today the appointment of
Mr. Francis Brown as Senior Vice President of Sales and Marketing. Mr. Brown
brings to Celgene more than 21 years of pharmaceutical experience with
Pharmacia Corporation. During his career at Pharmacia, Mr. Brown held key
senior management positions, including Global VP of marketing for the
injectable cox-2 program, Vice Pre... |
| | | 06/04/03 | New Data from Clinical Trials of THALOMID(R) in Broad Range Of Solid Tumor Cancers Presented at ASCO| THALOMID Combination Therapy in Renal Cell Carcinoma, Prostate Cancer and Melanoma Over 170 Additional Abstracts on THALOMID and REVIMID(TM) Presented at Recent Medical Meetings; Forty-three Abstracts at ASCO
WARREN, N.J., Jun 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) -- Clinical investigators from leading
cancer research centers around the world presented extensive clinical data on
THALOMID(R) (thalidomide) in a broad range of hematological and solid ... |
| | | 06/03/03 | IMiDs(TM) Multiple Mechanism of Action Demonstrate Potential Activity In Solid Tumors| Celgene advances clinical development of REVIMID(TM) and ACTIMID(TM)
in solid tumor cancers
CHICAGO, June 3 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) - Celgene advanced the development of
leading IMiD clinical candidates in solid tumor indications. In preclinical
studies, REVIMID has demonstrated potent anti-cancer activity through multiple
mechanisms of action, some or all of which may be responsible for clinical
response. Further clin... |
| | | 05/30/03 | Study Shows Ritalin(R) LA Provides Statistically Greater ADHD Symptom Management Over Concerta(R) Across the School Day| WARREN, N.J., May 30 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) -- Results from a recent study showed that
Ritalin(R) LA (methylphenidate HCl) extended-release capsules provided greater
improvement in core symptoms of Attention-Deficit/Hyperactivity Disorder
(ADHD) in a simulated classroom setting compared to Concerta(R)
(methylphenidate HCl) extended release tablets. Patients who received Ritalin
LA 20 mg experienced a nearly two-fold improvement in attention and a more... |
| | | 05/30/03 | Clinical Data on THALOMID(R) and REVIMID(TM) in Hematologic and Solid Tumor Cancers to be Presented at the American Society of Clinical Oncology| Forty-three Abstracts on THALOMID and REVIMID as Single Agents
And in Combination Therapy
WARREN, N.J., May 30 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators
from leading cancer research centers around the world will present data from
clinical trials of THALOMID(R) (thalidomide) and REVIMID(TM) (CC-5013) at the
Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago,
Illinois fr... |
| | | 05/30/03 | Initial Purchaser Exercises Option to Purchase an Additional $75 Million of the $325 Million of 1.75% Convertible Notes| WARREN, N.J., May 30 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that the initial purchaser
of $325 million of its 1.75% Convertible Notes due 2008 has elected to
exercise its option to purchase an additional $75 million principal amount of
such Notes. As a result, the final aggregate principal amount of the offering
of the Notes will be $400 million. These Notes will be convertible into
Celgene Corporation common stock at a conversion price of $48.45 per ... |
| | | 05/29/03 | Celgene Corporation Announces Pricing of $325 Million Convertible Note Offering| - Transaction Highlights: 1.75% Coupon and 50.0% Conversion Premium -
WARREN, N.J., May 29 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that it agreed to privately
place $325 million aggregate principal amount of Convertible Notes due 2008.
These Notes will be convertible into Celgene Corporation common stock at a
conversion price of $48.45 per share (reflecting a premium of 50%, relative to
the NASDAQ closing price for Celgene common stock of $32.30 o... |
| | | 05/28/03 | THALOMID(R) Evaluated in Every Stage of Multiple Myeloma Presented at Ninth International Myeloma Workshop| Sixty-nine Abstracts on THALOMID and IMiDs(TM) as Single Agents and In Combination Therapy
SALAMANCA, Spain, May 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) -- Clinical investigators from leading
cancer research centers around the world presented data from sixty-nine
clinical trials of THALOMID(R) (thalidomide) and REVIMID(TM) (CC-5013) in
multiple myeloma at the Ninth International Myeloma Workshop. The
investigators discussed their evaluations of T... |
| | | 05/28/03 | Celgene Corporation Announces Proposed $300 Million Convertible Notes Offering| WARREN, N.J., May 28 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that it proposes to offer a
new issue of $300 million of Convertible Notes due 2008 through a Rule 144A
offering to qualified institutional buyers. These Notes will be convertible
into Celgene Corporation common stock at a price to be determined.
The Notes and the common stock issuable upon conversion of the Notes have
not been registered under the Securities Act of 1933, as amended, or... |
| | | 05/22/03 | Data on THALOMID(R) in Every Stage of Multiple Myeloma to be Presented at Ninth International Myeloma Workshop| Sixty-nine Abstracts on THALOMID and IMiDs(TM) as Single Agents
And in Combination Therapy
WARREN, N.J., May 22 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators
from leading cancer research centers around the world will present data from
clinical trials of THALOMID(R) (thalidomide) at the Ninth International
Myeloma Workshop in Salamanca, Spain from May 23-27, 2003. The investigators
will discuss dat... |
| | | 05/21/03 | Celgene JNK Intellectual Property Estate Broadened With Tufts University Agreement| Agreement Includes U.S. Patent Application and International Patents Covering Insulin Resistance
WARREN, N.J., May 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that its extensive patent
portfolio for the Company's broad JNK (c-Jun N-terminal Kinase) inhibitor
program has been further strengthened with three issued European patents and a
pending U.S. patent application licensed from Tufts University. The patents
and application cover me... |
| | | 05/15/03 | New REVIMID(TM) Clinical Data Shows Potential as Novel Approach to Treating Myelodysplastic Syndromes (MDS)| Red Blood Cell Production Restored in 64 Percent of Evaluable Patients
8 of 8 Patients With Abnormal Chromosome Achieve Complete Response as Chromosomal Abnormality Disappears
PARIS, May 15, 2003 /PRNewswire-FirstCall via COMTEX/ -- Data presented at the Seventh
International Symposium on Myelodysplastic Syndromes in Paris demonstrates
REVIMID(TM) (CC-5013) as a potential new agent for treating myelodysplastic
syndromes (MDS). These are malignant disorders of blood cell production an... |
| | | 05/13/03 | Celgene Broadens S.T.E.P.S.(R) Intellectual Property Estate With Issuance of Two Fundamental U.S. Patents| WARREN, N.J., May 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that its intellectual
property estate for the Company's unique distribution program expanded with
two additional U.S. patents that issued today. The Celgene patent portfolio
covers managed distribution programs for products or drugs that are either
teratogens (causing birth defects) or have other adverse effects that require
contraindication for certain patients. The Company'... |
| | | 04/24/03 | Celgene Corporation Announces First Quarter 2003 Results| THALOMID(R) (thalidomide) Revenue Increased 74 Percent to Record $45.6 Million; Total Revenue Rose 60 Percent to $49.1 Million
Commercial Franchise and Commitment to Multiple Myeloma Patients Strengthened with Addition of ALKERAN(R) (melphalan)
REVIMID (TM) Received Fast Track Status from FDA for Myelodysplastic Syndromes and Multiple Myeloma
First Data Presented on THALOMID in Complex Regional Pain Syndrome; New Data on THALOMID, ALKERAN, REVIMID at Important Upcoming Medical Meetings... |
| | | 04/18/03 | Celgene Corporation Will Announce First Quarter Financial Results on April 24, 2003| WARREN, N.J.--(BUSINESS WIRE)--April 18, 2003--Celgene Corporation
(NASDAQ:CELG) will announce its first quarter financial results on
Thursday, April 24, 2003 by press release before the market opens.
Celgene's management will host a conference call and live audio
webcast at 9:00 AM ET to fully discuss the financial results and other
business results.
The webcast will be available in the investor relations section of
the Company's website at www.celgene.com and will be archived for ... |
| | | 04/15/03 | Celgene Receives Fast Track Status From FDA for REVIMID(TM) in Myelodysplastic Syndromes| WARREN, N.J., April 15 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that REVIMID(TM) (CC-5013)
received fast track designation from the U.S. Food and Drug Administration
(FDA) for the treatment of myelodysplastic syndromes (MDS). The FDA grants
fast track designation to compounds that may provide a significant improvement
in the safety or effectiveness of the treatment for a serious or
life-threatening disease. Compounds that receive the designation are al... |
| | | 04/14/03 | Celgene Signs Strategic Agreement With GlaxoSmithKline to Distribute and Promote ALKERAN(R) (melphalan)| ALKERAN Indicated for Palliative Treatment of Multiple Myeloma
WARREN, N.J., April 14 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that it has signed an
agreement with GlaxoSmithKline (NYSE: GSK) to distribute and promote
ALKERAN(R) (melphalan/melphalan hydrochloride), a therapy approved by the FDA
for the palliative treatment of multiple myeloma. Under the terms of the
agreement, Celgene will purchase ALKERAN tablets and ALKERAN for injection
from ... |
| | | 04/04/03 | Celgene Will Present at Gerard Klauer Mattison Healthcare Conference| WARREN, N.J., April 4 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that its presentation at
the Gerard Klauer Mattison Healthcare Conference on Tuesday, April 8, 2003 at
10:30 am ET will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com. John W.
Jackson, Chairman and Chief Executive Officer will highlight the Company's
recent accomplishments and review upcoming milestones.
Celgene Corpora... |
| | | 04/02/03 | Celgene Strengthens Broad Intellectual Property Estate for Kinase ProgramWith U.S. Patent Covering P38 and JNK Pathways| WARREN, N.J., Apr 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that its extensive
intellectual property estate for the Company's kinase program has been
strengthened with U.S. Patent No. 6,541,605 that issued yesterday. This
patent covers polypeptides of mitogen-activated protein kinase kinases (MKKs)
that are involved in the p38 and c-Jun N-terminal kinase (JNK) pathways. These
polypeptides are critical reagents for the development of mod... |
| | | 03/24/03 | Celgene Will Present at Banc of America Healthcare Conference| WARREN, N.J., Mar 24, 2003 /PRNewswire-FirstCall via Comtex/ -- Celgene
Corporation (Nasdaq: CELG) announced today that its presentation at the Banc of
America Healthcare Conference on Wednesday, March 26, 2003 at 6:50 p.m. ET will
be webcast live and will be available in the investor relations section of the
Company's website at www.celgene.com. John W. Jackson, Chairman and Chief
Executive Officer will highlight the Company's recent accomplishments and review
upcoming milestones.
Cel... |
| | | 03/21/03 | First Clinical Data on THALOMID(R) in Complex Regional Pain Syndrome| Three Abstracts Presented at Annual Meeting of American Pain Society
CHICAGO, Mar 21, 2003 /PRNewswire-FirstCall via COMTEX/ --Celgene Corporation
(Nasdaq: CELG) announced today that clinical investigators presented data from
the first pilot, open-label clinical trials of THALOMID(R) (thalidomide) in
complex regional pain syndrome (CRPS) at the Annual Meeting of the American Pain
Society.
Celgene initiated the pilot, open-label clinical trials of THALOMID monotherapy
in patients w... |
| | | 03/07/03 | Celgene Corporation Provides Product and Pipeline Update| Financial Guidance Reaffirmed THALOMID(R) Growth Drivers Reviewed New Class of Anti-Cancer Tubulin Inhibitors Discovered Acceleration of Pipeline Highlighted Placental Stem Cell Strategies and Synergies Outlined
NEW YORK, Mar 7, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) provided an overview of recent developments including highlights
from its extensive research and development pipeline at the Company's Analyst
and Investor Meeting yesterday in New York... |
| | | 02/28/03 | Celgene Will Present at Sixth Annual Lehman Brothers Global Healthcare Conference| WARREN, N.J., Feb 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that its presentation at the Sixth
Annual Lehman Brothers Global Healthcare Conference on Monday, March 3, 2003 at
3:00 p.m. ET will be webcast live and will be available in the investor
relations section of the Company's website at www.celgene.com . John W. Jackson,
Chairman and Chief Executive Officer of Celgene will highlight the Company's
recent accomplishments and review ... |
| | | 02/28/03 | Celgene Corporation Will Host 2003 Analyst and Investor Day In New York City on March 6, 2003| WARREN, N.J., Feb 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation announced today that it will host an Analyst and Investor Day on
Thursday, March 6, 2003 at the Grand Hyatt in New York City. Presentations by
Celgene researchers and collaborators will review recent advancements of the
Company's products, programs, technology and strategy.
Registration and breakfast will begin at 7:30 a.m. ET and presentations will
start at 8:15 a.m. ET. To register for the event, conta... |
| | | 02/26/03 | Celgene Will Present at BIO CEO and Investor Conference| WARREN, N.J., Feb 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that its presentation at the BIO CEO
and Investor Conference on Thursday, February 27, 2003 at 9:30 a.m. ET will be
webcast live and will be available in the investor relations section of the
Company's website at http://www.celgene.com. John W. Jackson, Chairman and Chief
Executive Officer of Celgene will highlight the Company's recent accomplishments
and review upcoming miles... |
| | | 02/05/03 | Celgene Expands Broad Intellectual Property Estate for Kinase Pipeline With Fundamental U.S. Patent Covering JNK| WARREN, N.J., Feb 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that its extensive intellectual
property estate for JNK (c-Jun N-terminal Kinase) has been further strengthened
with U.S. Patent No. 6,514,745 that issued yesterday. This fundamental patent
describes the polynucleotide sequences encoding JNK targets that are useful to
identify small molecule JNK inhibitors that could potentially treat cancer,
inflammatory diseases and ischemia ... |
| | | 02/04/03 | Celgene Receives Fast Track Status From FDA for Revimid(TM) in Multiple Myeloma| WARREN, N.J., Feb 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that REVIMID(TM) (CC-5013) received
fast track designation from the U.S. Food and Drug Administration (FDA) for the
treatment of relapsed or refractory multiple myeloma. The FDA grants fast track
designation to compounds that may provide a significant improvement in the
safety or effectiveness of the treatment for a serious or life-threatening
disease. Compounds that receive th... |
| | | 01/31/03 | Celgene Corporation to Present at Emerald Investment Forum|
LANCASTER, Pa.--(BUSINESS WIRE)--Jan. 31, 2003--Celgene
Corporation to present at Emerald Forum: Emerald Asset Management has
announced that Celgene Corporation (NASDAQ:CELG) will be presenting at
the Tenth Annual Emerald Groundhog Day Investment Forum, scheduled for
Thursday, February 6, 2003 at the Wyndham Franklin Plaza Hotel in
Philadelphia.
The Forum will showcase investment opportunities in some of the
region's fastest growing companies, as well as industry ... |
| | | 01/31/03 | Celgene Will Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference|
WARREN, N.J., Jan. 31 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that its presentation at
the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device
Conference on Tuesday, February 4, 2003 at 4:45 p.m. ET will be webcast live
and will be available in the investor relations section of the Company's
website at http://www.celgene.com. John W. Jackson, Chairman and Chief
Executive Officer will provide an overview of Celgene.
... |
| | | 01/30/03 | Celgene Corporation Announces Fourth Quarter and Full Year Results for 2002|
THALOMID(R) Revenue Increases 45 Percent to $119 Million for the Full Year
Achieving High End of Guidance
Anthrogenesis and EntreMed, Inc. Transactions Completed With One-Time
Charges Recorded in Fourth Quarter
Celgene Forecasts Strong Financial Performance in 2003:
THALOMID Revenue to Increase Approximately 40 to 50 percent to
$170-180 Million
R&D Expenses to Increase 30 to 35 Percent to $110-115 Million
to Support Multiple Pivotal Programs f... |
| | | 01/24/03 | Celgene Will Present at US Bancorp Piper Jaffray Health Care Conference|
WARREN, N.J., Jan. 24 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that its presentation at
the US Bancorp Piper Jaffray Health Care Conference on Tuesday, January 28,
2003 at 8:30 a.m. ET will be webcast live and will be available in the
investor relations section of the Company's website at http://www.celgene.com
John W. Jackson, Chairman and Chief Executive Officer, Sol J. Barer,
Ph.D., President and Chief Operating Officer and Rob... |
| | | 01/24/03 | Celgene Corporation Will Announce Fourth Quarter and Full Year Financial Results on January 30, 2003|
WARREN, N.J.--(BUSINESS WIRE)--Jan. 24, 2003--Celgene Corporation
(NASDAQ:CELG) will announce its fourth quarter and full year financial
results on Thursday, January 30, 2003 by press release before the
market opens. Celgene's management will host a conference call and
live audio webcast at 9:00 AM ET to fully discuss the financial
results and other business results.
The webcast will be available in the investor relations section of
the Company's website at www.cel... |
| | | 01/07/03 | Celgene Provides Update On Clinical Pipeline|
Celgene Announces First Target Indication for ACTIMID(TM), CC-8490
SelCID(TM) Program to Advance Based on Results from Phase I/II Trial of
CC-1088
First JNK Inhibitor Successfully Completes Phase I Trial
SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced late yesterday during the
Company's presentation at the JP Morgan H&Q Healthcare Conference that it had
advanced several... |
| | | 01/02/03 | Celgene Completes Anthrogenesis Acquisition|
Celgene Leverages Commercial and Scientific Franchises to Develop Transforming
Placental Stem Cell Therapeutics
WARREN, N.J., Jan. 2 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today the completion of its
merger with Anthrogenesis Corporation, a privately held biotherapeutics
company pioneering the recovery of stem cells from human placental tissue.
Anthrogenesis has developed proprietary methods for collecting, processing and
storing place... |
| | | 01/02/03 | Celgene Broadens Intellectual Property Estate Covering Thalidomide Analogs|
Celgene, EntreMed Sign Agreements to Terminate Litigation
Five-Year Collaboration to Develop Novel Anti-Cancer Therapies Initiated With
Children's Hospital, Boston
Celgene Acquires Equity Stake In EntreMed
WARREN, N.J., Jan. 2 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that it has broadened its
thalidomide analog patent estate through the acquisition of exclusive rights
to the intellectual property ... |
| | | 12/31/02 | Celgene Will Present at JP Morgan H&Q Annual Healthcare Conference|
WARREN, N.J., Dec. 31 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that its presentation at
the JP Morgan H&Q Annual Healthcare Conference on Monday, January 6, 2003 at
3:00 p.m. Pacific Time will be webcast live and will be available in the
investor relations section of the Company's website at http://www.celgene.com.
John W. Jackson, Chairman and Chief Executive Officer, Sol J. Barer,
Ph.D., President and Chief Operating Officer and... |
| | | 12/18/02 | Celgene Announces First Annual Achievement Awards|
WARREN, N.J., Dec. 18 /PRNewswire-FirstCall/ -- Celgene Corporation is
proud to announce the winners of its first annual Celgene Awards for
Achievement in Clinical Hematology Research. Bart Barlogie, MD, PhD, of the
University of Arkansas for Medical Sciences, Little Rock, AR, was the
recipient of the Career Achievements in Clinical Hematology Research award.
Rafael Fonseca, MD, of the Mayo Clinic, Rochester, MN, was the recipient of
the Young Investigator Award for Achieveme... |
| | | 12/11/02 | Data on THALOMID(R) in Numerous Hematological Malignancies Presented At Annual Meeting of American Society of Hematology|
Over 60 Abstracts on THALOMID as Both a Single Agent
And in Combination With Standard Therapies
WARREN, N.J., Dec. 11 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) -- Clinical investigators from leading
cancer research centers presented data from over sixty clinical trials of
THALOMID(R) (thalidomide) in numerous hematological malignancies at the 44th
Annual Meeting of the American Society of Hematology (ASH). The investigators
d... |
| | | 12/10/02 | First Data on REVIMID(TM) in Myelodysplastic Syndromes Demonstrates Fifty-Six Percent of Patients Achieved Hematologic Response|
Five of Five Patients with Deletion of Chromosome 5q31-33 Achieved A
Complete Cytogenetic Response
PHILADELPHIA, Dec. 10 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) -- Alan List, M.D., professor of medicine
and director of translational and clinical research at the Arizona Cancer
Center, reported at the American Society of Hematology annual meeting (ASH)
that 9 of 16 evaluable patients (56 percent) with myelodysplastic syndromes
(MDS) responded to RE... |
| | | 12/10/02 | Data on THALOMID(R) in Myelofibrosis Presented At Annual Meeting of the American Society of Hematology|
Data Will Be Published in Upcoming Issue of BLOOD
PHILADELPHIA, Dec. 10 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that Ayalew Tefferi, M.D.,
and colleagues at the Mayo Clinic presented data from a clinical trial of
THALOMID(R) (thalidomide) in combination with prednisone in myelofibrosis at
the annual meeting of the American Society of Hematology (ASH). The data
demonstrate that 13 of 21 patients (62 percent) achieved an objective c... |
| | | 12/09/02 | REVIMID(TM) Monotherapy Induces Reduction or Stabilization of Paraprotein Levels in Eighty-Five Percent of Advanced Multiple Myeloma Patients In Phase II Trial|
Rate Increases to Ninety-six Percent with Addition of Dexamethasone to
REVIMID Therapy for Non-responders
PHILADELPHIA, Dec. 9 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that Paul Richardson, M.D.,
of the Dana-Farber Cancer Institute at Harvard University presented
preliminary results from a randomized Phase II trial of REVIMID(TM) (CC-5013)
in relapsed or refractory multiple myeloma at the American Society of
Hematology annual meeti... |
| | | 11/21/02 | Preclinical Data Demonstrate Celgene Small Molecule P27 Ligase Modulator Inhibits Tumor Growth|
Proprietary Compound Induces Cell Cycle Arrest
And Apoptosis in Cancer Models
FRANKFURT, Germany, Nov. 21 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that the Company's novel,
small molecule p27 ligase modulator promotes apoptosis (cell death) and
inhibits tumorigenesis (the growth of new tumors) in several preclinical
models of cancer, according to preclinical data presented at the 2002 American
Association for Cancer... |
| | | 11/14/02 | Data On THALOMID(R) In Thyroid Cancer To Be Presented At Chemotherapy Foundation Symposium|
WARREN, N.J., Nov. 14 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that Kenneth B. Ain, M.D.,
Director of the Thyroid Cancer Research Laboratory at the University of
Kentucky Medical Center, will present interim data on THALOMID(R)
(thalidomide) in rapidly progressive, radioiodine-unresponsive metastatic
follicular or papillary thyroid cancer and medullary thyroid cancer at the
20th annual Chemotherapy Foundation Symposium. The clinical data d... |
| | | 11/13/02 | Celgene To Acquire Anthrogenesis For $45 Million|
Anthrogenesis' Proprietary Technology Recovers Large Quantities of Stem Cells
From Human Placental Tissue
Celgene To Distribute Adult-Dose Stem Cell Transplant Units
For Oncology and Other Serious Diseases
WARREN, N.J., Nov. 13 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) today announced that it has signed a
definitive agreement to acquire Anthrogenesis Corporation, a privately held
... |
| | | 11/13/02 | Data On Thalomid(R) and Revimid(TM) in Hematological and Solid Tumor Cancers Will Be Reported at Chemotherapy Foundation Symposium|
WARREN, N.J., Nov. 13 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) announced today that investigators from
leading cancer research centers will present clinical data on THALOMID(R)
(thalidomide) and REVIMID(TM) (CC-5013) in a variety of hematological and
solid tumor cancers at the 20th annual Chemotherapy Foundation Symposium
sponsored by Mount Sinai School of Medicine. The conference, held in New York
City from November 13-16, 2002, will highlight innovative canc... |
| | | 11/01/02 | BLOOD Reports REVIMID(TM) Has Anti-Tumor Activity in Patients with Relapsed and Refractory Multiple Myeloma|
Data Demonstrate REVIMID Overcomes Drug Resistance and Is Well Tolerated
WARREN, N.J., Nov. 1 /PRNewswire-FirstCall/ --
Celgene Corporation (Nasdaq: CELG) -- The first peer-reviewed data of
REVIMID(TM) (CC-5013) in relapsed or refractory multiple myeloma was published
in today's issue of BLOOD, the journal of the American Society of Hematology.
The article, titled "Immunomodulatory Drug CC-5013 Overcomes Drug Resistance
and Is Well Tolerated in Patients with Relapsed ... |
| | | 10/31/02 | First Peer-Reviewed Study of THALOMID(R) In Newly Diagnosed Multiple Myeloma Published In the Journal of Clinical Oncology| WARREN, N.J., Oct 31, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) -- The first peer-reviewed study evaluating the use
of the orally administered combination of THALOMID(R) (thalidomide) and
dexamethasone for newly diagnosed multiple myeloma will be published in the
November 1, 2002 issue of the Journal of Clinical Oncology. The article, written
by Dr. S. Vincent Rajkumar of the Mayo Clinic, reports that 32 of 50 patients
(64 percent) achieved a greater than... |
| | | 10/25/02 | Celgene Corporation to Present at Salomon Smith Barney Global Health Care Conference| WARREN, N.J., Oct 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation announced today that its presentation at the Salomon Smith Barney
2002 Global Health Care Conference on Monday, October 28, 2002 at 1:30 p.m. ET
will be webcast live. The webcast will be accessible in the investor relations
section of Celgene's website at http://www.celgene.com .
John W. Jackson, Chairman and Chief Executive Officer, Sol J. Barer, Ph.D.,
President and Chief Operating Officer, and Robert ... |
| | | 10/24/02 | Celgene Corporation Announces Third Quarter Results| THALOMID(R) Revenue Increases 41% to $30.5 Million Pivotal Programs for THALOMID and REVIMID(TM) Finalized Peer-Reviewed Publications of THALOMID and REVIMID Data First JNK Inhibitor Advanced to Phase I Clinical Trial
WARREN, N.J., Oct 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that THALOMID(R) (thalidomide) sales
increased 41 percent for the quarter ended September 30, 2002 to $30.5 million
from $21.7 million in the third quarter o... |
| | | 10/21/02 | Celgene Corporation Advances First JNK Inhibitor Into Phase I Clinical Trial| Phase I Trial Initiated in Healthy Human Volunteers
WARREN, N.J., Oct 21, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that it advanced its lead JNK (c-Jun
N-terminal Kinase) inhibitor, CC-401, into clinical testing. The recently
initiated Phase I, double-blind, placebo-controlled, ascending single
intravenous dose study is evaluating the safety and tolerability of CC-401 in
healthy human volunteers. Following the completion of this Pha... |
| | | 10/16/02 | Celgene Corporation Will Announce Third Quarter Financial Results on October 24, 2002| WARREN, N.J., Oct 16, 2002 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:
CELG) will announce its third quarter financial results on Thursday, October 24,
2002 by press release before the market opens. Celgene's management will host a
conference call and live audio webcast at 9:00 AM ET to fully discuss the
financial results and other business results.
The webcast will be available in the investor relations section of the Company's
website at www.celgene.com and will be archived for tw... |
| | | 08/12/02 | Celgene Corporation Elects Michael D. Casey, Former President And CEO of Matrix, to Board of Directors| WARREN, N.J., Aug 12, 2002 /PRNewsire-FirstCall via Comtex/ -- Celgene
Corporation (Nasdaq: CELG) announced today the election of Michael D. Casey to
the Company's Board of Directors.
Mr. Casey, who has over 30 years of experience in the pharmaceutical industry,
spent most of his career at Johnson & Johnson where he served as Vice President
of Sales and Marketing of Ortho Pharmaceutical Corporation and President of
McNeil Pharmaceuticals. Mr. Casey was most recently President, Chief Exe... |
| | | 07/25/02 | Celgene Corporation Announces Second Quarter Results| THALOMID(R) Revenue Increases 52% to $28.4 Million Ritalin(R) LA Approved Clinical Development Plan for REVIMID(TM) Advanced Clinical Data Demonstrate ACTIMID(TM) Well Tolerated and Active in Multiple Myeloma
WARREN, N.J., Jul 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that THALOMID(R) (thalidomide) sales
increased 52 percent for the quarter ended June 30, 2002 to $28.4 million from
$18.7 million in the second quarter of 2001. Total re... |
| | | 07/17/02 | Celgene Corporation Will Announce Second Quarter Financial Results on July 25, 2002| WARREN, N.J., Jul 17, 2002 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:
CELG) will announce its second quarter financial results on Thursday, July 25,
2002 by press release before the market opens. Celgene's management will host a
conference call and live audio webcast at 9:00 AM ET to fully discuss the
financial results and other business results.
The webcast will be available in the investor relations section of the Company's
website at www.celgene.com and will be archived for two ... |
| | | 07/09/02 | Celgene Corporation Presents Positive Preclinical Data on JNK Inhibitors For the Treatment of Asthma| JNK Intellectual Property Estate Expands With Newly Issued U.S. Patent
WARREN, N.J., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) scientists, in association with collaborators at the
National Heart and Lung Institute of Imperial College of Medicine in London,
presented preclinical data at the World Congress of Pharmacology during a
session titled "New Drugs for Respiratory Diseases" in San Diego, CA. The data
demonstrate that novel Celgene JNK (... |
| | | 07/08/02 | Clinical Data Demonstrate Actimid(TM) Well Tolerated And Active in Multiple Myeloma| Interim Report from Ongoing Phase I/II Trial Presented at ISEH
MONTREAL, Jul 8, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation
(Nasdaq: CELG) announced today that investigators from Guy's Hospital in London
presented interim data at the 31st Annual Meeting of the International Society
for Experimental Hematology from an ongoing Phase I/II trial of ACTIMID(TM)
(CC-4047) in relapsed and refractory multiple myeloma. Steven Schey, M.D., and
his colleagues reported that ACTI... |
| | | 06/25/02 | Celgene Expands Clinical Development Program for REVIMID(TM)| Five Additional Trials of REVIMID Initiated in Hematological And Solid Tumor Cancers
WARREN, N.J., Jun 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today the initiation of five additional
trials of REVIMID(TM) (CC-5013) in hematological and solid tumor cancers. The
trials, conducted in partnership with the Comprehensive Cancer Center of Wake
Forest University, the National Cancer Institute (NCI), the Dana-Farber Cancer
Institute at Harvard... |
| | | 06/20/02 | Celgene and Novartis Advance SERM Program For The Prevention and Treatment of Osteoporosis| First Preclinical Candidate Selected; Milestone Payment to Celgene WARREN, N.J., Jun 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that the Company advanced its joint
program with Novartis Pharma AG (NYSE: NVS) to develop selective estrogen
receptor modulators (SERMs) for the prevention and treatment of osteoporosis.
Novartis selected the first preclinical candidate after testing Celgene SERMs
for the most appropriate pharmacological pr... |
| | | 06/19/02 | Novel Celgene Ligase Inhibitors Regulate Key Cancer Pathways| Additional Preclinical Data to be Presented at 'Targeting Ubiquitinylation for Drug Discovery' Meeting in San Diego, CA on June 24-25, 2002 WARREN, N.J., Jun 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) researchers presented preclinical data on the
Company's extensive portfolio of novel ubiquitin ligases at the Anti-Cancer Drug
Discovery and Development Summit in Princeton, NJ. The data presented indicate
that novel Celgene ubiquitin ligases alter the ... |
| | | 06/11/02 | Celgene Scientists Will Present Data at Ubiquitin Ligase Conference| 'Targeting Ubiquitinylation for Drug Discovery' Meeting to be Held in San Diego, CA on June 24-25, 2002 Comprehensive Ubiquitin Ligase Website Launched
WARREN, N.J., Jun 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that preclinical data on the
Company's novel ubiquitin ligase modulators will be presented at the first
"Targeting Ubiquitinylation for Drug Discovery" meeting in San Diego, CA on June
24-25, 2002. Celgene has assembled an ... |
| | | 06/06/02 | FDA Grants Marketing Clearance for Ritalin LA, A Once-Daily Formulation of Ritalin For ADHD That Lasts Through the Entire School Day| EAST HANOVER, N.J., DUBLIN, Ireland & WARREN, N.J., Jun 6, 2002 (BW HealthWire)
-- Novartis Pharmaceuticals Corporation (NYSE: NVS), Elan Corporation, plc
(NYSE: ELN) ("Elan"), and Celgene Corporation (Nasdaq: CELG) announced today
that the U.S. Food and Drug Administration (FDA) has granted marketing clearance
for Ritalin(R) LA (methylphenidate HCl) extended-release capsules for the
treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Ritalin LA, a new
once-daily formulation of R... |
| | | 05/22/02 | Investigators Present Data From Clinical Trials of Thalomid(R) in Prostate Cancer, Metastatic Melanoma and Multiple Myeloma| WARREN, N.J., May 22, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) -- At the 38th annual meeting of the American Society
of Clinical Oncology (ASCO), clinical investigators presented data on
THALOMID(R) (thalidomide) in prostate cancer, metastatic melanoma and multiple
myeloma.
"The breadth of clinical data presented on THALOMID at ASCO enhances our
knowledge of THALOMID as a potential treatment of solid tumor and hematological
cancers," said Sol J. Bare... |
| | | 05/22/02 | Two Studies Show Focalin -dexmethylphenidate HCl- is an Effective Treatment for ADHD| PHILADELPHIA, May 22, 2002 (BW HealthWire) -- Data from two double-blind,
randomized, placebo-controlled studies presented today at the 155th Annual
Meeting of the American Psychiatric Association (APA) demonstrate that Focalin
(TM) (dexmethylphenidate HCl) is effective in the management of the symptoms of
Attention-Deficit/Hyperactivity Disorder (ADHD) at half the dose of Ritalin (R)
(d,l methylphenidate HCl). Focalin, a refined formulation of Ritalin, contains
only the effective, or d-is... |
| | | 05/22/02 | Data Presented at APA Meeting Suggest Ritalin -R- LA -methylphenidate HCl- Extended-Release Capsules Are an Effective Once-Daily Treatment for ADHD| PHILADELPHIA, May 22, 2002 (BW HealthWire) -- Data presented at the 155th
Annual Meeting of the American Psychiatric Association (APA), suggest that
Ritalin (R) LA (methylphenidate HCl) extended-release capsules, are an effective
and well-tolerated, once-daily formulation of Ritalin (R) (methylphenidate HCl),
designed to last the school day and eliminate the need for the midday dose of
Ritalin. Results from a double-blind, randomized, placebo-controlled study found
that a once-daily mornin... |
| | | 05/21/02 | Clinical Trial Results Reported at ASCO on the Use of THALOMID(R) in Metastatic Renal Cell Carcinoma| Celgene Announces Regulatory Plan for THALOMID in Renal Cell Carcinoma
ORLANDO, Fla., May 21, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) -- At the 38th annual meeting of the American Society
of Clinical Oncology (ASCO), leading oncology teams from around the country
presented data from clinical trials evaluating THALOMID(R) (thalidomide) in
metastatic renal cell carcinoma. Tolerability and survival data were also
reported.
"Based on these results,... |
| | | 05/20/02 | Clinical Data on THALOMID(R) in Combination With Irinotecan In Colorectal Cancer Patients Presented at ASCO| Celgene and Pharmacia Initiate Phase II/III Trial Of Combination in Advanced Colorectal Cancer Patients
ORLANDO, Fla., May 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that clinical data from a Phase II
trial of THALOMID(R) (thalidomide) and CAMPTOSAR(R) (irinotecan) in metastatic
colorectal cancer were reported at the 38th annual meeting of the American
Society of Clinical Oncology.
Rangaswamy Govindarajan, M.D. of the University... |
| | | 04/26/02 | Marketing Authorization Application for THALOMID(R) Accepted for Review in Europe| WARREN, N.J., Apr 26, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that the Marketing Authorization
Application (MAA) for THALOMID(R) (thalidomide) as a treatment for both relapsed
or refractory multiple myeloma and erythema nodosum leprosum (ENL), an
inflammatory condition of leprosy, has been accepted for review by the European
Agency for the Evaluation of Medicinal Products (EMEA). The MAA will be reviewed
under the centralized licensing p... |
| | | 04/25/02 | Celgene Corporation Announces Results for First Quarter| THALOMID(R) Sales Increase 54%; Total Revenue Rises 37%
WARREN, N.J., Apr 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) announced today that THALOMID(R) (thalidomide) sales
increased 54 percent for the quarter ended March 31, 2002 to $26.2 million from
$17.0 million in the first quarter of 2001. Total revenue was $30.7 million,
rising 37 percent over the prior-year quarter. Celgene posted a net loss of
$823,000 or $0.01 per share compared to a net in... |
| | | 04/12/02 | Nasdaq Life Sciences Forum Thursday, April 18, 2002, at 08:30 a.m. - 16:30pm GMT|
Friday, April 19, 2002, at 08:30 a.m. - 13:00pm GMT: PDLI, CELG, ADRX, GILD, ALKS
LONDON, Apr 12, 2002 (BUSINESS WIRE) -- The Nasdaq Stock Market will host it's
5th Life Sciences Forum, with presentations from some of the largest
Nasdaq-listed companies: Protein Design Labs, Inc. (NASDAQ: PDLI), Celgene
Corporation (NASDAQ: CELG), Andrx Group (NASDAQ: ADRX), Gilead Sciences, Inc.
(NASDAQ: GILD), Alkermes, Inc. (NASDAQ: ALKS). The Nasdaq Life Sciences Forum
web cast will start on ... |
| | | 04/10/02 | Celgene Corporation Presents Preclinical Data on JNK Inhibitors In Solid Tumor Cancers| Novel JNK Inhibitors Demonstrate Significant Anti-Tumor Effects
SAN FRANCISCO, Apr 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) scientists presented data at the 93rd Annual Meeting
of the American Association for Cancer Research (AACR) from preclinical studies
of JNK (c-Jun N-terminal kinase) inhibitors. The data demonstrate that JNK
inhibitors have significant anti-tumor effects in in vivo models of solid tumor
cancers.
"These findings further ... |
| | | 04/09/02 | Celgene Corporation Presents Preclinical Data on Two Classes Of Orally Available Cytokine Inhibitors| IMiDs(TM) and SelCIDs(TM) Demonstrate Significant Anti-tumor Effects in Preclinical Models of Solid Tumor Cancers
SAN FRANCISCO, Apr 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celgene
Corporation (Nasdaq: CELG) scientists presented data at the 93rd Annual Meeting
of the American Association for Cancer Research (AACR) from preclinical studies
of IMiDs (Immunomodulatory Drugs) and SelCIDs (Selective Cytokine Inhibitory
Drugs). The |
|
|
